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ABSTRACT
Osteoarthritis (OA) is a multifactorial disease of the joints and is a leading cause of pain and
disability in older adults. The knee is the most common joint affected by OA. Up to the date
of this thesis, there are no approved disease-modifying treatments available for knee OA.
Therefore, there is an urgent need for identifying modifiable risk factors for this disease. This
thesis aims to use a mixed approach to investigate multiple aspects of the disease, including
the roles of systemic risk factors in knee OA, the effects of vitamin D supplementation on
disease progression, as well as the predictive values of magnetic resonance imaging (MRI)
biomarkers for knee replacement.
Chapter 4 systematically reviews 32 studies on the relationship between serum C-reactive
protein levels measured by a high sensitivity method (hs-CRP) and OA, as well as the cor-
relation between circulating CRP levels and OA phenotypes. Serum hs-CRP levels in OA
were modestly but statistically significantly higher than controls. The levels were signifi-
cantly associated with pain and decreased physical function, but not radiographic OA. This
suggests low-grade systemic inflammation may play a greater role in symptoms rather than
radiographic changes in OA.
Chapter 5 describes the longitudinal relationship between adiposity and change in knee pain.
Data from a population-based sample of older adults show that body mass index (BMI) is
the most consistent correlate of knee pain. Fat mass is associated with non-weight-bearing
knee pain suggesting systemic mechanisms are involved.
Chapter 6 investigates the effects of vitamin D supplementation versus placebo on knee pain
i
and knee cartilage volume in symptomatic knee OA patients with low vitamin D levels in a
randomized clinical trial. Compared with placebo, vitamin D supplementation did not result
in significant differences in change in MRI-measured tibial cartilage volume or knee pain
score over 2 years. There were no significant differences in changes of tibiofemoral cartilage
defects or bone marrow lesions; however, fewer of those receiving vitamin D had increases
in bone marrow lesions.These findings do not support the use of vitamin D supplementation
for preventing tibial cartilage loss or improving knee pain in patients with knee OA.
Chapter 7 describes the longitudinal associations between serum levels of estrogen, proges-
terone and testosterone and MRI knee structural changes in both males and females with
symptomatic knee OA. For women, progesterone was associated with cartilage volume and
estradiol levels were inversely associated with grades of bone marrow lesions (BMLs), while
estradiol, progesterone and testosterone were inversely associated with effusion-synovitis
volume. No consistent associations were observed for men. This suggests endogenous sex
hormones may be protective for joint structural changes in women but not men, which may
contribute to observed sex differences in knee OA.
Chapter 8 describes the independent association of MRI markers and total knee replacement
(TKR) over 10.7 years in older adults from a general population. MRI markers studied
included cartilage defects, BMLs, effusion-synovitis and meniscal pathologies. Cartilage
defects, BMLs and meniscal tears, but not effusion-synovitis or meniscal extrusion in the
right knee were independent predictors of TKR in either knee over 10.7 years. The presence
of multiple pathologies increased the risk of TKR, suggesting that MRI structural markers
are good predictors of rapid knee OA progression in the general population.
In conclusion, this series of studies indicate that knee OA is a complex disease that is asso-
ciated with systematic factors such as low-grade inflammation, adiposity and sex hormones.
Vitamin D supplementation does not significantly prevent knee cartilage loss and knee pain
ii
in patients with symptomatic knee OA. MRI structural markers are good predictors of end-
stage knee OA in the general population. Future study should continue to validate the utility
of using a panel of MRI biomarkers in predicting clinical endpoints. When developing
disease-modifying OA drugs (DMOADS), systemic and metabolic inflammation should be
a potential treatment target. Further investigation is needed to examine the effects of exoge-
nous hormone replacement therapy on MRI structural changes in women.
iii
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CHAPTER 1
Introduction
1.1 Overview of osteoarthritis
Osteoarthritis (OA) is the most common form of arthritis. It is a chronic joint disease and
commonly affects weight-bearing joints such as the knees, hips and spine, with the hands
and neck also being frequently affected. Primary OA is an idiopathic disease associated with
aging. The disease may be confined to one or two joints, or present in three or more joints in
what is known as generalized OA. Secondary OA is caused by an underlying condition, such
as injury, congenital joint abnormalities, surgery, diabetes and other hormone disorders. The
course of secondary OA involves many similar disease processes as primary OA.
The definition of OA has evolved over the course of the past few decades and it is increas-
ingly recognized that OA is a disease of the whole joint. Although its signature structural
pathology is articular cartilage loss, many other surrounding joint structures are patholog-
ically involved including subchondral bone, ligaments, menisci, periarticular muscles, pe-
ripheral nerves and synovium. The collective changes of these joint tissues result in symp-
toms of pain, stiffness and functional disability [1].
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1.1.1 Epidemiology and economic burden
The prevalence of OA increases with age, in particular after the age of 45 years. The global
age-standardized prevalence of knee OA was 3.8% and hip OA was 0.85%. Knee and hip
OA is ranked as the 11th highest contributor of the 291 conditions to global disability and
38th highest in disability-adjusted life year (DALYs) [2]. In Australia, the burden of OA
was ranked 23rd and the disease was estimated to affect over 1.8 million Australians with
a prevalence rate of 8.0%, according to the 2011-2012 National Health Survey [3]. In in-
dustrialized countries, medical costs of OA account for 1.0% to 2.5% of the gross national
product (GNP) [4]. In Australia, OA and other musculoskeletal conditions were the fourth
most expensive disease group in the year 2008-2009, accounting for 9% ($5.7 billion) of the
total health care expenditure. OA accounted for 29% of this expenditure ($1.6 billion) and
the largest proportion (77%) were spent on hospital costs, mainly associated with knee and
hip joint replacement [5]. OA is expected to become the fourth leading cause of disability
by the year 2020 with increasing life expectancy and an aging population [6].
There are also indirect and intangible costs attributable to OA. The pain and disability which
OA patients experience can lead to a loss of health and well-being, loss of leisure time and
a decreased quality of life. This further contributes to indirect costs of OA through reduced
work performance and productivity, increased absenteeism and loss of production to the
economy as a result of the related disease morbidity [7]. A progressively aging population is
likely to further add to the disease burden and the cost of related health service in Australia.
1.1.2 Symptoms and signs
Pain is the predominant symptom of OA that causes patients to seek medical advice [8]. The
onset is gradual or insidious and the pain experienced is usually intermittent, typically wors-
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ens during and after using the involved joints. Inflammatory flares can happen during the
course of the disease. Initially, pain may be self-limited, pain at rest or during the night sug-
gests advanced or severe OA. Patients also experience joint stiffness, tenderness, a sensation
of instability with clinical signs such as crepitus, restricted range of joint movement, joint
deformity and muscle weakness. These symptoms lead to both physical and psychological
disability, and impaired quality of life [9]. Patients could experience major disability with
daily living activities including walking, stair-climbing and housekeeping.
1.1.3 Risk factors
For decades, OA was thought to be a degenerative joint disease as the result of ’wear and
tear’ that happens in joints as people get older. Research over the last decades has shown
evidence that OA is a multifactorial and complex disease affected by many systemic and
local factors.
Age remains one of the strongest systemic risk factors for the development of OA. The
prevalence of OA defined radiographically rises from nearly zero in young people to a strik-
ing rate of 29% in people aged 65 and over (Figure 1.1). There is a non-linear relationship
between aging and OA. The incidence rate of symptomatic OA increases rapidly around age
50 and then levels off after age 70 (Figure 1.2). The increase in incidence and prevalence of
OA with age is likely a consequence of several biologic changes that occur with aging, in-
cluding a decreased repairing ability of chondrocytes, an increase in laxity of joint ligaments
making older joint relatively unstable, and a failure of major shock absorbers or protectors
of the joint. [10].
Women are more likely to have OA than men. Estimates from Australia indicate that the
prevalence of OA is higher among women than men among all age groups [3]. Women are
more often affected with OA of the hand, foot and knee than men [10] and women also have
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Figure 1.1: Prevalence of osteoarthritis in Australia, 2011–12.
Source: AIHW analysis of unpublished ABS Australian Health Survey, 2011–12
Figure 1.2: Incidence of osteoarthritis between males and females.
Source: D. T. Felson and Y. Zhang. “An update on the epidemiology of knee and hip osteoarthritis with a view to prevention”. In:
Arthritis Rheum. 41.8 (1998), pp. 1343–1355
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more severe OA [11]. Moreover, this sex difference in prevalence increases with age and the
pattern suggests a role of post-menopausal hormone deficiency in increasing the risk of OA.
The role of hormonal factors is reviewed in detail in Section 1.2.4.
Obesity or overweight is perhaps the strongest modifiable risk factor for the development of
OA, especially for knee OA [12]. A 5-unit increase in body mass index is associated with an
35% increased risk of knee OA [13]. Obesity has also been shown to be a strong predictor
of hand OA with an overall risk ratio of 1.9 [14]. The link between obesity and hand OA is
particularly intriguing as it is suggestive of a systemic non-mechanical effect of body fat on
OA through altered metabolic and hormonal profiles [15, 16]. Other systemic factors include
chronic inflammation, vitamin D deficiency, ethnicity, congenital conditions and genetics.
Local risk factors for OA affects joints independently. While most local risk factors do not
increase the odds of OA in all sites of the body, some may be shared by some joints. In addi-
tion to metabolic effects, obesity and overweight could lead to increased risk of OA through
increases to mechanical loadings [17], particularly in the knee [18]. It is well understood
that injury is a strong local risk factor for OA [19]. Injury can cause damages to a number of
structural tissues, including cartilage, ligaments and meniscus, which can result in increased
risk of development of hip and knee OA [20, 21]. Inflammation is usually induced during
tissue repair due to injury, and the increase in inflammatory mediators may negatively affect
cartilage metabolism, predisposing the subjects to OA [22]. Malalignment of the knee can
increase the risk of OA progression by 4 to 5 times in the tibiofemoral compartment [23] or
2 times in the patellofemoral compartment [24]. Exercise is considered to have dual roles in
OA. While mild to moderate non-painful exercise in the absence of existing joint condition is
considered to have a beneficial effect [25], which may be mediated by muscle strengthening
[26], high-intensive and long-term weight bearing exercise may be associated with increased
risk of OA development [27].
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1.1.4 Knee osteoarthritis
The knee is the most common joint affected by OA. Nearly one in two adults will develop
symptomatic knee OA by the age of 85 with an estimated lifetime risk of 44.7% [28]. Knee
OA is the most common cause of knee pain in people over 50 years old. Frequent knee pain
affects approximately 25% of older adults [29] and it is the most important factor determin-
ing disability and a major reason for knee replacements in those with clinical knee OA [30].
The research conducted in this thesis focuses on knee OA.
Knee OA can be defined radiologically by structural pathology and diagnosed clinically
using joints symptoms. Many studies combine both of these for the purpose of an epi-
demiologic investigation, using the term radiographic osteoarthritis (ROA) and symptomatic
osteoarthritis.
Radiographic criteria
Conventional radiographs remain the gold standard for the diagnosis of knee OA. The first
criteria for definition of ROA were introduced in 1957 by Kellgren and Lawrence [31].
The Kellgren and Lawrence (K/L) grading system is an ordinal 5-point scoring system that
includes radiographic assessment of joint space narrowing (JSN) and osteophytes. The K/L
scoring system is displayed in Table 1.1. In 1961, the K/L scoring system was accepted as
standard criteria by the World Health Organization. Since then, it has been extensively used
in epidemiological studies. Figure 1.3 highlights joint space narrowing and osteophytes on
a radiograph.
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Table 1.1: Kellgren and Lawrence (K/L) grading system
Definition grades Description
Grade 0: Normal No osteoarthritis
Grade 1: Doubtful Doubtful narrowing of joint space and possible osteophytic lipping.
Grade 2: Mild Definite osteophytes and possible narrowing of joint space.
Grade 3: Moderate Multiple osteophytes, definite narrowing of joint space and some
sclerosis and possible deformity of bone ends.
Grade 4: Severe Large osteophytes, marked narrowing of joint space, severe sclerosis
and definite deformity of bone ends.
Figure 1.3: Joint space narrowing and osteophytes.
Joint space narrowing (yellow arrows), osteophytes (white arrows) and subchondral sclerosis (green arrows)
Source: A. Horng. “Gonarthrosis radiology: cross-sectional imaging in conventional diagnostic radiography”. In: ASU International.
9.2 (2015)
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Clinical criteria
Although the presence of radiographic knee OA carries a definite predisposition to symptoms
in the knee, there are potential limitations to the use of only radiographic criteria in clinical
research studies, because some people with radiographic knee OA have no symptoms in the
knee [33]. The American College of Rheumatology (ACR) defines symptomatic knee OA as
frequent knee symptoms defined as ”pain, aching, or stiffness in or around the knee on most
days” for at least one month during the past 12 months[34]. This definition has been used in
many epidemiological studies.
1.1.5 Treatment and management
Despite the high prevalence and severe socioeconomic burden of knee OA, there are no
registered disease-modifying osteoarthritis drugs (DMOADs) available to modify structural
progression. Proven preventive strategies are also quite limited as its etiology is not well es-
tablished. Current therapeutic treatments for knee OA are mostly palliative and focus on the
relief of pain. According to the ACR guideline 2012 [35], analgesics such as acetaminophen
[36, 37], oral or topical non-steroidal anti-inflammatory drugs (NSAIDs) [36] or more po-
tent painkiller tramadol are conditionally recommended for the pharmacologic management
of knee OA. Intraarticular injections with corticosteroid are recommended as an alternative
approach if acetaminophen or NSAIDs does not have a satisfactory clinical response [38].
These treatments often are only moderately effective, with over 75% of patients reporting
need for additional symptomatic treatment [39].
There is an emphasis on non-pharmacological management for knee OA including weight
loss, education and exercise. Recent guidelines published by the American Academy of
Orthopedic Surgeons (AAOS), ACR, the European league against rheumatism (EULAR)
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and Osteoarthritis Research Society International (OARSI) consistently recommend weight
management program for overweight patients with knee OA [40, 41, 35, 42]. A system-
atic review and meta-analysis found moderate weight reduction regime reduces pain and
physical disability for overweight patients with knee OA [43]. An exercise program is also
strongly recommended for all patients with symptomatic knee OA. A number of system-
atic reviews and meta-analyses have demonstrated small to moderate short-term benefits of
aerobic, resistance land-based [44, 45, 46, 47] and water-based exercises [48, 49, 50].
As many as 40% of patients with knee OA have used at least one dietary supplement to treat
their condition [51]. Dietary supplements containing cartilage synthesis precursors, such
as glucosamine and chondroitin are among the most popular products for OA. However,
the efficacy of these supplements are uncertain. Results from various systematic reviews
showed small to non-existent effect in symptom relief and disease modification with a high
degree of heterogeneity between included trials [52, 53, 54, 55, 56]. Therefore, they are not
generally recommended in clinical practice. Although dietary vitamin D supplementation is
not mentioned in the clinical guidelines, there is possible benefit to patients with knee OA
and it is discussed in the Section 1.2.3.
Surgical interventions are generally reserved for patients with advanced stage of OA when
non-surgical treatments are no longer effective [36]. Arthroscopic lavage and debridement
smooths out the rough portion of cartilage or meniscus and removes loose fragments of tis-
sue. However, the evidence from systematic reviews shows that arthroscopic surgery is not
effective for managing knee OA, because the inconsequential benefit of arthroscopic surgery
is limited in time and absent at one to two years after surgery [57, 58, 59]. Osteotomy in-
volves the removal of bone to reshape joints to correct malalignment [40]. Knee replacement
is the removal of large portions of bone and cartilage and substitution with artificial artic-
ulating surfaces. Knee replacement improves both symptoms and function and is indicated
for end-stage knee OA [60].
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1.2 Systemic factors of knee OA
Knee OA is a disease process driven by multiple risk factors. Some well-known risk factors
for knee OA including aging, obesity, gender, and genetic factors have been extensively
studied. This section reviews the literature of less well-established risk factors for knee
OA that could impact the knees through their effects on systemic metabolism rather their
contribution to the local joint structures. These systemic risk factors include obesity, low-
grade systemic inflammation, vitamin D deficiency and sex hormones.
1.2.1 Obesity
Knee OA and obesity are the two conditions whose prevalence are accelerating worldwide
[61]. The increasing prevalence of knee OA is likely linked to the increasing proliferation
of obesity. It is now recognized that knee OA exists in the highly metabolic environment of
obesity.
Obesity is usually defined as having a body mass index (BMI) more than 30 kg/m2. Although
the definition of obesity based on BMI was not widely adopted until the 1990s [62], obesity
has long been recognized as a risk factor for prevalent OA, especially knee OA [63, 64,
65]. Data from the Chingford study suggested that women in the highest tertile of BMI had
six-fold increased odds of knee OA and nearly 18 times higher odds of bilateral knee OA,
compared with women in the lowest tertile of BMI [66]. More recently, a systematic review
of 23 cohort studies demonstrated that all studies were consistent in reporting obesity as a
risk factor for the onset of knee OA in older adults with a pooled odds ratio (OR) of 2.66
[67].
In addition to the mechanical impacts on the knees, it is increasingly recognized that the
inflammatory environment associated with obesity contributes to the development and pro-
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gression of knee OA. Adipose tissue, once considered a passive storage portal of energy, is
now recognized as a highly metabolic endocrine organ with the capacity to secrete active
agents including adipocytokines, such as leptin, resistin, adiponectin and visfatin [68]. In
patients with knee OA, leptin, adiponectin and resistin levels have been detected in the syn-
ovial fluid [69, 70]. Adipocytokines acting in an autocrine or paracrine manner regulate the
expression of proteolytic enzymes such as metalloproteinases (MMPs) as well as inflamma-
tory cytokines, nitric oxide (NO) and prostaglandins (PGEs). Leptin is positively correlated
with BMI, body weight and fat mass percentage. Leptin was shown to be pro-inflammatory
as it enhanced NO synthesis, PGE2, interleukin-6 (IL-6) and IL-8 secretion in knee OA car-
tilage [71]. The presence of the soluble leptin receptor is associated with reduced cartilage
synthesis and increased cartilage degradation marker in knee OA [72]. Adiponectin may
have a protective effect on knee OA. In vitro, Chen and colleagues showed the protective
effect of adiponectin on articular cartilage by up-regulating the tissue metalloproteinase in-
hibitor (TIMP-2) and decreasing IL-1β mediated MMP-13 expression [70]. In patients with
knee OA, adiponectin levels in both plasma and synovial fluid decreased significantly as the
severity of OA increased [73] and the adiponectin to leptin ratio in synovial fluid was found
to predict reduced knee pain [74].
However, not all obese persons develop knee OA, nor are all individuals with knee OA obese
[75]. Because BMI is calculated based on weight and height, it is only a surrogate measure
of obesity which cannot discriminate fat and lean mass. It is increasingly clear that BMI is
a rather poor indicator of the percentage of body fat mass. Indeed, waist-to-hip and waist
circumference were better measures of central adiposity and were better predictors of knee
OA incidence than BMI [76]. Also, fat mass and muscle lean mass had a better statistical fit
than BMI to explain the odds of having and the severity of knee OA [77]. Furthermore, Ding
and colleagues suggested that body fat was a better predictor than BMI for tibial cartilage
loss. Body fat mass and muscle lean mass may have opposite effects on knee cartilage loss
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[78] and knee pain [79]. While body fat mass was associated with more cartilage volume loss
and increased knee pain, muscle lean mass appeared to be protective. Similar detrimental
effect of fat mass and a beneficial effect of lean mass on knee cartilage volume was found
in healthy adults [80]. Cicuttini and colleagues also showed that reduced lean mass was
associated with reduced tibial cartilage volume [81]. Taken together, these studies suggest
that body composition, in addition to excessive body weight measured by BMI, may play
an important role in the structural and symptomatic changes of knee OA. However, neither
of two longitudinal studies showed a significant relationship between body composition and
tibiofemoral cartilage defects or the progression of tibiofemoral cartilage defects [80, 81].
In a systematic review and best evidence analysis, Mezhove and colleagues suggested that
larger and longer cohort studies are required to understand the role of body fat distribution
in the risk of knee OA, because of a limited number of cohort studies having significant
findings between obesity and knee cartilage [82].
1.2.2 Inflammation
Knee OA has traditionally been classified as noninflammatory arthritis. This belief was
based on the observation that there are fewer leukocytes in knee OA synovial fluid com-
pared to rheumatoid arthritis, reactive arthritis and septic arthritis. Moreover, the only cell
type present in cartilage, chondrocytes, have very low metabolism activity with no ability to
repair cartilage. Once the articular cartilage is damaged, it cannot respond to the damage by
a usual inflammatory response because it is non-vascularized and non-innervated [83]. This
paradigm has been shifted in the last few decades as inflammation is increasingly recognized
as an important contributor to the symptoms and progression of knee OA [84]. The discovery
that inflammatory mediators such as cytokines or prostaglandins can increase the production
of MMPs by chondrocytes brought about the inflammatory theory. Many studies have ob-
served the presence of synovitis under arthroscopy, magnetic resonance imaging (MRI) or
12
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ultrasonography in knee OA and it is associated with increased risk of radiographic knee OA
[85, 86]. The mechanism leading to synovitis in knee OA remain controversial [87]. The
most accepted hypothesis is that joint trauma or overuse triggers cartilage degradation, then
cartilage fragments fall into the joint and contact the synovium. Because the cartilage debris
is considered as foreign bodies, synovial cells react by producing inflammatory mediators
and releasing them in synovial fluid. These mediators can activate chondrocytes present in
the superficial layer of cartilage, which leads to MMP synthesis and eventually increase car-
tilage degradation. Theses inflammatory mediators also induce synovial angiogenesis and
increase the production of inflammatory cytokines and MMPs by synovial cells. Tissue dam-
age, synovial activation, inflammation and cartilage degradation turn into a self-perpetuating
vicous cycle.
Additionally, inflammation occurring within the joint tissue may be reflected outside the
joint in patients with knee OA. C-reactive protein (CRP) is an acute-phase protein that is
produced by hepatocytes and regulated by the pro-inflammatory cytokine interleukin (IL)-6
in response to both acute and chronic inflammation. It has a constant half-life of 19 hours so
the sole determinant for circulating CRP level is the synthesis rate [88]. This unique property
of CRP makes it an excellent marker used to measure chronic systemic inflammation. One of
the key epidemiology studies conducted by Specter and colleagues demonstrated that serum
levels of CRP are strongly associated with the development and progression of knee OA
[89]. Another study by Pearle and colleagues showed a positive correlation between serum
CRP levels and histological evidence of synovitis and synovial fluid IL-6 at the time of joint
replacement [90]. Other studies showed that the levels of several inflammatory mediators
were higher in OA than healthy serum [91, 92]. These observations strongly suggest that the
systemic inflammation observed in knee OA is at least partially reflective of local synovial
inflammation.
The source and type of inflammation may differ by OA phenotypes. Bijlsma and colleagues
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proposed the division of OA into distinguishable phenotypes [93]. In post-trauma pheno-
type, damage of the cartilage causes the triggered chondrocytes to release pro-inflammatory
autocrine factors, which in turn trigger a local inflammatory response (synovitis) that accel-
erates the cartilage breakdown. This inflammatory activity is enhanced by the accelerated
release of catabolic cartilage constituent [94, 95]. In the aging phenotype, inflammation is
triggered by external mediators such as cytokines and proteases, as well as internal cellular
mechanisms leading to increased production of inflammatory mediators and lack of elimina-
tion of oxidated proteins. These proteins will, in turn, increase the concentration of reactive
oxygen species (ROS) in cells, further adding to the oxidative damage triggering the inflam-
mation [96]. Interestingly, oxidative stress can promote cell senescence, and in particular
chondrocyte senescence [97]. In obesity phenotype, the inflammatory theory could be ex-
plained by adipokines that are released mainly by abdominal adipose tissue [98]. Systemic
adipokines were found associated with local synovial tissue inflammation [99] and serum
adipokine concentration was associated with OA severity [100, 101]. Interestingly, recent
clinical studies have suggested that metabolic syndrome (MetS) rather than obesity itself
has the greatest impact on the initiation and severity of knee OA [102, 103, 104]. Lastly,
calcium pyrophosphate dihydrate and basic calcium phosphate crystals are common in knee
OA joint fluids and tissues [105]. These crystals may trigger innate immune responses lead-
ing to catabolic responses in chondrocytes and synovitis [106]. Figure 1.4 shows a diagram
for the role of inflammation in the pathogenesis of knee OA according to phenotype.
1.2.3 Vitamin D
Vitamin D is a fat-soluble secosteroid comprising two major molecules, vitamin D2 and
vitamin D3. Sun exposure is the major way to produce vitamin D in most humans [107].
Very few foods in nature contain vitamin D, such as the flesh of fatty fish and fish liver
oils [108]. Vitamin D from the skin and diet is circulated to the liver and converted to
14
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Figure 1.4: The role of inflammation in the pathogenesis of knee OA according to phenotype.
For each phenotype, the main pathway leading to the release of inflammatory mediators by the joint is highlighted. However, some
pathways are shared between phenotypes.
the prohormone calcidiol, or 25-hydroxyl vitamin D (25OHD), which is the most reliable
indicator of vitamin D status [109].
It is well known that vitamin D has important roles in bone health [110]. Vitamin D de-
ficiency not only causes rickets among children [111] but also precipitates and exacerbates
osteoporosis among adults and causes the painful bone disease osteomalacia [112]. In recent
decades, epidemiological studies suggested serum vitamin D levels were associated with the
risk of cancers [113], autoimmune diseases [114], type 2 diabetes [115], and cardiovascular
diseases [116].
Vitamin D deficiency, defined as a serum concentration less than 50 nmol/L, is very common
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in older people. It is estimated that 40 to 100% of U.S. and European elderly men and
women are deficient in vitamin D [107]. High rates of vitamin D deficiency have also been
reported in Australia, especially in the southern states including South Australia, Victoria
and Tasmania [117, 118, 119]. Knee OA frequently co-exists with vitamin D deficiency in
older adults, suggesting a link between them [120].
In vitro study has demonstrated that vitamin D receptors (VDRs) are expressed in human
articular chondrocytes in osteoarthritic cartilage and 1α,25− (OH)2D3 may regulate the
expression of MMPs and PGE2 in chondrocytes via VDRs [121]. It is hypothesized that
vitamin D could reduce bone turnover and cartilage degradation, thus preventing the devel-
opment and progression of knee OA [122, 123].
Epidemiological studies have shown evidence that supports a link between vitamin D and
knee OA. In the Framinghan study, dietary intake and serum levels of vitamin D were found
associated with progression of knee OA [124]. In the Rotterdam study, low dietary vita-
min D intake increased the risk of progression of knee ROA [125]. Recent data from the
Osteoarthritis Initiative (OAI) study suggested that individuals deficient in vitamin D had
an increased risk of knee OA progression [126]. Also, vitamin D deficiency was cross-
sectionally associated with knee pain [127] and was an independent predictor of worsening
knee pain in older adults [128]. All these suggest that correction of vitamin D deficiency
using supplementation could be beneficial in knee OA. However, results from two random-
ized controlled trials (RCTs) appear controversial [129, 130]. Both RCTs have limitations.
The first RCT included patients without vitamin D deficiency who may not benefit from vi-
tamin D supplementation and patients whose disease was too severe to respond to vitamin D
treatment. Also, it had a small sample size [129]. The latter RCT did not examine structural
changes and had one-year follow-up, which may be too short to observe disease progression
[130]. Further clinical trials are needed to address these limitations in methodology and
confirm the benefit of vitamin D supplementation for knee OA.
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Table 1.2: Cohort studies for the association between 25OHD and knee OA
Study Assessment of OA Follow-up (years) Adjustment Results
Ding 2009 [120] MRI tibial cartilage vol-
ume loss
2.9 Age, sex, BMI, smoking,
steps per day, knee pain,
cartilage defects, season,
tibial bone area, ROA and
disease status
Baseline 25OHD was as-
sociated with reduced car-
tilage volume loss; vi-
tamin D deficiency pre-
dicted increased cartilage
loss.
McAlindon 1996 [124] Modified KL score, JSN
and OP
8 Age, sex, BMI, weight
change, physical activity,
knee injury, energy intake
and health status
Lower tertile of 25OHD
predicted knee JSN, OP
and ROA progression but
not incident ROA.
Bergink 2009 [125] KL score, JSN and OP 6.5 Age, sex, BMI, BMD,
smoking, health status,
disability index, fall ten-
dency, baseline JSN and
season
Lowest tertile of 25OHD
was associated with inci-
dence of JSN in women
and progression of ROA.
Konstari 2012 [131] Definite and probable
knee OA diagnosed by
physician
22 Age, sex, BMI, education,
physical workload, smok-
ing, leisure physical activ-
ity, injuries and season
No association between
serum 25OHD and the in-
cidence of knee OA, but
the effects differ in season.
Felson 2007 [132] KL score, JSN and OP;
MRI WORMS assessment
for cartilage loss
9.5 or 2.5 Age, sex, BMI, weight
change and baseline KL
score
25OHD was not asso-
ciated with radiographic
worsening (JSN and OP)
and cartilage loss.
Zhang 2014 [126] Incidence and progressive
knee JSN
2 Age, sex, ethnicity, BMI,
physical activity, alco-
hol intake, smoking,
dietary vitamin D and
calcium, season, and knee
injury/surgery
Low 25OHD (<15ng/ml)
increased the risk of JSN
progression by >2-fold
compared to greater
25OHD concentrations.
ROA, radiographic osteoarthritis; JSN, joint space narrowing; OP, osteophyte; BMD, bone marrow density; WORMS, Whole-Organ Magnetic Resonance
Imaging Score.
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Table 1.3: Comparison of two randomized controlled trials on vitamin D for knee OA
McAlindon 2013 [129] Sanghi 2013 [130]
Participants 146 patients with symptomatic
knee OA
107 patients with knee OA with vi-
tamin D insufficiency
25OHD level 55.7±24.7 nmol/L <50 nmol/L
Intervention Oral vitamin D3 2,000IU/day Vitamin D2 60,000IU/day for 10
days followed by 60,000IU/month
Follow-up 2 years 1 year
Outcomes WOMAC for pain; WOMAC, VAS for pain;
cartilage volume loss assessed us-
ing MRI
KL scoring for radiographic OA
Conclusion Vitamin D had no symptom or
structure-modifying benefits for
knee OA
Vitamin D intake was beneficial
in improvement of knee pain and
physical function in knee OA; no
significant difference in radiologi-
cal features in both groups
1.2.4 Sex hormones
Sex hormones have long been considered a possible systemic factor for OA, especially in
women [133, 134]. The prevalence of knee OA in men and women are similar up to the age
of 50, however, after menopause women have a significantly higher prevalence of knee OA
than age-matched men [135, 136], suggesting an influence of hormonal factors in the patho-
genesis of the disease. The relationship between hormonal changes due to menopause and
OA was first described in a group of women with Herberden’s nodes characterized by a rapid
onset of symptoms and multiple joint involvement. The term ‘menopausal arthritis’ was
used to described the condition and was later changed to ‘primary generalized osteoarthritis’
[137].
Numerous studies have been carried out to evaluate the relationship between estrogen and the
development of knee OA. Two types of estrogen receptor (ER) are widely but differentially
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expressed in most tissues and organs [138]. ER−α is highly expressed in the hypothalamus,
where it plays a pivotal role in regulating food intake and energy expenditure by estrogens.
ER−β , on the other hand, has an important role in tissue homeostasis such as bone and
cartilage stabilization [139]. Estrogen has been demonstrated by in vitro studies to have
protective effects on articular cartilage [140, 141, 142]. Moreover, the protective effect
of estrogen appears to be sex-dependent as the chondroprotective effect was found only in
female chondrocytes [141, 143, 144].
However, the findings from epidemiological studies regarding the risk of knee OA in relation
to endogenous and exogenous sex hormones are conflicting. In the Southeast Michigan
Arthritis Cohort, women having lower baseline concentrations of endogenous estradiol had
an increased risk of developing radiographic knee OA [145]. Some studies have shown that
women receiving estrogen therapy had a lower risk of developing radiographic knee OA
and that the protective effect increased with increasing duration of estrogen therapy [135,
146, 147]. The results from the Framinghan Study showed that current use of estrogen
replacement therapy had a moderate, although not statistically significant, protective effect
against worsening of radiographic knee OA [148]. Similarly, the findings from the Women’s
Health Initiative also showed that women taking estrogen with more than 80% compliance
had a 50% reduction in total knee joint replacement [149]. In contrast, there are other studies
which have shown no effects of post-menopausal hormone replacement on knee OA. In a
randomized clinical trial in a group of older post-menopausal women with heart disease,
no significant difference was found in terms of knee pain or associated disability between
those who were on estrogen plus progestin therapy and those taking placebo [150]. In a
recent systematic review, no clear association was observed between female sex hormones
and knee OA [151], suggesting that relationship may be too complex or that other unknown
mechanisms may play a role in the increased prevalence of knee OA in menopausal women.
In summary, while there is a growing body of evidence that suggests a protective effect
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of estrogen on cartilage and radiographic knee OA, it remains uncertain whether it has a
beneficial effect on MRI structural biomarkers or total knee replacement due to a lack of
long-term studies. Hormone replacement therapy is currently not recommended as a first-
line treatment against the progression of knee OA, considering that the health risks of HRT
may outweigh the potential benefit [152].
1.3 MRI structural biomarkers
The current imaging standard for evaluating structural changes associated with OA is plain
radiography. Although plain radiography, which mainly focuses on joint space narrowing
and osteophytes, is useful for the diagnosis of knee OA, it is only weakly associated with
clinical symptoms and it is a poor predictor of cartilage loss and total knee replacement
[153]. Plain radiography is also not sensitive to structural changes. By the time when struc-
tural changes are present on a radiograph, an estimate of over 10% of knee cartilage has been
lost and over 40% patients have had cartilage defects [154]. In addition, joint space narrow-
ing observed on knee radiograph does not distinguish cartilage volume loss and meniscal
pathologies [155].
MRI has become an increasingly popular research tool for evaluating structural changes of
knee OA in recent decades. The main advantage of MRI over traditional knee radiography
is the ability to perform a holistic, three-dimensional assessment of early structural changes
that are not discernible on x-ray. MRI can show the direct visualization of cartilage, sub-
chondral bone, effusion-synovitis, menisci and other joint tissues in multiple tomographic
planes. MRI can detect the presence of OA with high specificity and moderate sensitiv-
ity compared with radiography and arthroscopy [156]. The most promising MRI structural
biomarkers identified in systematic reviews with respect to reliability, responsiveness and
validity, were quantitative cartilage morphometry, cartilage defects and bone marrow lesions
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on semi-quantitative analysis [157]. These structural pathologies were found associated with
clinical and structural progression of knee OA [158, 159, 160, 161, 162]
1.3.1 Cartilage volume
Loss of cartilage is the primary feature of knee OA progression. Comparative analysis stud-
ies demonstrated that MRI-based knee cartilage volume measurement is highly accurate with
an error of less than 10% compared to the volume estimated by means of water displacement
[163, 164, 165]. Regardless of the health status of the patients, the coefficient of variation
(CV) is less than 5% for intra-observer reliability and up to 7.8% for inter-observer reliabil-
ity [165, 166]. These studies demonstrated that knee cartilage volume can be accurately and
reproducibly measured by the same scanner and a single experienced reader. Various meth-
ods have been developed to semi-automatically measure the whole cartilage volume (Figure
1.5) in the knee [167, 168].
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Figure 1.5: Cartilage volume segmentation on MRI.
Cartilage segmentation using improved watershed transform and 3D reconstruction for whole cartilage volume measurement.
Source: V. Grau et al. “Improved watershed transform for medical image segmentation using prior information”. In: IEEE Trans Med
Imaging 23.4 (2004), pp. 447–458
Higher knee cartilage volume without defects may reflect healthier hyaline cartilage. Ci-
cuttini et al reported that quantitative cartilage volume measured on MRI is considered an
accurate method for assessing cartilage health and changes in cartilage volume predict future
need for surgical intervention in patients with mild to moderate symptomatic radiographic
knee OA [169]. MRI cartilage volume loss is found to have a significantly high correlation
with radiographic assessment [170]. Both medial and lateral tibial cartilage volume shows a
strongly inverse association with radiographic joint space narrowing [171].
Cartilage volume loss measured by MRI may be associated with knee pain and may predict
change in symptoms. Wluka et al reported that symptoms of knee OA, including pain, stiff-
ness and function, are inversely but weakly associated with tibial cartilage volume. Also,
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there is a weak association between increased tibial cartilage volume loss and worsening of
symptoms in knee OA [172]. Similarly, Raynaud et al found a weak association of cartilage
volume loss with simultaneous knee pain change over 24 months [173]. The greatest carti-
lage volume loss is found in the central area of the medial tibial plateau and of the medial
femoral condyle [174].
These studies have also found that cartilage volume loss was predictive of the occurrence of
total knee replacement. Cicuttini et al found that 1% increase in tibial cartilage volume loss
over two years was associated with a 20% increase in risk for surgery and patients with tibial
cartilage volume loss over 8% had a higher risk for surgery than those with less than 3% loss
[169]. This result was confirmed by Raynauld and colleagues that medial cartilage volume
loss over two years was a strong predictor for total knee replacement over 4 to 7 years [175].
1.3.2 Cartilage defects
In addition to quantitative assessment of cartilage volume, semi-quantitative measurement
of focal cartilage defects is another way to evaluate the morphological characteristics of re-
gional articular cartilage. Cartilage defects are localized lesions or tears within the cartilage
visible on T1-weighted or T2-weighted MRI (Figure 1.6) [176]. Knee cartilage defects are
very common in healthy individuals [177, 178]. Cartilage defects have a relatively variable
natural history, but they are less likely to regress in older adults than in younger population
[178]. Although the etiology of cartilage defects remains unclear, they are often thought to
be related to trauma [179] and could be an important MRI marker of early cartilage damage.
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Figure 1.6: Development of a focal cartilage defect over 24 months.
(A) Coronal intermediate-weighted image showing a small superficial cartilage defect in the weight-bearing part of the medial femoral
condyle (arrow). (B) Follow-up MRI at 12 months reveals extension of defect to the subchondral bone, now representing a full-thickness
focal lesion (arrow). (C) MRI image at 24 months showing a slight increase in the size of the focal full thickness defect.
Source: Role of imaging in osteoarthritis: diagnosis, prognosis, and follow-up.
http://www.medicographia.com/2013/10/role-of-imaging-in-osteoarthritis-diagnosis-prognosis-and-follow-up/.
Cartilage defects are associated with radiographic features of knee OA measured using
Kellgren-Lawrence score [180, 181, 158]. In a study of 224 patients with symptomatic knee
OA, the grade of cartilage defects was associated with joint space narrowing [182]. Simi-
larly, osteophyte score has been shown to be correlated with the grade of cartilage defects
[158, 183].
The severity of cartilage defects has been shown associated with knee pain in a number of
studies [172, 154, 159, 160]. One study found that the grades of cartilage defects were
associated with clinical symptoms including pain, stiffness and limited function assessed by
WOMAC scores [158]. The correlation between cartilage defects and knee pain has been
reported in particular when the defect was moderate to severe (grade 2-3) on a modified
Outerbridge scoring system [161, 162], and full-thickness cartilage defects accompanied by
subchondral bone exposure were most significantly associated with pain in knee OA [159].
While cartilage defects are not synonymous with cartilage loss, there is a dose-response
relationship between cartilage defect score and cartilage volume loss [183]. However, there
was only a moderate correlation between histology of grade 1 cartilage defect (abnormal
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intrachondral signal) and cartilage breakdown [184]. Cartilage defects are also associated
with bone marrow lesions [185] as full-thickness cartilage defects expose the subchondral
bone plate to increased loading pressure leading to bone injury.
Cartilage defects are predictive of total knee replacement. One study in a population with
established OA showed that higher total cartilage defect scores increased the risk of joint
replacement over 4 years by six times compared to those with lower scores [186]. This
finding was confirmed in a population-based cohort study where knee cartilage defects were
found to independently predict the risk of total knee replacement over 5 years [178].
1.3.3 Bone marrow lesions
Bone marrow lesions (BMLs) on MRI have been recognized as an important feature in knee
OA [187, 188]. They are characterized as non-cystic ill-defined subchondral areas of low
signal intensity on T1-weighted and high signal intensity on T2-weighted or proton density-
weighted fat-suppressed (FS) fast spin echo (FSE) or short tau inversion recovery (STIR)
images (Figure 1.7) [189].
Figure 1.7: Bone marrow lesions on T1-weighted (left) and STIR (right) MRI scans.
Sagittal T1-weighted (left) and STIR (right) images demonstrate bone marrow lesions at the patellofemoral compartment (arrows).
Source: Osteoarthritis (OA) of the Knee. Radsource. http://radsource.us/osteoarthritis-oa-of-the-knee/.
Regional bone marrow signal intensity alteration on MRI was initially described by Wilson
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et al, using the term ‘bone marrow edema’ to describe MRI findings in patients with severe
knee and hip pain without any specific radiographic abnormalities [190]. Since then, histo-
logical studies have shown that various pathologic entities could exhibit the same pattern on
MRI, not only edema [191, 192, 193]. Histological study by Zanetti et al found that BMLs in
knees in subjects with severe OA undergoing total knee replacement consisted of several ab-
normalities including bone marrow necrosis (11%), abnormal trabeculae (8%), bone marrow
fibrosis (4%), bone marrow edema (4%), and bone marrow bleeding (2%) [194]. Recently,
Hunter et al [195] demonstrated that BMLs are sclerotic compared with unaffected regions
from the same individual based on the increased bone volume fraction and increased trabec-
ular thickness. As a result, the term ‘BML’ has become more commonly used in the OA
research community [196].
There is increasing evidence linking BMLs to knee pain. In a cross-sectional study in pa-
tients with knee OA, Felson et al found that BMLs were associated with the presence of
knee pain and large lesions appeared exclusively in those with pain [187]. Similarly, Sowers
et al reported that BMLs >1 cm were more frequently found in the painful knee OA group
than the painless knee OA group [159]. The cross-sectional association between BMLs and
pain was confirmed by Zhai et al in a population-based study of older adults [161]. The
longitudinal relationship between progression of BMLs and pain was also observed in a
number of prospective cohort studies. Data from the Multicenter Osteoarthritis (MOST)
Study showed that incidence or progression of BMLs was higher at follow-up in subjects
with pain than those without [197] and changes in BMLs were associated with fluctuation in
knee pain [198]. Similarly, in a prospective study in community-dwelling older adults, Dore
et al found that a change in BML size was associated with changes in pain in those with early
stage disease [199], although some studies reported no association between pain and BMLs
[200, 201, 158]. A recent systematic review including 9 cohort, 18 cross-sectional and 5
case-control studies concluded that BMLs are independently associated with longitudinally
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increasing pain severity and are associated with incident frequent knee pain [202].
It has been suggested that BMLs may be an early MRI biomarker for knee OA and an
independent predictor of structural progression in knee OA. Studies have shown that BMLs
predict cartilage defect progression [203, 204, 205, 206] and cartilage volume loss [207, 173,
174, 208, 209] on MRI. Increasing or progressive BMLs are also associated with increased
cartilage loss [210, 211, 212]. Despite the fact that BMLs predict cartilage damage, it still
remains unclear whether BMLs precede, accompany, or follow cartilage damage and volume
loss in OA [208].
A handful number of studies have also examined the predictive ability of BMLs for total
knee replacement [199, 213, 214, 175]. In one study, Tanamas et al showed that the severity
of BMLs was positively associated with the risk of total knee replacement over four years
in 109 patients with well-established knee OA [214]. In a recent study by Roemer et al, the
risk of total knee replacement was significantly increased in knees with BMLs in more than
two subregions [215]. However, most of the studies examined total knee replacement in a
severe knee OA sample which has very high rates of total knee replacement, therefore, it is
unknown whether BMLs in a community-based sample also predict total knee replacement.
1.3.4 Effusion-synovitis
Synovitis is a common feature of knee OA and occurs in nearly 90% of patients [216]. Be-
cause definite synovitis is present in 96.3% knees with effusion [216] and non-enhanced MRI
(Figure 1.8) could not readily differentiate synovitis and effusion [217], the term ‘effusion-
synovitis’ indicates that MRI-detected joint effusion equals both inflamed synovium and
synovial fluid. Effusion-synovitis could present in different regions within the knee joint,
including peri-patellar areas, intercondylar region and around the anterior and posterior cru-
ciate ligament [216].
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Figure 1.8: Comparison of contrast-enhanced MRI and non-contrast enhanced for synovitis.
Contrast-enhanced T1-weighted (left) and non-contrast DESS (right) demonstrate effusion-synovitis (*) at the suprapatellar pouch.
Source: MRI Assessment of Synovitis. http://med.stanford.edu/bmrgroup/Research/musculoskeletal-mri.html.
Effusion-synovitis could occur in early stages of knee OA [218, 219] and is frequently cor-
related with pain or other clinical outcomes [220, 221]. One study by Torres et al examined
the relationship between specific tissue lesion and pain severity in 143 patients with knee OA
found that higher grades of effusion-synovitis were significantly associated with the increase
in pain severity [160]. A more recent study reported that the association between effusion-
synovitis and knee pain may be independent of other structural markers. Effusion-synovitis
was more correlated with non-weight-bearing pain, suggesting an important role of inflam-
mation [222]. The association with knee pain was strongest when effusion-synovitis was
present within the infra-patellar and supra-patellar areas [223].
It has been suggested that effusion-synovitis in knee OA predisposes to further structural
progression [224, 85, 225]. One study using arthroscopy as a reference standard demon-
strated a positive correlation between the severity of synovitis and the degree of progression
of cartilage lesions over time [86]. Roemer and colleagues examined 514 knees without OA
and found that the risk of cartilage loss was significantly increased in knees with effusion-
synovitis [85]. More recently, Wang and colleagues reported that effusion-synovitis not only
independently predicted the progression of cartilage defects, but also the worsening of BMLs
in a general older population over 3 years [225].
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There are only a few studies which examined the predictive value of effusion-synovitis for
TKR [226]. A large prospective study followed over 500 subjects with knee OA for 3 years
demonstrated that the presence of a joint effusion at baseline was a significant predictor of
joint replacement at 3 years [227]. A more recent study by Roemer and colleagues reported
that the risk of TKR in the subsequent 12 months was significantly increased for knees that
exhibited effusion-synovitis at two or more subregions, compared with knees that did not
[215].
In summary, MRI has become an important tool to visualize multiple tissues abnormalities
in knee OA. Further investigation is needed to examine the predictive validity of these MRI
biomarkers for TKR over the long term. Chapter 8 describes the association between these
MRI biomarkers and the risk of TKR over 10 years in a general older population.
1.4 Summary
OA is the most common form of arthritis and the knee is the most common joint affected
by OA. It is affecting over 1.8 million Australians or 8% of the population. By 2050, it
is projected that there will be 3.1 million Australians or 11% of the population with OA.
It is a leading cause of disability and costs Australians $1.6 billion of the total health care
expenditure in the year 2008-2009.
Currently, there are no approved disease-modifying treatments available for knee OA. There
is an urgent need for identifying modifiable risk factors for this disease. Systemic risk factors
such as obesity, low-grade systemic inflammation, vitamin D and sex hormones insufficiency
may contribute to the disease development through systemic metabolic mechanisms.
It has become clear that knee OA is a disease of the whole joint. MRI is becoming a popular
research tool for the visualization of all structures within the knee joint. MRI structural
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biomarkers, such as cartilage volume, cartilage defects, BMLs and effusion-synovitis, are
found to correlate with disease symptoms and predict the progression of knee OA.
The following chapters investigate the roles of systemic risk factors in disease progression of
knee OA and the predictive values of MRI biomarkers for knee replacement, as well as the
effects of vitamin D supplementation on the disease. The research questions which directed
this work are described in the following chapter.
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Research Questions
Chapter 1 reviews the background and rationale of this thesis. The research questions of this
thesis are summarized as follows:
1. To determine whether low-grade inflammation plays a role in the pathogenesis of OA
by a systematic review of existing evidence.
(a) Is serum level of high-sensitivity C-reactive protein (hs-CRP) elevated in OA
patients compared to control?
(b) Is serum hs-CRP level correlated with the prevalence or progression of radio-
graphic features of OA?
(c) Is serum hs-CRP level correlated with the prevalence or progression of clinical
symptoms of OA?
2. To describe the longitudinal relationship between adiposity and change in knee pain in
a population-based cohort of community-dwelling adults aged 50-80 years examined
at baseline and 2.6 and 5 years later.
3. To evaluate the effects of vitamin D supplementation versus placebo on knee pain and
knee cartilage volume loss in symptomatic knee OA patients with low vitamin D levels
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over 2 years.
4. To describe the longitudinal associations between serum levels of estrogen, proges-
terone and testosterone and knee structural changes using MRI in both males and
females with symptomatic knee OA at baseline and 2 years later.
5. To examine whether cartilage defects, BMLs, effusion-synovitis and meniscal patholo-
gies measured on MRI at baseline predict TKR over 10.7 years in a population-based
cohort of community-dwelling adults aged 50-80 years.
(a) Do semiquantitative MRI measures of cartilage defects, BMLs, effusion-synovitis
and meniscal pathologies independently predict the risk of TKR over 10.7 years?
(b) Does the number of MRI structural pathologies present at baseline predict the
occurrence of TKR over 10.7 years?
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Methodology
Chapter 4 arose from a systematic review of the literature. Chapter 5 and 8 arose from
analyses using the data from the Tasmanian Older Adult Cohort (TASOAC) study. Chapter
6 and 7 arose from analyses using the data from the Vitamin D Effect on Osteoarthritis
(VIDEO) study, which is a randomized, double-blind, placebo-controlled clinical trial. This
chapter describes the study population and design for the TASOAC and VIDEO study, as
well as the protocols for measurement of factors which are common to multiple chapters in
this thesis. Additional factors which are unique to each chapter are described in more detail
in the methodology section of each of the subsequent chapters.
It should be noted that the following chapters are presented in the form in which they were
submitted to, or accepted by, peer-reviewed journals for publication. Thus, throughout these
chapters, there are some differences in the description of methods, analyses, results, and
interpretations, due chiefly to requests from journal reviewers.
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3.1 Study Design of Tasmanian Older Adult Cohort
(TASOAC) study
The TASOAC study is an ongoing prospective, population-based study that aims at identi-
fying the environmental, genetic, and biochemical factors associated with the development
and progression of OA at multiple sites (hand, knee, hip, and spine).
3.1.1 Study population and design
The cohort consisted of both males and females aged between 50 and 80 years (mean: 62
years; standard deviation (SD): 7 years), selected from the roll of electors in southern Tas-
mania (population 229,000) using stratified simple random sampling without replacement.
Electoral rolls represent the complete population information available in Australia because
voting in federal and state elections is compulsory. The sample was stratified by sex to
provide equal numbers of men and women, and equal distribution was drawn from urban
and rural areas in Southern Tasmania. As TASOAC was designed to examine community-
dwelling older adults, institutionalized older adults were excluded. Participants were also
excluded if they reported contraindication for MRI (including metal sutures, the presence of
shrapnel, iron filings in the eye and claustrophobia), as these tests were required to examine
OA progression.
Figure 3.1 provides an overview of participant recruitment and withdrawal during the study
period. The first phase of the study was carried out between March 2002 and September
2004. 2,135 initially eligible participants were identified from which 1,904 were able to
be contacted. Of all initially eligible participants, 1,100 enrolled in the study, and 1,099
attended a baseline clinic (response rate 51%). The phase 2 follow-up study was conducted
2.6 years later (range 1.4–4.9 years), with a set of measures taken also at a phase 3 follow-up
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after 5.1 years (range 3.6–6.9 years), and a phase 4 follow-up after 10.7 years (range 9.2–
12.5 years). The MRI machine was decommissioned halfway through the phase 2 follow-up
period; therefore, MRI scans were only available for approximately half of the phase 2
follow-up participants. As a result, the sample size used in Chapters 5 and 8 of this thesis
varies depending on the available data for each of the research questions.
3.1.2 Sample size
As the TASOAC study was in progress before the commencement of the PhD candidature,
formal sample size calculations were not performed during the design of this thesis. There-
fore, participant numbers in the analyses reported in this thesis were limited to the numbers
recruited at baseline and follow-up, and to those who provided complete data for relevant
outcome and study factors. As such, sample sizes vary between chapters, and the reasons for
exclusion are described in each chapter. Nevertheless, it subsequently proved that sample
sizes were more than adequate to answer the thesis research questions.
3.1.3 Ethical issues
All procedures in TASOAC were approved by the Southern Tasmanian Health and Medical
Human Research Ethics Committee (Ethics Approval Number: H6488). Written informed
consent was obtained from all participants prior to enrollment in the study.
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Figure 3.1: Flowchart of TASOAC study participants.
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3.2 Study Design of Vitamin D Effect on Osteoarthritis
(VIDEO) Study
Vitamin D Effect on Osteoarthritis (VIDEO) study is a randomized, double-blind, placebo-
controlled trial with the aim to examine the effects of vitamin D supplementation on knee
pain and knee structural changes utilizing pioneering MRI techniques in symptomatic knee
OA patients with low serum vitamin D levels.
3.2.1 Study population and design
The VIDEO study recruited patients with symptomatic knee OA in Southern Tasmania and
Melbourne, by using a combined strategy, including collaboration with general practitioners,
specialist rheumatologists, and orthopaedic surgeons, as well as advertising through local
media. The participant inclusion and exclusion criteria for the VIDEO study are listed below:
Inclusion criteria:
1. Age 50-79 years old;
2. Men and women with symptomatic knee OA for at least 6 months with a pain visual
analogue scale (VAS) of at least 20 mm;
3. Meet the America College of Rheumatology (ACR) criteria [34] for symptomatic knee
OA assessed by a rheumatologist;
4. Have an ACR functional class rating of I, II and III [228];
5. Have relatively good health (0-2 according to the investigators global assessment of
disease status on a 5-point Likert scale, range 0 [very well] to 4 [very poor]); and
6. Have serum vitamin D level of >12.5 nmol/L and <60 nmol/L.
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7. Is able to read, speak and understand English, capable of understanding the study
requirements and willing to co-operate with the study instructions.
Exclusion criteria:
1. Patients with severe radiographic knee OA (grade 3 according to Altmans atlas [229]);
2. Patients with severe knee pain (on standing more than 80 mm on a 100-mm VAS);
3. Any contra-indication to having an MRI.
4. Patients with rheumatoid arthritis, psoriatic arthritis, lupus, or cancer;
5. Patients with severe cardiac or renal function impairment
6. Patients with hypersensitivity to vitamin D;
7. Patients with any condition possibly affecting oral drug absorption (eg. gastrectomy
or clinically significant diabetic gastro-enteropathy);
8. having significant trauma to the knees including arthroscopy or significant injury to
ligaments or menisci of the knee within 1 year preceding the study;
9. having anticipated need for knee or hip surgery in the next 2 years;
10. having taken Vitamin D supplements in last 30 days;
Figure 3.2 provides an overview of participant recruitment and withdrawal during the study
period. A total of 599 participants were screened for eligibility from 5 Jun 2010 to 1 Dec
2011.
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Figure 3.2: Flowchart of VIDEO study participants.
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3.2.2 Randomization and masking
Participants were allocated to either vitamin D or placebo at a ratio of 1:1 based on computer-
generated random numbers. Allocation concealment was ensured by a central automated
allocation procedure that was independent of the investigators. Participants, research coor-
dinators and investigators were all blinded to the treatment assignment. Blinding was main-
tained until all the data were collected, confirmed for accuracy and cleaned, and statistical
analyses were performed.
3.2.3 Interventions
Participants in the treatment group were given a monthly capsule of 50,000 IU (1.25 mg)
vitamin D3 (cholecalciferol) for 24 months. The vitamin D3 compound was purchased
from Nationwide Compounding Pharmacy, Melbourne, Australia. Participants in the control
group received an identical inert placebo provided by the same company.
3.2.4 25OHD assays
Serum 25OHD was assayed at screening, month 3 and 24, utilizing a direct competitive
chemiluminescent immunoassay (DiaSorin Inc., Stillwater, Minnesota, USA). The intra-
assay and interassay coefficients of variation were 3.2% and 6.0%.
3.2.5 Outcomes
Primary outcome measures were change in knee pain assessed using the Western Ontario
and McMaster University Index of OA (WOMAC) score [230] and change in tibial cartilage
volume on MRI from baseline to month 24. Secondary outcomes included visual analogue
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scale (VAS) knee pain, lower limb muscle strength and other structural changes on MRI. A
full list of outcome measures for the VIDEO study is shown in Table 3.1.
Table 3.1: Outcomes and timetable
Screening Month(s)
0 3 6 12 24
Co-primary outcome measure
MRI (cartilage volume) • •
WOMAC • • • • •
Secondary outcome measure
MRI (other structural changes) • •
Lower limb muscle strength • • • • •
Visual analogue scale • • • • • •
Other measures
Core musculature measure • • •
Hand grip strength • • • • •
Central and upper arm blood pressure • • • •
Aortic stiffness • • • •
Physical activity (IPAQ) • •
Body fat • • •
Low foot pain • • • • •
Low back pain • • • •
Depression • • • • •
Quality of life • • • •
Previous knee injury and occupation • •
Weight • • • • •
Height • •
Girth measurements • • •
Knee radiograph •
Serum 25-(OH)D • • •
Serum calcium, phosphate, creatinine • •
Sun exposure • • • •
Cigarette smoking • •
Diet (FFQ) and pedometer • •
Medications • • • • • •
Pill counts and adverse events • • • • •
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3.2.6 Sample size
Sample size calculation assumed α = 0.05 and β = 0.20 , and was performed based on the
Cohen formula [231]. Previous studies reported that mean annual medial tibial cartilage
volume loss in knee OA patients was 4.5% [232]. Monthly 50,000 IU vitamin D would
achieve serum 25OHD levels above 60 nmol/L [233] and this change was estimated to lead
to an absolute reduction in medial tibial cartilage loss of 2.2% annually [120], which was
expected to translate into a risk reduction of 44% for total knee replacement over 4 years
[169]. 400 participants at baseline (200 in each group), allowing 20% dropouts, would have
at least 80% power to detect a 2.2% between-group difference in medial tibial cartilage
loss. For change in WOMAC pain, the previous study reported a standard deviation of 70.5
on a score from 0 to 500 [130]. The minimal clinically important difference (MCID) for
WOMAC pain was previously reported to be 16% reduction of the score from baseline [234,
235]. With 400 participants a difference between groups of 20 units on the score is detectable
with 80% power.
3.2.7 Ethical issues
Ethics approval was received from the Tasmania Health and Human Medical Research Ethics
Committee (reference number H1040) and Monash University Human Research Ethics Com-
mittee (reference number CF10/1182-2010000616). Informed written consent was obtained
from all participants.
3.3 Anthropometrics
Each subjects body weight was measured to the nearest 0.1 kg (with shoes, socks, and bulky
clothing removed) using a single pair of electronic scales (Seca Delta Model 707, Bradford,
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MA, USA). Height was measured to the nearest 0.1 cm (with shoes and socks removed)
using a stadiometer. BMI was calculated as kg/m2.
3.4 Body composition assessment
Fat mass was measured using a Dual energy X-ray absorptiometry (DEXA) scanner (Hologic
Corp, Waltham, Massachusetts, USA). Percentages of total body fat mass and trunk fat mass
were calculated as the ratio of total body or trunk fat mass or lean mass by total body or
trunk mass (the sum of fat mass, lean mass and bone mass). The coefficients of variation
for total body fat, trunk fat mass and lean mass measures were 31.0%, 36.8% and 20.2%,
respectively.
3.5 X-ray
A standing anteroposterior semiflexed view of the right knee with 15◦ of fixed knee flex-
ion was performed. Radiographs were assessed using the atlas developed by Altman et al
[229]. Each of the followings was assessed on a scale of 0–3: medial joint space narrowing
(JSN), lateral JSN, medial femoral osteophytes, medial tibial osteophytes, lateral femoral
osteophytes, and lateral tibial osteophytes. Each score was determined by consensus of two
readers who simultaneously assessed the radiograph with immediate reference to the atlas.
Intra-observer repeatability was assessed in 40 subjects with an interval of at least one week
between the two measurements. Intraclass correlation coefficients (ICCs) ranged from 0.65–
0.85. The presence of radiographic osteoarthritis (ROA) was defined as any score ≥ 1 for
JSN or osteophytes.
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3.6 Magnetic resonance imaging
In the TASOAC study, MRI of the right knee was acquired with a 1.5T whole-body mag-
netic resonance unit (Picker, Cleveland, OH, USA) using a commercial transmit/receive
extremity coil. Image sequences included the following: (1) a T1-weighted fat saturation
three-dimensional (3D) gradient-recalled acquisition in the steady state, flip angle 30◦, rep-
etition time 31 ms, echo time 6.71 ms, field of view 16 cm, 60 partitions, 512 × 512 pixel
matrix, acquisition time 5 min 58 s, one acquisition; sagittal images were obtained at a slice
thickness of 1.5 mm without an inter-slice gap; and (2) a T2-weighted fat saturation two-
dimensional (2D) fast spin echo, flip angle 90◦, repetition time 3067 ms, echo time 112 ms,
field of view 16 cm, 15 partitions, 228 × 256 pixel matrix; sagittal images were obtained at
a slice thickness of 4 mm with an inter-slice gap of 0.5–1.0 mm.
In the VIDEO study, MRI scans of the study knee were obtained according to a standardized
protocol, on a 1.5T whole-body MRI unit using a commercial transmit-receive extremity
coil. The sequences used for cartilage volume assessment were sagittal fat saturated (FS)
T1-weighted spoiled gradient echo (GRE) with flip angle 30◦, repetition time 31 ms, echo
time 6.71 ms, field of view (FOV) 160 mm, acquisition time 5 min 58 s, 60 slices, 512 ×
512 pixel matrix slice thickness of 1.5 mm without between-slice gap. Cartilage defects and
bone marrow lesions were assessed on the T2-weighted/proton density-weighted fast spin
echo (FSE) sequences: sagittal FS T2-weighted 3D FSE sequence, flip angle 90◦, repetition
time 3,067 ms, echo time 112 ms, FOV 16 cm, 15 slices, 228 × 256 pixel matrix slice
thickness of 2 mm with a between-slices gap of 0.5–1.0 mm; coronal FS proton density-
weighted FSE sequence, repetition time 3,400 ms, echo time 64 ms, flip angle 90◦, slice
thickness 3 mm, FOV 16 cm, pixel matrix 256 × 256, acquisition time 5 min 26 s. MRIs
were assessed by trained readers blinded to treatment allocation.
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3.7 Knee pain assessment
Knee pain was assessed on the right knee using the Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC), a self-administered questionnaire [230]. There are
five categories of pain in the questionnaire (walking on flat surface, going up/down stairs,
standing upright, in bed when at night, and sitting/lying). In the TASOAC study, each cat-
egory of WOMAC knee pain was rated on a 10-point numeric scale from 0 (no pain) to 9
(most severe pain). In the VIDEO study, it was measured on a 100 mm visual analogue scale
(score range 0–100).
3.8 Statistical analysis
T-tests and chi-squared tests were used to compare differences in means and proportions as
appropriate. Standard diagnostic checks of model fit and residuals were routinely performed,
and data points with large residuals and/or high influence were investigated for data errors.
A p value less than 0.05 (two-tailed) is considered statistically significant. A more detailed
description of statistical analyses performed is presented in their relevant chapters. All sta-
tistical analyses were performed on Stata for Windows (version 13.0, Stata Corporation, TX,
USA).
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CHAPTER 4
Circulating C-Reactive Protein in
Osteoarthritis: a Systematic Review and
Meta-Analysis
4.1 Introduction
Although OA has generally been perceived as a “non-inflammatory ”arthropathy, recent
studies have suggested that local inflammation plays a prominent role in its pathogenesis
[236]. Pro-inflammatory cytokines, including interleukin 1β (IL-1β ), tumor necrosis factor-
α (TNF-α), IL-6 and others, are produced by synovium and chondrocytes and contribute to
the progression of cartilage degradation [237]. A number of studies suggest that this local
inflammation may be observed systemically [101, 238, 239, 240].
C-reactive protein (CRP) is an acute-phase protein that is produced by hepatocytes and
adipocytes and regulated by pro-inflammatory cytokines [241]. An immunoassay was in-
troduced in 1992 by Montagne and colleagues, to perform high sensitive C-reactive protein
(hs-CRP) measurement [242]. In 1997, a study by Loose et al showed that OA patients had
higher serum hs-CRP levels than age-matched controls [243]. Since then, numerous studies
have been conducted to explore the association between serum CRP levels and OA. While
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some studies reported that serum CRP levels were significantly increased in OA [90, 244,
245], others showed no association between hs-CRP levels and OA after the adjustment for
body mass [246, 247, 248]. The aim of this study, therefore, was to perform a systematic
review of the associations between hs-CRP levels and OA and the individual features of OA.
4.2 Objectives
1. To determine whether hs-CRP levels are elevated in OA patients compared to control;
2. To determine the correlation between serum hs-CRP levels and the following OA fea-
tures:
• Prevalence or progression of radiographic features of OA (eg. joint space width,
osteophyte, classified Kellgren-Lawrence score, etc).
• Prevalence or progression of joint symptoms (joint pain, stiffness or physical
dysfunction).
4.3 Method
4.3.1 Literature Search
A systematic search on literature from January 1992 to December 2012 was performed
on electronic databases including MEDLINE, EMBASE and CINAHL. MeSH terms “os-
teoarthritis”, “inflammation”, “c-reactive protein”and related free text terms were used for
the search. Search filters designed by Scottish Intercollegiate Guidelines Network (SIGN)
for observational studies were incorporated into the electronic database search strategies
[249]. Results were then limited to human epidemiological and clinical studies in English.
The search strategy for each electronic database is detailed in the Appendix A. We tried to
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identify ongoing clinical trials by electronically searching ClinicalTrials.gov, WHO Interna-
tional Clinical Trial Registration Platform Search Portal, and Australian and New Zealand
Clinical Trial Registry. The reference lists of obtained studies from the initial electronic
search were scanned for further unidentified relevant studies. Conference abstracts from the
American College of Rheumatology (ACR) and the European League Against Rheumatism
(EULAR) were also searched.
4.3.2 Selection of Studies
Two independent investigators (XJ and JRB) were assigned for the selection of studies.
Titles, abstracts, keywords and information of identified studies were entered in an Inclu-
sion/Exclusion form (Appendix A). The initial screening was set to be relatively open-ended
to retain as many relevant studies as possible. Full-text was then further examined if the col-
lected information of a primary study suggested that it might meet the inclusion criteria for
this review. When information from the published article was not sufficient to make a judg-
ment, correspondent authors were contacted to obtain further information. Discrepancies
between two investigators were addressed by consensus after discussion.
Inclusion Criteria
Studies that fulfilled the following criteria were included in this systematic review.
1. Studies included patients with OA;
2. Serum CRP levels were measured using high-sensitivity methodology;
3. Study compared OA patient with healthy subjects, or associated serum hs-CRP levels
with phenotypes of OA (e.g. radiological grading, joint space narrowing, pain score
and dysfunction score);
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4. The article represented original data;
5. Human study;
6. Studies published in English.
4.3.3 Exclusion Criteria
1. Studies included patients with inflammatory joint diseases and other acute inflamma-
tory conditions;
2. Review article;
3. In vitro, animal or ex vivo study.
4.3.4 Data Extraction
One investigator (XJ) extracted the data from included studies using a pre-designed data
extraction form (Appendix A). The accuracy of the data was verified by a second investigator
(JRB). Study characteristics were recorded including publication information, study design,
origin of study, study setting, time frame of study, age, gender split, BMI, definition of
OA, affected joints, hs-CRP measuring method, serum hs-CRP levels, relative measures and
correlational data with OA.
4.3.5 Quality Assessment
Two investigators (XJ and JRB) independently evaluated the methodological quality of all
included studies. The assessment was based on the Newcastle-Ottawa Quality Assessment
Scale (NOS) for Case-Control Studies [250] with modifications to accommodate the topic of
this review (Appendix A). The NOS was identified to be one of the two useful tools to assess
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the quality of non-randomized studies in a systematic review of 182 tools [251]. The total
quality score was not utilized in the meta-analyses, as we believed it was more appropriate
to assess different aspects of methodological quality of a study in a separate manner.
4.3.6 Assessment of Heterogeneity
Heterogeneity across included studies was examined using Cochran Q test and I2 test. A re-
sult of Chi2 >25% and p <0.10 was defined as evidence of significant heterogeneity across
studies. To further analyze heterogeneity, the I2 test was used to estimate the extent of hetero-
geneity, for example, the percentage of variation across studies that is not caused by chance.
A I2 value higher than 30% would indicate moderate heterogeneity and a value higher than
50% would represent substantial heterogeneity [252]. Possible sources of heterogeneity and
their effects on the results were explored by subgroup analyses and sensitivity analyses.
4.3.7 Assessment of Publication Bias
Publication bias and ”small-study effects” were evaluated using a funnel plot. Asymmetry
identified on the funnel plot would imply possible publication bias. A modified Eggers
regression test was performed to detect the publication bias. When p-value equaled or was
less than 0.10, significant publication bias was considered [253].
4.3.8 Data Synthesis and Analysis
For dichotomous data, a pooled odd ratio (OR) and a 95% confidence interval (95% CI) were
computed by the Mantel-Haenszel method. For studies that reported relative risks (RR), we
made an attempt to reconstruct a 2 × 2 table with information provided in the text and
calculated the OR.
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Because crude hs-CRP levels are frequently skewed, some individual studies had normalized
the hs-CRP by logarithmic transformation in the statistical analysis while others reported the
results on the original scale. In order to allow meta-analysis to be conducted on a common
scale, we adopted the methods proposed by Higgins et al to transform data from a logarith-
mic scale to a raw scale [254]. The unit of hs-CRP measurement was uniformly converted
to mg/l in the meta-analysis. The difference in means and its 95% CI were calculated to
estimate the difference in hs-CRP levels between OA patients and healthy controls. Generic
inverse variance method on the random-effects model was used for the statistical pooling as
we expected the true effects would vary across individual studies.
For correlational data, we obtained correlation coefficients (r) and calculated the correspond-
ing standard error by computing the square root of sample variance as below.
SE =
√
1− r2
n−2 (4.1)
Correlation coefficients were combined using generic inverse variance method and the random-
effects model.
When data were sufficient and appropriate, pre-specified subgroup analyses stratified by
age, BMI, joints of OA, definition of OA, hs-CRP measuring methods and study designs
were performed to assess the influence of the above parameters. Meta-regression analysis
was performed to assess the influence of age, BMI and female sex using the random-effects
model.
Statistical analyses were performed using Revman version 5.2 (The Nordic Cochrane Centre,
The Cochrane Collaboration, 2012) and STATA (Release 12. College Station, TX. StataCorp
LP). All reported p-values were two-sided and p <0.05 was considered to be statistically
significant.
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4.4 Results
4.4.1 Literature Search
1,198 records were retrieved from the initial search on electronic databases, with 523 from
MEDLINE, 346 from EMBASE, and 329 from CINAHL. Twenty relevant abstracts were
identified from ACR and 40 from EULAR. Reference mining identified another 14 articles.
A total of 1,272 records were identified. A total of 185 duplicated records were removed.
After title and abstract screening, 1,025 articles were excluded. Sixty-seven full texts were
examined for the eligibility of inclusion. Thirty-five articles were further excluded because
they were ex-vivo studies, in-vitro study, review articles, and studies in which OA was not
the disease of interest, or CRP levels were not measured, or analysis data on CRP were not
performed or not reported in the article. Two articles [239, 255] were also excluded because
same data were reported in another article. One study [256], which used the number of OA-
affected knees instead of the number of OA patients in the analysis, was excluded. Finally,
thirty-two studies met the inclusion criteria (Figure 4.1).
4.4.2 Included Studies
Ten case-control [257, 258, 259, 260, 261, 262, 263, 264, 265, 266], 15 cross-sectional [248,
267, 268, 269, 270, 271, 272, 258, 273, 274, 275, 89, 276, 245], 4 longitudinal studies [277,
278, 279, 280] and 3 clinical trials were included [243, 281, 282]. The three clinical trials
had data comparing CRP levels in OA patients with healthy controls at baseline; therefore,
their data were included and were assessed as a case-control design. The characteristics of
included studies are summarized in Table 4.1. The 32 included studies provided data of
17,090 participants (6,440 OA cases and 10,650 controls) in 12 countries.
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Figure 4.1: Flowchart of Study Selection.
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Table 4.1: Characteristics of included studies
Characteristics Longitudinal Cross-sectional Case-control Clinical-trial Total
No. of studies 4 15 10 3 32
No. of subjects 1461 13093 2002 534 17090
Mean age (range) 64.9 (62.1–69.1) 60.5 (42.9–71.9) 59.2 (51.1–68.5) 61.1 (59.0–61.9) 61.4 (42.9–71.9)
Female (%) 62.8 38.4 38.2 68.8 52.0
Mean BMI (range) 27.3 (25.7–28.6) 28.12 (19.9–60.45) 27.2 (19.1–46.5) 27.7 (24.3–32.6) 27.6 (19.1–60.45)
Single-centre (%) 25 46.7 90 100 62.5
OA definition* (%)
Clinical 1 (25.0) 6 (40.0) 5 (50.0) 1 (33.3) 13 (40.6)
Radiographic 3 (75.0) 4 (26.7) 4 (40.0) 0 (0) 11 (34.4)
Both 0 (0) 4 (26.7) 1 (10.0) 0 (0) 5 (16.6)
Registry data 0 (0) 1 (6.6) 0 (0) 2 (66.7) 3 (9.4)
OA sites
Knee 2 (50.0) 4 (26.7) 5 (50.0) 2 (66.7) 13 (40.6)
Hip 1 (25.0) 3 (20.0) 1 (10.0) 0 (0) 5 (15.6)
Hand 0 (0) 1 (6.6) 2 (20.0) 0 (0) 3 (9.4)
Not specified 1 (25.0) 7 (46.7) 2 (20.0) 1 (33.3) 11 (34.4)
CRP measurement
ELISA 1 (25.0) 6 (40.0) 4 (40.0) 3 (100) 14 (43.8)
Nephelometry 3 (75.0) 9 (60.0) 6 (60.0) 0 (0) 18 (56.2)
*Clinical, clinically defined OA—for example, ACR criteria; radiographic, radiographically defined OA — for example, KL≥ 2; both, clinically and
radiographically defined OA, including knee or hip replacements. ACR, American College of Rheumatology; BMI, body mass index; KL, Kellgren-Lawrence;
OA, osteoarthritis.
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Table 4.2: Reasons for excluded studies
Study ID Reasons for exclusion
Agarwal 2009 OA was not the disease of interest
Attur 2011 CRP was not measured
Attur 2012 CRP was not measured
Botha 2008 CRP was not measured
Calguneri 2003 CRP was not measured
Ding 2009 CRP was not reported
Fonseca 2009 CRP was not measured
Fraenkel 1998 Ex vivo study
Garnero 2006 Review (abstract)
Goekoop 2010 Ex vivo study
Golightly 2011 The number of knees was used as sample size
Gomes 2012 CRP was not measured
Jorgensen 2012 No major observation
Keyszer 1999 OA was not the disease of interest
Ling 2009 CRP was not measured
Massicotte 2002 In vitro study
Meliconi 2006 CRP was not measured
Miller 2008 No comparison between OA and healthy control
Naguib 2010 CRP data were not reported (conference abstract only)
Neidhart 2000 No OA subjects were involved
Otterness 1995 CRP data are reported in another related paper (Otterness 2000)
Otterness 2001 CRP data are reported in another related paper (Otterness 2000)
Pantsulaia 2010 CRP was not measured
Richette 2008 CRP was not measured
Richette 2011 No correlational analysis between CRP and severity of OA
Riyazi 2004 CRP was not measured (conference abstract only)
Romero 2006 CRP was not measured
Scanzello 2009 Commentary review
Sipe 1995 Review
Smith 2012 No available data
Stannus 2010a CRP was not measured
Stannus 2010b CRP was not reported
Tian 2011 CRP was not measured
Trontzas 1998 CRP was not measured
Uson 1997 CRP was not measured
4.4.3 Excluded Studies
Excluded studies after full text assessment and reasons for exclusion are listed in Table 4.2.
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Table 4.3: Summary of methodological quality of included studies
Study ID
Selection Comparability Exposure Total
S1 S2 S3 S4 C1 C2 E1 E2 E3 (out of 9)
Bos 2008 • • • • • • 6
Brenner 2003 • • • • • • 6
Chen 2008 • • • • • • • • • 9
Conronzier 1998 • • • • • • • • • 9
Conronzier 2000 • • • • • • 6
Engstrom 2009 • • • • • • • • • 9
Garnero 2005 • • • • • 5
Garnero 2001 • • • • • • • • • 9
Gungen 2012 • • • • • • • • • 9
Hulejova 2007 • • • • • • • 7
Hussein 2008 • • • • • • 6
Keenan 2008 • • 2
Kerkhof 2010 • • • • • • • • • 9
Kraus 2007 • • • • • • • • • 9
Livshits 2009 • • • • • • • • • 9
Lee 2011 • • • • • • • • • 9
Mazieres 2006 • • • • • • • 7
Melikglu 2009 • • • • • • 6
Meulenbelt 2007 • • • • • 5
Otterness 2000 • • • • • • 6
Pearle 2007 • • • • • • • • • 9
Punzi 2005 • • • • • • • • 8
Sharif 1997 • • • • • • • 7
Sharif 2000 • • • 3
So 2003 • • • • • • 6
Spector 1997 • • • • • • • • • 9
Sower 2002 • • • • • • • • • 9
Sturmer 2004 • • • • • • • • • 9
Takahashi 2004 • • • • • 5
Vlad 2011 • • • • • • • • • 9
Wolfe 1997 • • • • • • • 7
Loose 1996 • • • • 4
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4.4.4 Quality Assessment
The results of methodological quality assessment for each individual study were summa-
rized in Table 4.3. Discrepancies between two reviewers were resolved by consensus after
discussion. The average methodological quality across included studies was satisfactory.
Seventeen studies were scored above six out of nine. However, two studies, Keenan 2008
[274] and Sharif 2000 [278], were graded 2 and 3 respectively, suggesting a higher risk of
bias. Another study [243] was only published in abstract and scored in only four items due
to limited information. All studies but two [243, 274] provided clear definitions of OA and
description of CRP measurement.
4.4.5 Meta-Analyses
The results of all meta-analyses are summarized in Table 4.4.
Table 4.4: Summary of results of meta-analyses
Outcomes
No. studies Summary
95% CI P value
(No. participants) measure
Serum hs-CRP levels and OA
Absolute difference (mg/l) 14 (5,483) MD = 1.19 0.64 – 1.73 <0.001*
(OA vs control)
Odds ratio
(progressive vs non-progressive) 4 (10,619) OR = 0.99 0.81 – 1.21 0.93
Correlation between hs-CRP levels and OA phenotypes
Kellgren-Lawrence grade 2 (95) r = 0.13 -0.08 – 0.35 0.22
Joint space width 2 (205) r = -0.10 -0.29 – 0.10 0.33
Pain 5 (1,233) r = 0.14 0.09 – 0.20 <0.001*
Physical function reduction 2 (244) r = 0.25 0.13 – 0.39 <0.001*
OA, osteoarthritis; hs-CRP, high sensitivity c-reactive protein.
MD, mean difference; OR, odds ratio; r, coefficient correlation.
* indicates statistically significance.
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4.4.6 Comparison of hs-CRP levels between OA and non-OA
We made efforts to retain all available data from included studies in the meta-analysis. Cor-
respondent authors were contacted by email for studies that had missing data or insufficient
information. Eventually, data from 15 primary studies were available for this component
of the meta-analysis. Two studies [269, 270] reported hs-CRP levels in different OA sub-
groups; therefore, we separately entered the subgroup data in the meta-analysis. Six studies
[243, 257, 262, 272, 90, 89] had either missing data or insufficient information for trans-
forming data that allow being pooled in the meta-analysis. Data from one study [277] were
also not included because observations in the control group were not completely free of OA.
A summary of results from these seven studies is presented in Appendix A.
Fifteen studies were included in the meta-analysis of the difference in means of hs-CRP
levels between OA patients and healthy controls (Figure 4.2). Except for one study [261]
showing no difference between OA and controls, all other studies revealed that circulating
levels of hs-CRP were higher in OA patient than in healthy controls. The pooled mean
difference showed that hs-CRP level was significantly higher in OA than in controls, with
an average increase in value of 1.19 mg/l (95% CI 0.64 to 1.73, p <0.001). There was
significant variation across the included studies in terms of the mean difference (MD) of
hs-CRP levels, which ranged from 0.06 mg/l to 3.43 mg/l. The test for heterogeneity was
statistically significant (Chi2 = 76.23, p <0.001; I2 = 79%), indicating substantial inter-
study variation. Possible explanations for the variation were explored in subgroup analyses
and sensitivity analyses.
Publication bias was examined by the evaluation of the symmetry of a funnel plot (Figure
4.3) as well as the Eggers test. The funnel plot suggested that there were potential publica-
tion bias and small-study effects in the results. The existence of ”small study effects” was
confirmed by the Eggers test. Therefore, we subsequently performed a sensitivity analysis
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Figure 4.2: Comparison of CRP levels between OA and non-OA.
to examine the impacts of small studies.
Figure 4.3: Funnel plot of included studies.
4.4.7 Subgroup and sensitivity analyses
Subgroup analyses based on OA joint sites (hip and knee) and diagnosis (clinical and ra-
diological) were performed. Sensitivity analyses based on CRP measurement techniques
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(ELISA and nephelometry) (Figure 4.4), study size (small and large) (Figure 4.5), study de-
sign (case-control and cross-section) (Figure 4.6) and adjustment for BMI were performed
(Figure 4.7). A summary of results is presented in Table 4.5. The increase in hs-CRP level
was more considerable in hip OA than in knee OA (3.37mg/l vs 1.15mg/l). Elevated hs-
CRP levels were observed both in clinical OA and radiographic OA, 1.76mg/l and 1.07mgl
higher than non-OA, respectively. Compared to nephelometry, high sensitivity ELISA was
the more sensitive measuring technique. Small studies (N <100) were more likely to report
significant differences. The increase in hs-CRP was reported to be more moderate in a case-
control design than in a cross sectional design (0.91mg/l vs 1.82mg/l). Control for BMI in
a study or adjustment for BMI in an analysis did not significantly change the increase of
hs-CRP in OA.
Figure 4.4: Sensitivity analysis: hs-CRP measurement techniques.
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Figure 4.5: Sensitivity analysis: large studies versus small studies.
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Figure 4.6: Sensitivity analysis: case-control studies versus cross-sectional studies.
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Figure 4.7: Sensitivity analysis: adjustment for BMI versus no adjustment.
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Table 4.5: Summary of subgroup and sensitivity analyses of difference in hs-CRP between OA and
non-OA
Outcomes
No. studies Mean difference
95% CI P value
(No. participants) (mg/l)
Joints of OA
Knee 8 (2,922) 1.15 0.18–2.12 0.02*
Hip 3 (196) 3.37 0.60–6.13 0.02*
Hand 1 (81) 0.58 0.00–1.16 0.05
Not specified 5 (2,343) 1.51 0.49–2.53 <0.01*
Diagnosis of OA
Clinical OA 10 (2,316) 1.07 0.47–1.66 <0.01*
Radiographic OA 5 (3,167) 1.76 -0.04–3.57 0.05*
Measuring techniques
ELISA 6 (1,251) 1.74 0.80–2.67 <0.01*
Nephelometry 8 (2,677) 0.6 -0.01–1.21 0.06
Study size
N ≥ 100 8 (4,968)§ 0.7 0.16–1.25 0.01*
N <100 8 (515)§ 2.43 1.02–3.83 <0.01*
BMI controlled/adjusted
Yes 9 (4,848) 1.25 0.63–1.88 <0.01*
No 6 (635) 1.21 -0.38–2.79 0.13
Study design
Cross-section 8 (820) 1.82 0.48–3.15 <0.01*
Case-control 7 (4,663) 0.91 0.32–1.73 <0.01*
OA, osteoarthritis; hs-CRP, high sensitivity c-reactive protein.
§Comparative analyses from one study (Chen 2008) are grouped separately according to their sample size.
* indicates statistically significance.
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4.4.8 CRP levels and OA progression
Three studies reported relative measures, either RR or OR (Figure 4.8), on the predictive
value of hs-CRP levels for progression of OA as either exacerbation of joint space narrowing
or total joint replacement. The pooled OR showed no significant predictive value of hs-CRP
level in the progression of OA (OR = 0.99, 95% CI 0.81 to 1.21, p = 0.93). The test for
heterogeneity was borderline significant (Chi2 = 7.02, p = 0.07; I2 = 57%).
Figure 4.8: Serum hs-CRP levels and progression of OA.
4.4.9 Correlations between hs-CRP levels and OA phenotypes
hs-CRP and radiographic OA
The links between serum hs-CRP levels and knee radiographic OA were investigated in four
studies (Figure 4.9). The pooled correlation coefficient showed that the link between serum
hs-CRP levels and knee radiographic OA was weak and it was not statistically significant (r =
0.11, 95% CI -0.03 to 0.26, p = 0.13). The correlation coefficients remained non-significant
when we separated studies into Kellgren-Lawrence grading subgroup (r = 0.13, 95% CI -
0.08 to 0.35, p = 0.22) and joint space narrowing subgroup (r = 0.10, 95% CI -0.10 to 0.29,
p = 0.33). There was no significant difference between the two subgroups (Chi2 = 0.07, p =
0.79; I2 = 0%).
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Figure 4.9: Correlation between hs-CRP levels and radiographic OA.
hs-CRP and symptoms of OA
The correlation coefficients between hs-CRP levels and pain in OA patients were available
in six studies. A total of 840 OA patients were included in the meta-analysis (Figure 4.10).
Brenner study reported a negative correlation between hs-CRP levels and VAS pain score,
while the other four all reported a positive correlation. The pooled result of the meta-analysis
showed that there was a weak but statistically significant correlation between hs-CRP levels
and pain scale score (r = 0.14, 95% CI 0.08 to 0.20, p <0.001). There was no significant
heterogeneity observed across the studies (Chi2 = 4.12, p = 0.39; I2 = 3%).
Two studies reported the correlation coefficient of hs-CRP with physical function (Figure
4.10) [262, 276] . The results from both studies were consistent with each other, indicating
a correlation between increased hs-CRP levels and worsening physical function. The pooled
correlation coefficient was statistically significant (r = 0.26, 95% CI 0.13 to 0.39, p<0.001).
The pooled results of correlation data for symptoms of OA were statically significant (r =
0.16, 95% CI 0.11 to 0.22, p <0.001). There was no significant difference between cor-
relation with pain and correlation with physical function loss (Chi2 = 2.48, p = 0.12; I2 =
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59.7%).
Figure 4.10: Correlation between hs-CRP levels and symptoms of OA.
4.5 Discussion
This study is a comprehensive systematic review of serum hs-CRP levels in OA. A related
meta-analysis of three studies previously performed in 2010 by Kerkhof et al did not pro-
vide evidence of an association between serum CRP levels and knee OA [277]. In the present
systematic review, we included all available data in our meta-analysis on the difference of
serum hs-CRP levels between OA population and healthy controls. In addition, the associa-
tion between hs-CRP levels and different OA phenotypes was also examined.
The major findings of this systematic review are: 1) serum hs-CRP level is modestly elevated
in the OA population, as reported in most studies (19 out of 21). (MD = 1.19 mg/l, p<0.001);
2) serum hs-CRP level is associated with symptoms of OA, such as pain and loss of physical
function,; 3) serum hs-CRP level is not significantly associated with KL scores and joint
space narrowing.
The first result above should be regarded with caution due to the significant heterogeneity.
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We identified some reasons for this with the apparent difference being greater in studies us-
ing ELISA as compared to nephelometry, smaller studies, cross-sectional studies and those
restricted to hip or radiographic OA. This suggests variation between studies is due to both
study quality issues and varying methodology. Cross-sectional studies should not be used for
causal inference and there were only four longitudinal studies which are stronger method-
ologically.
Obesity may influence serum hs-CRP levels. Adipose tissue mediates the secretion of pro-
inflammatory cytokines, such as IL-6, which in turn triggers the hepatic synthesis of CRP
[283, 284, 285]. A previous meta-analysis did not show an association between serum CRP
levels and knee OA independent of BMI [277], however, the meta-analysis included only
three studies; in contrast, Sower and colleagues reported that difference in CRP levels be-
tween participants with knee OA and without knee OA remained statistically significant in
both BMI 30 and BMI>30 subgroups [270].Our subgroup analysis, which compares studies
adjusted for BMI with those did not, suggests that BMI does not explain the variation be-
tween studies and the association appears to be independent of BMI. Chronic inflammation,
reflected by increased hs-CRP levels, may directly contribute to the occurrence of OA.
With regard to OA phenotypes, our results show a consistent and homogeneous association
with pain levels and activity limitations. The magnitude of the association is small sug-
gesting a minor explanatory proportion but would be consistent with a recent paper from our
group where CRP predicted the development of knee pain over 5 years [244]. In comparison,
the associations between hs-CRP and radiographic OA are not significant.
There are also statistical challenges for data transformation and synthesis. The distribution
of hs-CRP values is skewed in most studies. The use of means and standard deviations to
calculate the mean difference in the meta-analysis requires an assumption of normal distri-
bution. Because the standard deviation is larger in a skewed distribution, this may weaken
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the statistical significance of our results. Furthermore, the majority of studies report crude
values of hs-CRP levels while others present the data on the geometric scale. In order to pool
data on a common scale, logarithmic back-transformation to the raw scale was required. The
method requires small effect sizes and similar distributional shapes in the two groups, which
may not be the case in some studies.
Future research is therefore suggested based on this meta-analysis: 1) cohort studies with
adequate adjustment for body mass and other common confounding factors such as age, sex
and smoking to examine causal relationship between OA structure damage and subsequent
elevation of the CRP and other inflammation markers; 2) studies to examine the effects of
inflammation alone and in combination with structure abnormalities on OA symptoms; 3)
studies using more sensitive OA imaging technologies such as magnetic resonance imaging
(MRI) are also desired.
In conclusion, this systematic review suggests that low-grade systemic inflammation may
play a greater role in symptoms rather than radiographic changes in OA.
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CHAPTER 5
Longitudinal Associations between
Adiposity and Change in Knee Pain
5.1 Introduction
Obesity is a well-established risk factor for knee osteoarthritis (OA) and the worldwide obe-
sity epidemic is expected to increase the burden of knee OA [30]. Knee OA commonly
presents with knee pain and knee pain is a major musculoskeletal complaint in the elderly
[286], therefore, it is important to understand the precise role of obesity in knee pain.
There is limited understanding of the mechanism how obesity is associated with knee pain
[287]. Knee pain may be caused by both mechanical-structural factors [287] and metabolic-
inflammatory factors [75]. There are a number of cross-sectional studies [161, 288] and
longitudinal studies [289, 290] showing that obesity, as defined by increased body mass
index (BMI), is associated with knee pain. Unfortunately, the use of BMI alone does not
provide adequate information about the metabolic environment that may contribute to the
obesity-OA-pain association, because BMI does not discriminate the relative contribution
of body fat mass and muscle mass. By using dual energy x-ray absorptiometry (DXA),
the amount of fat mass was found to be greater in people with knee pain than in those
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without [291]. Assessment of body fat in addition to BMI may help to further elucidate the
complex mechanisms in which excess adipose tissue may impact knee pain, though a cross-
sectional study suggests that precise measurements of body composition and measures of
fat distribution may offer no advantage over the more simple measures of BMI or weight
in assessment of risk of radiographic knee OA [292]. There are no longitudinal studies
that incorporate body composition assessment using DXA to characterize the association
between obesity and knee pain.
We hypothesized that fat mass was associated with increased knee pain over time. Therefore,
this study aims to describe the longitudinal association between adiposity assessed in a num-
ber of ways and change in knee pain over an average of 5.1 years in older community-living
subjects.
5.2 Methods
5.2.1 Study design, setting and participants
This study used the data from the Phase I–III (average 5.1 years) of the Tasmanian Older
Adult Cohort (TasOAC) Study as described in Section 3.1.
5.2.2 Knee pain
Knee pain was assessed on the right knee using the Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC) as described in Section 3.3.
The five pain subscales were grouped into weight-bearing pain (walking on flat surface, go-
ing up/down stairs and standing) and non-weight bearing pain (in bed when at night, and
sitting/lying) according to the nature of pain [293]. Presence of knee pain was defined as a
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pain score of 1 or greater. Change in WOMAC pain score was calculated by subtracting base-
line value from follow-up value. Increasing knee pain was defined as a change in pain score
of ≥ 1. This outcome definition was based on the calculated minimal clinically important
difference (MCID) of 0.9 for WOMAC knee pain for this population [244]. The frequency
of knee pain was calculated from the number of time points when knee pain was present.
Three levels of frequency were defined as following: 1) consistent knee pain, presence of
knee pain at all three time-points (phase 1, 2 and 3); 2) fluctuating knee pain, presence of
knee pain in any one or two time-points; 3) no knee pain, WOMAC total pain score = 0 at
all time-points.
5.2.3 Anthropometry
Height and weight were measured according to standard protocols as described in Section
3.3. Body mass index (BMI) was calculated as weight/height2 (kg/m2). Waist circumference
measurement (cm) was taken at the level of the mid-point between the inferior margin of the
last rib and the crest of the ilium in the mid-auxiliary plane. Hip circumference measurement
(cm) was taken at the level of the greatest posterior protuberance of the buttocks and the
symphysis pubis.
5.2.4 Body composition
Fat mass was measured using a DXA scanner (Hologic Corp, Waltham, Massachusetts,
USA). Percentages of total body fat mass and trunk fat mass were calculated as the ratio
of total body or trunk fat mass or lean mass by total body or trunk mass (the sum of fat mass,
lean mass and bone mass).
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5.2.5 Radiographic OA
Radiographic OA was assessed using the Altman atlas as described in Section 3.5.
5.2.6 Data analysis
Propensity score weighting method was utilized to address missing data in subjects who were
lost to follow-up. A weighting score was obtained by the estimation of response propen-
sity based on the baseline characteristics of the participant. The score was used as sample
weights in subsequent statistical analyses. Partial correlation analyses were performed to
measure the relationship between BMI and body composition after adjustment for age and
sex. Standardization of the coefficients was carried out in order to compare the effects be-
tween different measures of obesity.
Statistical analyses were performed to evaluate the association of baseline BMI, waist cir-
cumference, waist/hip ratio, body fat mass and lean mass with frequency of knee pain and
increase in WOMAC pain scores over follow-up period. Log multinomial regression was
used to analyze the frequency of knee pain (consistent or fluctuating knee pain vs no knee
pain) and log-binomial regression was used to analyze the increase in WOMAC pain scores
(increase vs no increase). Multivariable analyses were adjusted for age, sex, height (not for
BMI) and radiographic OA. Sensitivity analyses were performed to examine if the results
were the same using different cut-offs for the increase in knee pain (≥ 2, 3, 4 and 5).
To fully utilize the longitudinal data of multiple obesity measures and knee pain scores, a
linear mixed-effect model with subjects as a random effect was employed to analyze the
association between change in obesity indicators and change in WOMAC total pain score.
The number of years between the baseline and the follow-up visit was used as a time variable.
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5.3 Results
5.3.1 Descriptive analyses
A total of 767 participants (69.8%) had complete knee pain data. 49 of them did not
have knee X-ray at baseline. Compared to those lost to follow-up, study participants were
younger, less obese as assessed by BMI, had less body fat mass and more lean mass, and had
lower WOMAC total pain scores at baseline. The prevalence of knee pain was comparable
between the two groups (Table 5.1).
Table 5.1: Baseline characteristics by those who did and did not complete the follow-up.
Baseline Characteristics
Complete follow-up Loss to follow-up
P value
(n = 767) (n = 332)
Age (years) 61.6 (7.00) 64.7 (8.14) <0.001
Female 381 (50%) 181 (55%) 0.140
BMI (kg/m2) 27.7 (4.58) 28.4 (5.11) 0.027
<25 kg/m2 229 (30%) 89 (27%) 0.307
25 – 29.9 kg/m2 340 (44%) 138 (42%) 0.397
>30 kg/m2 198 (26%) 105 (32%) 0.048
Weight (kg) 77.8 (14.60) 78.1 (15.85) 0.733
Waist circumference (cm) 93.4 (12.76) 95.8 (13.77) 0.004
Body fat (%) 33.5 (7.94) 35.3 (8.25) 0.001
Lean mass (%) 63.5 (7.64) 61.8 (7.92) 0.001
Knee Pain 392 (51%) 190 (58%) 0.051
Total WOMAC pain 3.3 (5.69) 4.9 (7.74) <0.001
Radiographic OA* 423 (59%) 187 (61%) 0.654
Joint space narrowing* 418 (59%) 187 (61%) 0.511
Osteophyte* 69 (10%) 30 (10%) 0.968
WOMAC, Western Ontario and McMaster University Osteoarthritis Index;
Results are shown as mean (standard deviation) or number of participants (percentage) unless stated
otherwise;
Bold p values indicate statistically significant difference between study participants and loss to follow-up at
α=0.05;
*49 participants in the complete follow-up and 18 participants in the loss to follow-up did not have an x-ray
at baseline.
The partial correlations are 0.48 (p<0.01) and 0.65 (p<0.01) for BMI with total body fat
percentage and trunk fat percentage, respectively. Over the average follow-up period of 5.1
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years, the mean change in WOMAC total pain score was -0.5 (standard deviation 5.1, range
-36 to 24). 175 subjects (23%) had increased pain score from baseline to follow-up. Table
5.2 presents the comparison of baseline characteristics between study participants with and
without any increase in knee pain score. Compared to those without increased knee pain,
participants with increased knee pain score had higher BMI, weight, waist circumference,
body fat percentage and trunk fat mass. There were no significant differences in age, sex and
baseline pain score between the two groups.
Table 5.2: Baseline characteristics between participants with and without increased pain over an
average of 5.1 years (n = 766)
Baseline Characteristics
Increase in pain No increase in pain
P value
(n = 175) (n = 591)
Age (year) 62.4 (7.16) 61.9 (6.97) 0.46
Female 95 (54%) 285 (48%) 0.16
BMI (kg/m2) 29.1 (5.25) 27.3 (4.27) <0.01
Total WOMAC pain 2.96 (4.9) 3.35 (5.9) 0.42
Radiographic OA* 111 (68%) 312 (57%) 0.01
Joint space narrowing* 109 (67%) 309 (56%) 0.02
Osteophyte* 33 (22%) 33 (6%) <0.01
Anthropometry
Weight (kg) 80.8 (14.17) 76.9 (14.63) <0.01
WC (cm) 96.0 (12.53) 92.6 (12.73) <0.01
W/H ratio 0.92 (0.08) 0.92 (0.09) 0.49
Body composition
Body fat (kg) 30.2 (7.83) 27.0 (7.83) <0.01
Trunk fat (kg) 13.7 (4.84) 12.1 (4.31) <0.01
Lean mass (kg) 52.9 (9.65) 52.4 (10.65) 0.62
Results are shown as mean (standard deviation) or the number of participants (percentage) unless stated
otherwise.
BMI, body mass index; WC, waist circumference; W/H ratio, waist-to-hip ratio;
Bold p values indicate statistically significant difference at α=0.05.
*12 participants with an increase in pain and 37 participants with no increase in pain did not have an x-ray
at baseline.
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Table 5.3: Baseline obesity measures and increase in knee pain over 5.1 years.
Univariable analysis Multivariable analysis§
Relative risk (95% CI) Relative risk (95% CI)
(n = 767) (n = 718)
BMI (per SD) 1.33 (1.19, 1.48)* 1.34 (1.20, 1.49)*
Weight (per SD) 1.21 (1.08, 1.36)* 1.41 (1.22, 1.64)*
WC (per SD) 1.24 (1.09, 1.41)* 1.37 (1.18, 1.59)*
W/H ratio (per SD) 1.04 (0.92, 1.18) 1.23 (1.03, 1.47)*
Total fat (per SD) 1.34 (1.20, 1.51)* 1.36 (1.20, 1.55)*
Trunk fat (per SD) 1.31 (1.16, 1.49)* 1.32 (1.15, 1.50)*
WOMAC, Western Ontario and McMaster University Osteoarthritis Index;
BMI, body mass index; WC, waist circumference; W/H ratio, waist/hip ratio; SD, standard deviation;
§All multivariable analyses are adjusted for age, gender, height (not for BMI) and radiographic OA;
* P value <0.05
5.3.2 Baseline obesity measures and increasing knee pain
The relative risk of increase in knee pain (developing knee pain and having worsening knee
pain) associated with adiposity is presented in Table 5.3. There were no significant interac-
tions between sex and obesity measures on knee pain (data not shown), therefore data from
females and males were combined for analyses. Except for waist-to-hip ratio, all baseline
obesity indicators were significantly associated with increasing knee pain in both univariable
and multivariable analyses with the association for total fat mass being marginally stronger
than the other obesity indicators. Lean mass was associated with increase in pain, however,
the association became non-significant after adjustment for fat mass (data not shown). The
results were very similar if different cut-offs were used to defined an increase in knee pain.
Figure 5.1 and 5.2 show the association between different adiposity measures and increasing
knee pain in each WOMAC subscale after adjustment for covariates. The relative risks for
weight-bearing pains are present in Figure 5.1 and the relative risks for non-weight-bearing
pains are present in Figure 5.2. BMI was the strongest and most consistent predictor of
increased pain scores in both weight-bearing and non-weight-bearing pain. The associations
between body fat mass, trunk fat mass and increasing weight-bearing knee pain subscales
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were not statistically significant (Figure 5.1), but surprisingly, was for non-weight-bearing
knee pain subscales (Figure 5.2). Waist-to-hip ratio was significantly associated with weight-
bearing knee pain going up/down stairs and non-weight-bearing knee pain sitting.
5.3.3 Baseline obesity measures and consistency of knee pain
Figure 5.3 describes the association between obesity measures at baseline and consistency
of knee pain in a multinomial logistic regression model. Participants who were pain-free for
the entire course of the study were used as the reference group. Higher BMI, heavier weight,
larger waist circumference and more fat mass were associated with both consistent and fluc-
tuating knee pain over follow-up. A larger waist-to-hip ratio was significantly associated
with fluctuating knee pain but not with consistent knee pain. Among all adiposity measures,
total fat mass percentage was the strongest predictor for both consistent and fluctuating knee
pain.
5.3.4 Mixed modeling between obesity measures and knee pain
The results of the analyses are presented in Table 5.4. In order to compare the strength
of associations across different obesity measures, standardized coefficients were calculated.
All fat measures were significantly and positively associated with WOMAC total pain score.
After adjustment for common covariates, one standard deviation increase in BMI was asso-
ciated with 1.27 (p<0.01) unit increase in WOMAC total pain score. Similarly, one standard
deviation increase in total body fat resulted in 1.17 (p<0.01) higher in WOMAC total pain
score. The results remained largely unchanged when radiographic OA was not included in
the statistical models as an adjusting covariate (data not shown).
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Figure 5.1: Adiposity and weight-bearing pain.
78
Chapter 5. Longitudinal Associations between Adiposity and Change in Knee Pain
Figure 5.2: Adiposity and non-weight-bearing pain.
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Figure 5.3: Obesity measures, body composition and frequency of knee pain over 5.1 years (com-
pared to no pain).
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Table 5.4: Mixed modeling of the association between obesity measures and repeated total WOMAC
pain measures over 5.1 years.
Univariable analysis Multivariable analysis§
Standardized β (95% CI) Standardized β (95% CI)
(n = 767) (n = 718)
BMI (per SD) 1.15 (0.87, 1.44)* 1.27 (0.89, 1.66)*
Weight (per SD) 0.74 (0.45, 1.04)* 1.46 (1.02, 1.90)*
WC (per SD) 0.82 (0.54, 1.09)* 1.38 (0.97, 1.80)*
W/H ratio (per SD) 0.34 (0.08, 0.62)* 1.36 (0.83, 1.90)*
Total fat (per SD) 0.92 (0.65, 1.20)* 1.17 (0.76, 1.59)*
Trunk fat (per SD) 0.84 (0.57, 1.12)* 1.00 (0.61, 1.39)*
WOMAC, Western Ontario and McMaster University Osteoarthritis Index;
BMI, body mass index; WC, waist circumference; W/H ratio, waist/hip ratio; SD, standard deviation;
§All multivariable analyses are adjusted for age, gender, height (not for BMI) and radiographic OA;
* P value <0.05
5.4 Discussion
Our study adds to previous cross-sectional studies by examining the longitudinal association
between adiposity measures and change in knee pain over an average of 5.1 years. Our
results suggest that adiposity measures at baseline are significant predictors of consistent and
increasing knee pain over time. In addition, the change in adiposity measures corresponds to
the change in WOMAC total pain score in time series analyses. Obesity measures, including
BMI, waist circumference, waist-to-hip ratio, and percentage body fat, are deleteriously
associated with knee pain in older adults. This study also suggests that body fat mass is more
consistently associated with non-weight-bearing than weight-bearing knee pain, suggesting
metabolic and inflammatory mechanisms may underlie knee pain.
Obesity-specific mechanisms associated with knee pain include mechanical stress, systemic
inflammation and relative loss of muscle mass and strength [294]. As reported in a system-
atic review [19], being overweight and obese is associated with incident OA and this may be
a result of increased loading, which affects the knee joint structure and biomechanical prop-
erties of the joint. Apart from mechanical causes, increased adipose tissues may exert a pro-
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inflammatory and metabolically active effect, by producing cytokines and adipokines, such
as interleukin (IL)-6, tumor necrosis factor (TNF)-α , and leptin [69]. Our previous studies
have shown that the serum levels of these cytokines and adipokines are independently asso-
ciated with cartilage loss and may play an important role in the diseases process of OA [244,
295, 296]. Adiposity might also have a role in the perception of pain. Pro-inflammatory
cytokines IL-6 and TNF-α secreted by adipose tissue can act as pain modulators to induce
production of histamine and substance P [297], which contribute to the more musculoskele-
tal complaints seen in obese people [298]. Epidemiological data have shown that the levels
of TNF-α , IL-6 and high sensitivity C-reactive protein (CRP) are associated with increased
knee pain [244]. Although previous research has not examined adipose tissue in relation to
knee pain, a number of studies have reported that increased fat mass and central obesity are
associated with the severity of pain from other body regions [299, 300]. The results of the
current study support the hypothesis that obesity, reflected by increased BMI and body fat
mass, is associated with knee pain through multiple mechanisms. BMI, as an obesity mea-
sure, may reflect both metabolic effects of adiposity and increased loading on the knee joint.
Indeed, BMI was highly correlated with total body fat and trunk fat, and was consistently
associated with total knee pain, weight-bearing and non-weight-bearing knee pain, suggest-
ing both mechanic and metabolic mechanisms are involved in the pathogenesis. Compared
to BMI, the results for body fat mass percentage and non-weight-bearing pain suggest a
potential systemic effect.
Our results showed that one standard deviation (4.6 kg/m2) increase in BMI at baseline
would result in 34% more risk or one standard deviation (8.7 kg) increase in total body fat
mass at baseline would result in 36% more risk of having an increase in knee pain over
average 5.1 years. Although these differences over 1 year would be modest, the clinical
significance is high at a population level given the high prevalence of overweight. Although
males and females are known to differ their adiposity deposition, we did not find significant
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interactions between adiposity measures and gender. This suggests that the effects of adi-
posity on pain could be the same in both genders. In general, females have more fat mass
than males and adiposity may account for the higher prevalence of knee pain in women [30].
The major limitation of our study is potential selection bias resulting from loss to follow-
up. The retention rate after follow-up was 69.7%. Those who remained in the study were
younger (61.6 versus 64.7 years) and less obese (26% versus 32%) than those lost to follow-
up. However, sensitivity analyses using inverse propensity weighting did not significantly
differ from the results of the original analyses. Thus our results are generalizable to this
population. In addition, such bias may have underestimated our findings given that age and
obesity are associated with increased risk of knee pain.
Although the present study has identified significant associations between adiposity and knee
pain, the exact underlying mechanisms for the relationship between adiposity and knee pain
are beyond the scope of this study. More studies are needed to explore the causal pathways
between obesity and knee pain in the future.
In conclusion, BMI is the most consistent correlate of knee pain in older adults suggesting
simple measures may provide the most information. Fat mass is only associated with non-
weight-bearing knee pain suggesting mechanisms other than mechanical load are important.
83
CHAPTER 6
Effect of Vitamin D Supplementation on
Symptomatic Knee OA: a Randomized
Clinical Trial
6.1 Introduction
Symptomatic knee osteoarthritis (OA) occurs in 10% men and 13% women aged 60 years
or older [301]. Worldwide, knee OA together with hip OA are the 11th leading cause of
global disability, accounting for 2.2% of total years lived with disability [2]. Medical costs
of OA account for 1% to 2.5% of the gross domestic product in developed countries [302].
Currently, there are no disease-modifying therapies for knee OA; therefore, there is an urgent
need to develop cost-effective approaches to prevent the development and progression of this
disease.
Vitamin D can reduce bone turnover and cartilage degradation, thus potentially preventing
the development and progression of knee OA [122, 129]. Epidemiological studies showed
that low serum 25-hydroxyvitamin D (25OHD) levels were associated with greater knee pain
[127, 128], a higher prevalence of radiographic knee OA [120], as well as higher risk of pro-
gression [124, 125]. While observational data is promising, these studies are subject to in-
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herent bias and confounding factors such as physical activity and sun exposure [303]. In ad-
dition, two small existing randomized controlled trials (RCTs) reported contradictory results
[129, 130]. The inconsistencies are likely due to variations in inclusion criteria, outcome
measures, follow-up time and sample size. An updated systematic review called for fur-
ther larger well-designed RCTs to determine whether vitamin D supplementation can slow
disease progression [304]. Therefore, we designed an RCT, addressing the shortcomings
of the previous studies by recruiting a sufficient sample size of participants with clinically
relevant inclusion criteria [305], to evaluate the effects of vitamin D supplementation over
two years versus placebo on knee pain and knee cartilage volume in symptomatic knee OA
patients with low 25OHD levels. Effects on knee physical function and other knee structural
abnormalities, including cartilage defects and bone marrow lesions, were also assessed.
6.2 Method
6.2.1 Trial design, setting and participants
This study used the primary data from the Vitamin D Effect on Osteoarthritis (VIDEO) study.
The details of the study are described in Section 3.2
6.2.2 Outcomes
Primary outcome measures were change in knee pain assessed using the Western Ontario
and McMaster University Index of OA (WOMAC) score [230] and change in tibial cartilage
volume on MRI from baseline to month 24 [306]. Secondary outcomes included cartilage
defects and BMLs on MRI. Post hoc analysis outcomes include 20% and 50% improvement
rates in WOMAC pain score, WOMAC function, visual analogue scale knee pain, and the
responder criteria developed by the Outcome Measures in Rheumatology Arthritis Clinical
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Trials-Osteoarthritis Research Society International (OMERACT-OARSI) criteria.
6.2.3 Assessment of pain
Knee pain was assessed at baseline and at month 3, 6, 12 and 24. Five items of WOMAC
pain scale in 100 mm visual analogue format were used to assess pain during walking, using
stairs, in bed, sitting or lying, and standing. Items were summed to create a total pain score
(range 0-500) [307]. Knee pain in most days of last month was assessed using a 100 mm
visual analogue scale.
6.2.4 WOMAC
Total WOMAC score is the sum of subscale scores including pain, stiffness and physical
function. Missing responses were managed according to the WOMAC user guide.[21] The
WOMAC pain score was considered invalid if more than one item was missing. In the event
of a missing item, the remaining four items were averaged and then multiplied by five.
6.2.5 OMERACT-OARSI Responder Criteria
The OARSI Standing Committee for Clinical Trials Response Criteria Initiative developed
a set of responder criteria (OMERACT-OARSI) to categorize individual response to treat-
ment as a single variable for clinical trials [308]. Response using the exact OMERACT-
OARSI criteria could not be directly evaluated because the patient global assessment was
not recorded in this trial, therefore, we employed a modified OMERACT-OARSI responder
definition without patient global assessment. OMERACT-OARSI responders in our study
were defined as participants with (i) ≥ 50% improvement and an absolute change of at least
20 points in the mean WOMAC pain score or mean WOMAC function score, or (ii) ≥ 20%
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improvement and an absolute change of at least 10 points in both the mean WOMAC pain
score and the mean WOMAC function score.
6.2.6 MRI assessment of knee structural changes
MRI scans of the study knee were obtained according to a standardized protocol as described
in Section 3.6
Cartilage volume
Cartilage volume was determined using the previously described image processing tech-
niques [120]. The volumes of individual cartilage plates (medial tibial and lateral tibial)
were isolated by manually drawing disarticulation contours around the cartilage boundaries
on a section-by-section basis then resampled by means of bilinear and cubic interpolation for
final 3D rendering using OsiriX Lite imaging software (32-bit version 5.9, Pixmeo SARL,
Geneva, Switzerland). The coefficient of variation (CV) was 2.1% for medial tibia and 2.2%
for the lateral tibia [309].
Cartilage defects
Cartilage defects (0–4) were graded on T2-weighted images using a modified Outerbridge
classification [306] at medial tibial, medial femoral, lateral tibial and lateral femoral sites:
grade 0, normal cartilage; grade 1, focal blistering and intracartilaginous hyperintensity with
an normal contour; grade 2, irregularities on the surface and loss of thickness of less than
50%; grade 3, deep ulceration with loss of thickness of more than 50% without exposure of
subchondral bone; grade 4, full-thickness chondral wear with exposure of subchondral bone.
A total score was calculated as the total of subregional scores. Intra-observer reliability
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expressed as the intra-class correlation coefficient (ICC) ranged from 0.77 to 0.94.
Bone marrow lesions
Bone marrow lesions were defined as discrete areas of increased signal adjacent to the
subcortical bone and measured using modified Whole-Organ Magnetic Resonance Imag-
ing Score (WORMS)25: 0=none; 1 ≤ 25% of the subregion; 2 = 25–50%; 3 ≥ 50%. A total
score of the tibiofemoral compartment was calculated as the total of 13 subregional scores
(0–39). The ICC of this bone marrow lesion ranged from 0.93 to 0.98.
6.2.7 25OHD assays
Serum 25OHD was assayed at screening, month 3 and 24, utilizing a direct competitive
chemiluminescent immunoassay (DiaSorin Inc., Stillwater, Minnesota, USA). The intra-
assay and inter-assay coefficients of variation were 3.2% and 6.0%.
6.2.8 Sample size
The sample size calculation is described in Section 3.2.6
6.2.9 Statistical analysis
WOMAC and VAS knee pain scores were analyzed using a repeated measures mixed model
with terms for age, sex, body mass index, treatment, month and trial center. The correlation
within the repeated measures was addressed by using individual participant ID as a random
effect. The effect of treatment was evaluated by the month× treatment interaction. In a post-
hoc analysis, we evaluated the proportion of participants who achieved at least 20% and 50%
improvement in WOMAC pain score, which has been shown to be clinically relevant [310].
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The independent t-test was used to compare annual changes in cartilage volume and abso-
lute changes of cartilage defects and bone marrow lesions between groups. An increase in
cartilage defects and bone marrow lesions was defined as a change of more than one unit
in the score. The presence of an increase in cartilage defects or bone marrow lesions was
compared between the two groups using logistic regression.
Both intention to treat and per protocol analyses were utilized. Per protocol was defined as
achieving a 25OHD level >60 nmol/L at the month 3 visit. Multiple imputations by chained
equations was used to address missing data due to loss to follow-up and non-responses.
Imputations were performed separately for each treatment group and each outcome, using
baseline values, age, gender, body mass index and serum 25OHD level.
6.3 Results
6.3.1 Participants
Figure 3.2 in the Section 3.2.1 shows the flow of the study. A total of 599 participants were
screened for eligibility from 5 Jun 2010 to 1 Dec 2011 and 413 participants were randomly
assigned to either vitamin D or placebo. The mean age of participants was 63.2 years, with
208 (50%) females and a mean body mass index of 29.6 kg/m2. Participants demographic
characteristics were comparable at baseline between two groups (Table 6.1). Twenty-eight
participants (13.4%) in the vitamin D group and 45 (22.1%) in the placebo group withdrew
from the study (p = 0.021). 340 participants (82.3%) completed the trial. There were no
significant differences between those who completed and those who withdrew apart from
more females and lower tibial cartilage volume in those who withdrew (Table 6.2). Fewer
participants discontinued treatment in the vitamin D group than the placebo group (8 versus
21). The major reason for a higher drop-out rate in the placebo group was that participants
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had their 25OHD levels checked by a primary health provider and started taking vitamin
D after finding low vitamin D levels. Consequently, they were withdrawn from the study.
All available data from the randomized participants were analyzed in the intention-to-treat
analyses.
Table 6.1: Baseline characteristics of the vitamin D and the placebo groups.
Vitamin D Placebo
(n=209) (n=204)
Hobart 129 (61%) 132 (64%)
Melbourne 80 (38%) 72 (35%)
Age (years) 63.5 (6.9) 62.9 (7.2)
Female (%) 106 (50%) 102 (50%)
BMI (kg/m2) 29.6 (5.4) 29.6 (4.6)
Serum 25OHD (nmol/L) 43.7 (11.8) 43.8 (12.7)
Radiographic OA (%) 163 (96%) 157 (96%)
Total WOMAC score (0–2400) 687.3 (426.3) 664.7 (390.8)
Pain (0–500) 137.8 (88.9) 134.4 (83.2)
Stiffness (0–200) 61.5 (41.6) 61.7 (40.1)
Function (0–1700) 487.9 (318.1) 467.6 (292.8)
VAS pain (0–100) 51.4 (18.8) 49.6 (17.8)
Tibial cartilage volume (cm3) 3.47 (1.04) 3.64 (1.04)
Medial tibial region (cm3) 1.46 (0.46) 1.52 (0.47)
Lateral tibial region (cm3) 2.01 (0.72) 2.12 (0.68)
Total bone area (cm2) 32.8 (5.4) 32.6 (5.1)
Cartilage defects (%) 194 (93%) 192 (94%)
Medial tibiofemoral region (%) 176 (84%) 164 (80%)
Lateral tibiofemoral region (%) 159 (76%) 157 (77%)
Bone marrow lesions (%) 134 (64%) 147 (72%)
Medial tibiofemoral region (%) 90 (43%) 95 (46%)
Lateral tibiofemoral region (%) 81 (39%) 89 (43%)
BMI, body mass index; 25OHD, 25-hydroxyvitamin D; OA, osteoarthritis;
WOMAC, Western Ontario and McMaster University Index; VAS, visual analogue scale;
Higher scores in WOMAC and VAS pain indicate a more severe stage of the condition.
Results are shown as mean (SD) or number (percentage) unless stated otherwise.
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Table 6.2: Baseline characteristics of those completed and dropouts.
Completed Dropout
P-value
(n=340) (n=73)
Hobart 214 (62.9%) 47 (64.4%) 0.817
Melbourne 126 (37.1%) 26 (35.6%)
Vitamin D 181 (53.2%) 28 (38.4%) 0.021*
Placebo 159 (46.8%) 45 (61.6%)
Age (years) 63.2 (7.1) 63.1 (7.0) 0.886
Female (%) 158 (46.5%) 50 (68.5%) <0.001*
BMI (kg/m2) 29.5 (4.9) 30.0 (5.7) 0.408
Serum 25OHD (nmol/L) 44.0 (12.1) 42.5 (13.0) 0.334
Radiographic OA (%) 279 (95.6%) 60 (98.4%) 0.306
Total WOMAC score (0-2400) 662.4 (405.7) 741.7 (420.6) 0.138
Pain (0–500) 133.8 (86) 148.2 (86) 0.197
Stiffness (0–200) 61.3 (40.4) 63.2 (42.9) 0.710
Function (0–1700) 467.2 (302.8) 529.1 (316.5) 0.121
VAS pain (0–100) 47.1 (20.7) 48.6 (22.7) 0.593
Tibial cartilage volume (cm3) 3.63 (1.05) 3.20 (0.93) 0.002*
Cartilage defects (%) 330 (97.6%) 69 (97.2%) 0.824
Bone marrow lesions (%) 267 (79.0%) 58 (81.7%) 0.609
BMI, body mass index; 25OHD, 25-hydroxyvitamin D; OA, osteoarthritis;
WOMAC, Western Ontario and McMaster University Index; VAS, visual analogue scale;
Results are shown as mean (SD) or number (percentage) unless stated otherwise.
Student t-test or Chi2 test was used for the comparison.
Asterisk signs indicate statistical significance.
6.3.2 Primary endpoints
25OHD level increased more in the vitamin D group (40.6 vs. 6.7 nmol/L, p <0.001) over
two years. Overall, 165 (79%) participants in the vitamin D group and 88 (43%) participants
in the placebo group reached a 25OHD level over 60 nmol/L at month 3.
Changes in WOMAC knee pain are presented in Table 6.3. At baseline, the mean and stan-
dard deviation of WOMAC pain score were 137.9 ± 88.8 in the vitamin D group and 134.7
± 83.4 in the placebo group (95% CI of difference [-13.5, 19.8], p = 0.712). Total WOMAC
pain decreased over 24 months in both groups (Figure 6.1). At month 24, the mean and stan-
dard deviation of WOMAC pain score were 87.0 ± 90.1 in the vitamin D group and 97.2 ±
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87.5 in the placebo group (95% CI of difference [-28.8, 8.4], p = 0.283). There was no dif-
ference in change in WOMAC pain between groups in the mixed-effect model in which all
time-points were included (-49.9 vs. -35.1, between-group difference 14.8, 95% CI [-32.5,
2.9], p = 0.102).
Figure 6.1: Comparison between vitamin D and placebo on change in WOMAC pain.
Tibial cartilage volume (mean± standard deviation) was not different between the vitamin D
group (3466± 1038 mm3) and the placebo group (3640± 1036 mm3) at baseline (between-
group difference -174 mm3, 95% CI of difference [-375, 27], p = 0.091). At month 24, tibial
cartilage volume was also not different between the vitamin D group (3238 ± 989 mm3)
and the placebo group (3398 ± 1030 mm3) (between-group difference -160 mm3, 95% CI
of difference [-369, 49], p = 0.134). Change in tibial cartilage volume (Table 6.3) was not
different between the groups (-242.6 mm3 vs. -301.4 mm3, between-group difference 58.8
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mm3, 95% CI [-13.9, 131.4], p = 0.114). Per protocol analysis comparing those achieved
25OHD level>60 nmol/L at month 3 visit to those who did not (253 vs. 146, 14 participants
withdrew within 3 months) showed similar results (-261.9 mm3 vs. -284.8 mm3, between-
group difference 22.9 mm3, 95% CI [-51.5, 97.3], p = 0.547).
6.3.3 Secondary endpoints
The results for tibiofemoral cartilage defects and bone marrow lesions are shown in Table
6.3. The difference in cartilage defect score was not statistically significant between groups.
Bone marrow lesion scores decreased in both groups and no significant difference was ob-
served.
6.3.4 Post-hoc analyses
In post-hoc analyses (Table 6.3), participants in the vitamin D group had statistically signifi-
cant improvements in VAS knee pain (Figure 6.2) scores compared to the placebo group. The
vitamin D group had more improvement in total WOMAC score (Figure 6.3) and WOMAC
function (Figure 6.4), but not WOMAC stiffness (Figure 6.5). There were 115 (64%) par-
ticipants in the vitamin D group and 95 (57%) participants in the placebo group (p = 0.164)
who achieved a 20% improvement in WOMAC knee pain score over two years. There were
90 (50%) participants in the vitamin D group and 65 (39%) participants in the placebo group
(p = 0.036) that showed at least a 50% improvement in WOMAC pain. Furthermore, there
were significantly more OMERACT-OARSI responders in the vitamin D group than the
place group (35% versus 25%, p = 0.029). However, the proportion of participants that had
an increase in bone marrow lesions was significantly lower in vitamin D group (17% versus
27%, p = 0.031).
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Figure 6.2: Comparison between vitamin D and placebo on change in VAS pain.
Figure 6.3: Comparison between vitamin D and placebo on change in total WOMAC score.
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Figure 6.4: Comparison between vitamin D and placebo on change in WOMAC function.
Figure 6.5: Comparison between vitamin D and placebo on change in WOMAC stiffness.
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Table 6.3: Change in study endpoints over two years between vitamin D and placebo [mean (95% CI)]
Vitamin D (n = 209) Placebo (n = 204) Between-group
P-value
Baseline Month 24 Baseline Month 24
difference
in change†‡
Primary Endpoints
WOMAC pain (0–500) 137.9 ± 88.8 87.0 ± 90.1 134.7 ± 83.4 97.2 ± 87.5 -14.8 (-32.5, 2.9) 0.102
Tibial cartilage volume (mm3) 3466 ± 1038 3238 ± 989 3640 ± 1036 3398 ± 1030 58.78 (-13.86, 131.40) 0.114
Medial tibial cartilage volume (mm3) 1461 ± 463 1369 ± 464 1522 ± 474 1407 ± 456 31.68 (-10.04, 73.38) 0.138
Lateral tibial cartilage volume (mm3) 2005 ± 716 1870 ± 673 2118 ± 681 1992 ± 689 26.70 (-19.44, 72.86) 0.258
Change in tibial cartilage(% p.a.) -3.44 (-4.17, -2.72) -4.23 (-4.97, -3.48) 0.78 (-0.23, 1.80) 0.132
Medial tibial cartilage (% p.a.) -3.29 (-4.28, -2.30) -4.39 (-5.40, -3.39) 1.10 (-0.28, 2.48) 0.119
Lateral tibial cartilage (% p.a.) -3.44 (-4.30, -2.58) -4.09 (-4.96, -3.22) 0.65 (-0.55, 1.84) 0.290
Secondary Endpoints
Tibiofemoral cartilage defects (0–16) 9.27 ± 3.10 9.70 ± 3.15 8.77 ± 2.94 9.17 ± 3.14 -0.17 (-0.43, 0.09) 0.208
Medial tibiofemoral defects (0–8) 4.87 ± 2.11 5.17 ± 2.13 4.65 ± 2.14 4.95 ± 2.16 -0.12 (-0.30, 0.06) 0.197
Lateral tibiofemoral defects (0–8) 4.40 ± 1.89 4.53 ± 1.87 4.12 ± 1.75 4.22 ± 1.87 -0.05 (-0.23, 0.13) 0.570
Tibiofemoral BMLs (0–39) 2.36 ± 2.95 2.29 ± 2.96 2.64 ± 2.88 2.89 ± 3.66 -0.45 (-0.92, 0.01) 0.059
Medial tibiofemoral lesions (0–18) 1.28 ± 2.24 1.21 ± 2.10 1.41 ± 2.26 1.51 ± 2.56 -0.22 (-0.54, 0.10) 0.186
Lateral tibiofemoral lesions (0–18) 0.83 ± 1.39 0.78 ± 1.41 0.91 ± 1.33 1.02 ± 1.56 -0.22 (-0.47, 0.03) 0.087
Post-hoc Endpoints
VAS pain (0–100) 48.7 ± 21.4 33.7 ± 27.1 46.4 ± 20.5 36.4 ± 25.1 -5.4 (-10.7, -0.1) 0.048*
WOMAC total (0-2400) 687 ± 426 434 ± 419 665 ± 391 505 ± 436 -91.4 (-165.1, -17.7) 0.015*
Function (0-1700) 488 ± 318 306 ± 304 468 ± 293 362 ± 323 -72.9 (-126.4, -19.4) 0.008*
Stiffness (0-200) 61.5 ± 41.5 41.1 ± 44.1 61.7 ± 40.1 45.7 ± 41.1 -4.2 (-12.5, 4.0) 0.313
WOMAC, Western Ontario and McMaster University Index; VAS, visual analogue scale; p.a., per annum.
Between group difference is calculated using vitamin D group minus placebo group.
†WOMAC scores and VAS pain results are generated from mixed models adjusted for age, sex, body mass index, center and month.
‡Cartilage volume, cartilage defect and bone marrow lesion results are generated from multiple imputed datasets.
Higher scores in WOMAC, VAS pain, cartilage defects and bone marrow lesions indicate a more severe stage of the condition.
All analyses compare baseline versus 24 months. Asterisk signs indicate statistical significance.
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6.3.5 Adverse events
Fifty-six participants in the vitamin D group reported at least one adverse event compared to
37 participants in the placebo group (Table 6.4). Four participants developed hypercalcemia
in the vitamin D group, comparing to two in the placebo group. One participant in the
vitamin D group had symptoms of hyperparathyroidism (e.g. muscle cramps, brittle bone
and kidney dysfunction). There was one episode of renal calculus in each group.
Table 6.4: Adverse events.
Vitamin D Placebo
(N=209) (%) (N=204) (%)
Serious Adverse Events
Death 1 (0.5) 0 (0.0)
Malignancy 4 (1.9) 2 (1.0)
Coronary artery disease 1 (0.5) 1 (0.5)
Severe infection 0 (0.0) 3 (1.5)
Major depression 1 (0.5) 0 (0.0)
Nephrolithiasis 1 (0.5) 1 (0.5)
Hospitalization* 3 (1.4) 0 (0.0)
Adverse Events
Hypercalcemia 4 (1.9) 2 (1.0)
Hyperparathyroidism 1 (0.5) 0 (0.0)
Renal 2 (1.0) 0 (0.0)
Falls 2 (1.0) 0 (0.0)
Musculoskeletal 1 (0.5) 1 (0.5)
Neurological 5 (2.4) 4 (2.0)
Gastrointestinal 7 (3.3) 5 (2.5)
Respiratory 2 (1.0) 2 (1.0)
Ocular 1 (0.5) 2 (1.0)
Infection 6 (2.9) 4 (2.0)
Cardiac arrhythmia 3 (1.4) 0 (0.0)
Chest pain 4 (1.9) 5 (2.5)
Pain 7 (3.3) 2 (1.0)
Allergy/immunology 0 (0.0) 2 (1.0)
Other eventsˆ 9 (4.3) 7 (3.4)
*Two were admitted to hospital after a fall and one was due to severe diarrhea.
Iˆncluding headache, lethargy, flu symptoms and other events.
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6.4 Discussion
This RCT aimed to determine whether vitamin D supplementation could reduce knee pain
and cartilage loss, and prevent progression of other knee structural abnormalities in knee
OA patients with low 25OHD levels. Results showed that even in people with low 25OHD,
supplementation did not slow cartilage loss or improve WOMAC assessed pain. These data
suggest a lack of evidence to support vitamin D supplementation for slowing disease pro-
gression/structural change in knee OA.
Although epidemiological studies suggest that knee OA is more prevalent in those who are
deficient in vitamin D, and vitamin D deficiency is associated with cartilage loss810 and
knee OA symptoms [127, 128, 311], the results from two prior RCTs were mixed. In one
study, supplementation of vitamin D3 2000 IU/day over two years showed no benefit for
symptoms and structural changes in patients with knee OA, regardless of their 25OHD lev-
els [129]. The other reported a small but statistically significant benefit on symptoms in
patients with vitamin D insufficiency over one year [130]. Both studies have limitations.
The first study included patients without vitamin D deficiency who may not benefit from
vitamin D supplementation and patients whose disease was too severe to respond to vitamin
D treatment. Also, it had a small sample size [305]. The second study did not examine
structural changes and had a one-year follow-up, which may be too short to observe disease
progression [312]. Our study addressed these limitations by recruiting patients without se-
vere knee OA with low 25OHD levels and followed them for two years. Nonetheless, our
results are largely consistent with the prior two trials.
Structural changes in cartilage and non-cartilaginous joint tissue assessed using MRI, are
now recommended outcomes for clinical trials in OA [313]. An observational study showed
that lower serum 25OHD levels were associated with greater cartilage volume loss over 2.7
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years [120]. In the current study, the amount of tibial cartilage volume loss in the placebo
group is consistent with the findings of a previous RCT [129]. We did not find significant
effects on change in knee cartilage defects and bone marrow lesions.
Vitamin D side effects may include hypercalcemia. While intermittent very high dose vi-
tamin D, for example 500,000 IU annually, may not be safe [314], our study suggests that
the monthly regimen at a dosage of 50,000 IU is safe for the elderly, even though the serum
25OHD levels of long-term users are at the upper limit of the normal range [315].
The key strength of this RCT is the inclusion/exclusion criteria. We included only people
with knee OA who had a vitamin D insufficiency, who may be the most likely to benefit
from vitamin D supplements. We also used a predefined range of knee pain to prevent a
ceiling or floor effect in the statistical analyses. We excluded patients with late stage knee
OA, because there is very little cartilage left in these patients thus any possible benefits of
therapy on cartilage would be difficult to identify. By using these criteria, we studied a
patient population in whom the likelihood of demonstrating an effect (if truly present) of
vitamin D supplementation was maximized.
The study also had limitations. First, WOMAC pain as a co-primary outcome was added
during the recruitment period at the time the protocol was published. However, this change
was made before the trial was completed, before any data analyses, and the original sample
size had sufficient power to detect the expected difference in WOMAC pain. Second, loss
to follow-up was 17.7% and was less in the vitamin D group (28 vs. 45 participants, p =
0.021). There were fewer participants who withdrew from their assigned intervention in the
vitamin D group (8 vs. 21). Participants who did not comply with their assigned intervention
could be expected to have a worse outcome than those who did. While this could bias the
result towards the null, similar results were seen in per protocol analysis suggesting the
differential drop out had minimal impact on our results. Last, we did not pre-specify clinical
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outcomes such as visual analogue scale knee pain and WOMAC physical function as primary
or secondary endpoints.
In conclusion, among patients with symptomatic knee OA and low serum 25OHD levels, vi-
tamin D supplementation, compared with placebo, did not result in significant differences in
change in MRI-measured tibial cartilage volume or change in WOMAC knee pain score over
2 years. These findings do not support the use of vitamin D supplementation for preventing
tibial cartilage loss or improving WOMAC knee pain in patients with knee OA.
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CHAPTER 7
Associations between Endogenous Sex
Hormones and MRI Structural Changes in
Patients with Symptomatic Knee
Osteoarthritis
7.1 Introduction
The prevalence of knee OA in males and females is similar up to age 50 years, after which the
prevalence for females increases more quickly than men [301, 316], suggesting a possible
influence of the change in hormonal factors at the time of menopause on the development and
progression of the disease. The relationship between hormonal changes due to menopause
and OA was first described as early as 1926 and was referred to as ‘menopausal arthritis’
[317]. However, a clear causal relationship has yet to be established.
The available evidence for the relationship between sex hormones and knee structural changes
in OA was systematically reviewed by Tanamas and colleagues in 2011 [318]. 27 studies
were included in this review. However, due to the heterogeneity among the studies, there
was insufficient evidence to draw any clear conclusion. One longitudinal study suggests
an association between endogenous estrogen and radiographic OA in 842 premenopausal
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and perimenopausal women [145]. One small cohort study of asymptomatic men showed
a positive cross-sectional association between endogenous testosterone and tibial cartilage
volume [319]; however, the longitudinal analysis found that testosterone was also associ-
ated with loss of cartilage volume over 2 years [320]. No significant relationship was found
between testosterone and cartilage morphology or bone structure in an asymptomatic popu-
lation [321].
The effects of endogenous sex hormones on knee OA structures remain uncertain, partly
due to the lack of a longitudinal study with sufficient sample size in knee OA patients.
Therefore, the aim of this study was to describe the longitudinal associations between serum
levels of estrogen, progesterone and testosterone and knee structural changes using magnetic
resonance imaging (MRI) in both males and females with symptomatic knee OA.
7.2 Method
7.2.1 Study design, setting and participants
This study included data on 200 participants who were randomly selected from the Vitamin
D Effect on Osteoarthritis (VIDEO) study, which is described in Section 3.2. In the study,
treatment and placebo groups were combined together as a cohort.
7.2.2 Assessment of pain
Knee pain was assessed at the baseline visit and at month 3, 6, 12 and 24 using a 100
mm visual analogue scale (VAS). Patients were asked to rate the severity of knee pain they
experienced in the last month.
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7.2.3 MRI assessment of knee structural changes
MRI scans of the study knee were obtained according to a standardized protocol as described
in Section 3.6
Cartilage volume
Cartilage volume was determined using the previously described image processing tech-
niques [120]. The volumes of individual cartilage plates (medial tibial and lateral tibial)
were isolated by manually drawing disarticulation contours around the cartilage boundaries
on a section-by-section basis then resampled by means of bilinear and cubic interpolation for
final 3D rendering using OsiriX Lite imaging software (32-bit version 5.9, Pixmeo SARL,
Geneva, Switzerland). The coefficient of variation (CV) was 2.1% for medial tibia and 2.2%
for the lateral tibia [309].
Cartilage defects
Cartilage defects were graded using a modified Outerbridge classification [306] at medial
tibial, medial femoral, lateral tibial and lateral femoral sites: grade 0, normal cartilage;
grade 1, focal blistering and intracartilaginous hyperintensity with a normal contour; grade
2, irregularities on the surface and loss of thickness of less than 50%; grade 3, deep ulceration
with loss of thickness of more than 50% without exposure of subchondral bone; grade 4, full-
thickness chondral wear with exposure of subchondral bone. A total score was calculated as
the total of subregional scores. Intra-observer reliability (expressed as ICC) was 0.90 for the
medial tibiofemoral compartment, 0.89 for the lateral tibiofemoral compartment, 0.94 for
the patellar compartment and 0.94 for the total score. Inter-observer reliability was assessed
in 50 MR images and yielded an ICC of 0.90 for the medial tibiofemoral compartment, 0.85
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for the lateral tibiofemoral compartment, 0.93 for the patellar compartment and 0.93 for the
total [177].
Bone marrow lesions
BMLs were defined as discrete areas of increased signal adjacent to the subcortical bone.
The areas were measured semi-quantitatively using a modified Whole-Organ Magnetic Res-
onance Imaging Score (WORMS) [322] method in 15 sub-regions. The medial and lateral
compartments of the tibial and femoral were divided into three sub-regions (anterior, central
and posterior), and the tibia has one additional sub-region which represents the area be-
neath the tibial spines. Patellar was divided into medial and lateral sub-regions. BMLs were
scored from 0 to 3 based on the extent of sub-regional involvement (0 = none; 1 = <25% of
the sub-region; 2 = 25-50%; 3 = >50%). A total score (0-45) was calculated as the total of
15 sub-regional scores. The intra-observer reliability of this BML scoring system has been
shown to be excellent [212, 323].
Effusion-synovitis volume
Effusion-synovitis volume was measured according to previously published methodology in
the following sub-regions: 1) suprapatellar pouch, extends superiorly from the upper surface
of the patellar, between the posterior suprapatellar fat pad (quadriceps femoris tendon) and
the anterior surface of the femur; 2) central cavity, which includes the area between the
central femoral and tibial condyles, around the ligaments and menisci, and the area behind
the posterior portion of each femoral condyle, inside of the joint capsule. The effusion-
synovitis volume was isolated by selecting a region of interest (ROI) with the intra-articular
fluid-equivalent signal on a section-by-section basis. The total 3D volume was generated
using OsiriX Lite imaging software. The intra-rater reliability (ICC = 0.96–0.97) and inter-
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rater reliability (ICC = 0.93–0.99) were excellent.
7.2.4 Sex hormone assays
Fasting blood was drawn at baseline and two-year follow-up, and stored at -80C until as-
sayed. Estradiol (E2) and progesterone (P) were measured using commercial enzyme-linked
immunosorbent assay (ELISA) kits (Phoenix Pharmaceuticals Inc.; Burlingame, CA, USA).
All assays were performed according to the manufacturers protocol. For estradiol, the assays
Intra-class Correlation Coefficient (ICC) was 0.993, with a detection limit of 10 pg/ml. For
progesterone, the ICC was 0.993, with a detection limit of 0.0625 ng/ml. Total testosterone
(T) and sex hormone binding globulin (SHBG) was measured using a commercial ELISA
kits (Demeditec Diagnostics GmbH, Kiel, Germany). For total T, the ICC was 0.997, with a
detection limit of 0.083 ng/ml. For SHBG, the ICC was 0.994, with a detection limit of 0.2
nmol/L.
7.2.5 25OHD assays
Serum 25OHD was assayed by Liaison method utilizing a direct competitive chemilumines-
cent immunoassay (DiaSorin Inc., Stillwater, Minnesota, USA). The intra-assay and inter-
assay coefficients of variation were 3.2% and 6.0%.
7.2.6 Statistical methods
Baseline characteristics were analyzed by descriptive statistics and were compared between
males and females using Students t-test for continuous data and Chi-square test for dichoto-
mous data.
Because of skewed distributions, serum sex hormone concentrations were categorized into
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quartiles based on the distribution of values separately for males and females. The longitu-
dinal associations between sex hormones and MRI structures were analyzed using a linear
mixed-effects model. In the model, we entered terms for age, body mass index, sex hormone
concentration, and vitamin D treatment allocation as fixed effects, and individual subject IDs
as random intercepts. The analysis was performed separately for males and females due to
sex differences in associations. The temporal relationship between sex hormone and MRI
structures was further explored by adding the interaction term between sex hormone and age
in the model.
7.3 Results
7.3.1 Participants
Table 7.1 shows the comparison of baseline characteristics between males and females.
There was no significant difference in age, body mass index and serum vitamin D levels at
baseline between sexes. Mean estradiol and progesterone levels were comparable between
males and females, while testosterone levels were significantly higher for males and SHBG
levels were significantly higher for females. There was no significant difference in VAS
pain score. While males had more cartilage volume than females in both tibial and patellar
compartments, the grades of cartilage defects and BMLs were similar between males and
females. The volume of effusion-synovitis was greater in males than females.
7.3.2 Sex hormones and cartilage morphology
Table 7.2 shows the longitudinal associations between sex hormones and cartilage morphol-
ogy. For males, sex hormone quartiles were not associated with total cartilage volume and
cartilage defects. Similar results were observed for females, except for progesterone, where
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Table 7.1: Baseline characteristics between males and females.
Male (n = 107) Female (n = 93) P-value
Age (years) 63.9 ± 7.4 62.1 ± 7.2 0.10
BMI (kg/m2) 29.0 ± 4.0 30.0 ± 5.6 0.16
25(OH)D (nmol/L) 44.4 ± 12.0 41.3 ± 12.2 0.08
Sex hormone profiles
Estradiol (pg/ml) 28.9 ± 15.7 32.9 ± 26.5 0.19
Progesterone (ng/ml) 0.4 ± 0.2 0.5 ± 1.1 0.93
Testosterone (ng/ml) 3.5 ± 1.5 0.4 ± 0.4 <0.01*
SHBG (nmol/L) 34.0 ± 15.3 52.3 ± 27.8 <0.01*
Clinical symptoms
VAS pain (0–100) 45.8 ± 19.8 49.2 ± 20.6 0.24
MRI structures
Tibial cartilage volume (mm3) 4.3 ± 1.0 3.0 ± 0.6 <0.01*
Patellar cartilage volume (mm3) 2.8 ± 0.8 1.7 ± 0.6 <0.01*
Total cartilage defects (0–24) 14.2 ± 4.0 14.7 ± 4.4 0.47
Total BMLs (0–45) 3.7 ± 3.7 3.4 ± 3.0 0.5
Total effusion volume (mm3) 12.3 ± 10.8 7.7 ± 7.0 <0.01*
Total effusion grade (0–3) 2.1 ± 0.9 1.6 ± 0.9 <0.01*
BMI, body mass index; SHBG, sex hormone binding globulin;
Results are shown as mean (standard deviation).
Unpaired student t-test was used for the comparison.
* indicates statistical significance at α = 0.05.
higher progesterone quartiles were significantly associated with more cartilage volume (β =
0.12 per quartile, p = 0.01). There were no statistically significant interactions between any
sex hormones and age.
7.3.3 Sex hormones, BMLs and effusion-synovitis
Table 7.3 shows the longitudinal relationships of sex hormones quartiles with BMLs and
effusion-synovitis. No statistically significant relationship was observed for males. In con-
trast for females, higher quartiles of estradiol levels were associated with a lower grade of
BMLs (β = -0.45 per quartile, p = 0.03), but there were no associations between BML grade
and progesterone, testosterone or SHBG levels. Higher quartiles of estradiol (β = -1.26 per
quartile, p = 0.05), progesterone (β = -1.60 per quartile, p <0.01) and testosterone (β = -
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Table 7.2: Linear mixed-effect model for association between sex hormones and cartilage morphol-
ogy over 2 years.
Male (n = 107) Female (n = 93)
β (95% CI)† P-value β (95% CI)† P-value
Total cartilage volume (mm3)
Estradiol -0.06 (-0.22, 0.10) 0.48 -0.07 (-0.17, 0.04) 0.20
Progesterone 0.13 (0.00, 0.27) 0.06 0.12 (0.03, 0.21) 0.01*
Testosterone 0.05 (-0.09, 0.20) 0.47 -0.02 (-0.12, 0.07) 0.65
SHBG 0.06 (-0.11, 0.24) 0.49 0.08 (-0.04, 0.20) 0.18
Total cartilage defects (0-24)
Estradiol -0.22 (-0.62, 0.18) 0.28 0.02 (-0.39, 0.43) 0.93
Progesterone 0.03 (-0.32, 0.37) 0.89 0.21 (-0.15, 0.57) 0.26
Testosterone -0.02 (-0.38, 0.34) 0.92 -0.14 (-0.51, 0.23) 0.45
SHBG 0.21 (-0.23, 0.66) 0.35 0.30 (-0.17, 0.77) 0.21
SHBG, sex hormone binding globulin; CI, confidence interval.
†Multivariable analysis adjusted for age, body mass index and randomization.
Beta coefficient represents change in cartilage per quartile increase in corresponding sex hormone.
* indicates statistical significance at α = 0.05.
Table 7.3: Linear mixed-effect model for association between sex hormones and bone marrow lesions
and effusion-synovitis over 2 years.
Male (n = 107) Female (n = 93)
β (95% CI)† p-value β (95% CI)† p-value
Total BML (0-45)
Estradiol -0.13 (-0.63, 0.37) 0.62 -0.45 (-0.86, -0.05) 0.03
Progesterone 0.03 (-0.45, 0.50) 0.9 -0.19 (-0.58, 0.19) 0.32
Testosterone 0.12 (-0.38, 0.62) 0.64 -0.20 (-0.58, 0.19) 0.32
SHBG 0.21 (-0.34, 0.76) 0.45 -0.04 (-0.50, 0.41) 0.85
Effusion volume (mm3)
Estradiol -0.73 (-2.33, 0.86) 0.37 -1.26 (-2.50, -0.02) 0.05
Progesterone 0.86 (-0.61, 2.34) 0.25 -1.60 (-2.77, -0.43) <0.01
Testosterone -0.13 (-1.67, 1.42) 0.87 -1.49 (-2.71, -0.27) 0.02
SHBG 0.90 (-0.84, 2.65) 0.31 -0.25 (-1.62, 1.12) 0.72
BML, bone marrow lesion; SHBG, sex hormone binding globulin; CI, confidence interval.
†Multivariable analysis adjusted for age, body mass index and randomization.
Beta coefficient represents change in BML or effusion volume per quartile increase in corresponding sex
hormone.
Bold values indicate statistical significance at α = 0.05.
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1.49 per quartile, p = 0.02) were associated with less effusion-synovitis volume for females.
The levels of SHBG were not associated with effusion-synovitis. There were no statistically
significant interactions between any sex hormones and age.
7.3.4 Sex hormones and VAS pain
Table 7.4 shows the longitudinal association of sex hormones quartiles with knee VAS pain.
For males, none of the sex hormones was associated with VAS pain score. In contrast,
higher quartiles in testosterone were associated with a lower VAS pain for females (β = -
3.90 per quartile, p = 0.02). Neither estradiol nor progesterone in females were significantly
associated with VAS pain score.
Table 7.4: Linear mixed-effect model for association between sex hormones and VAS pain over 2
years.
Male (n = 107) Female (n = 93)
β (95% CI)† p-value β (95% CI)† p-value
VAS pain (0-100)
Estradiol 2.26 (-0.68, 5.19) 0.13 -1.61 (-4.92, 1.70) 0.26
Progesterone 0.54 (-2.40, 3.47) 0.93 -1.05 (-4.37, 2.27) 0.54
Testosterone 0.13 (-2.94, 3.20) 0.93 -3.90 (-7.12, -0.68) 0.02
SHBG 2.97 (-0.18, 6.12) 0.06 -1.93 (-5.47, 1.60) 0.28
SHBG, sex hormone binding globulin; CI, confidence interval.
†Multivariable analysis adjusted for age, body mass index and randomization.
Beta coefficient represents change in VAS per quartile increase in corresponding sex hormone.
Bold values indicate statistical significance at α = 0.05.
7.4 Discussion
Our study is the first to examine the longitudinal associations between endogenous sex hor-
mone levels and different MRI-assessed joint structures in both males and females with
symptomatic knee OA. Our hypothesis was that sex hormone deficiency was associated with
OA-related joint structural abnormalities, and this was supported by our data in females but
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not in males. We found no associations between endogenous sex hormones and joint struc-
tural changes measured as cartilage volume, cartilage defects, BMLs and effusion-synovitis
in male patients with knee OA. However, in females, progesterone was positively associated
with cartilage volume, estradiol was negatively associated with BMLs, and all sex hormones
had inverse relationships with total effusion-synovitis volume. The discrepancy in the ef-
fect of sex hormones between males and females may be attributable to the fact that gene
expression patterns for sex hormone receptors differed by sex and the regulatory effect of
sex hormones on collagen gene expression in the cartilage was different among males and
females [324].
MRI provides higher sensitivity than radiograph in detecting early structural changes and has
become a popular tool for OA research. Measurement of cartilage morphology, BMLs and
effusion-synovitis has been found associated with the progression of knee OA [325]. There
are very few epidemiological studies examining associations between endogenous sex hor-
mones and MRI structures in the symptomatic knee OA population. In a small 2-year cohort
study of 28 healthy men aged 51.9 years, Hanna and colleagues found that increased serum
testosterone was associated with greater cartilage volume in a cross-sectional analysis, while
higher serum free testosterone was associated with increased tibial cartilage volume loss over
2 years. The authors suggested that the benefit of testosterone on cartilage volume was only
temporary and that the longitudinal inverse association may be due to a higher level of phys-
ical activity which results in greater biomechanical stress in the articular cartilage [319].
However, in another cross-sectional study conducted by the same research group, no associ-
ations were found between testosterone and cartilage morphology or bone structures in 139
asymptomatic midlife females [321]. No significant relationship was found between knee
estrogen and knee structure [319, 320, 321]. Our findings were similar to these studies as
no significant associations were observed in between estradiol, testosterone and total carti-
lage volume in both males and females. Interestingly, we found progesterone was positively
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associated with cartilage volume for females. Progesterone is the precursor for all steroid
hormones and its receptors have been localized in the chondrocytes of knee cartilage [326].
Progesterone may play a role in the maintenance of cartilage volume by suppressing the pro-
duction of matrix metalloproteinases (MMPs) family [327], which are primarily responsible
for the degradation of articular cartilage. In addition, combined therapy with estrogen and
progesterone was found to be more effective in suppressing cartilage turnover compare to
estrogen alone treatment in a murine model of OA [328].
The fact that the prevalence of knee OA in women increases dramatically in the years after
menopause suggest that the drop in sex hormones at the time of menopause increase the risk
getting knee OA in women. Urinary cross-linking telopeptide of type II collagen (uCTX-II)
is a prognostic biomarker candidate for knee OA [329] and its levels have been found to
increase after menopause, consistent with the acceleration of knee OA in postmenopausal
women [330]. uCTX-II has unique relations with bone metabolism [331] and Garnero and
colleagues found that BMLs on MRI were significantly associated with uCTX-II [332]. It is
well established that estrogen plays a major role in regulating bone turnover and remodeling
by modulating the activity of osteoblasts and osteoclasts [333]. The findings of the present
study confirm the link between estrogen, bone metabolism and OA-related subchondral bone
abnormalities as higher estradiol levels in women were observed to be associated with lower
total BML scores. This result is consistent with previous findings where postmenopausal
women taking estrogen replacement therapy showed a significantly decreased prevalence of
BMLs compared with those not taking it [334].
Joint swelling is one clinical feature of knee OA reflecting the presence of effusion- synovi-
tis on MRI. Low-grade inflammation and synovitis-effusion have been strongly implicated
in the pathogenesis of knee OA [237, 83]. It has been known for many decades that sex
hormones are involved in the modulation of immune responses [335]. Estrogen and pro-
gesterone receptors were found in the lining cells of human synovium [326, 336]. While
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progesterone and testosterone are thought to be anti-inflammatory [337, 338], estradiol has
been demonstrated to have pro-inflammatory effects at high doses, but anti-inflammatory
properties via inhibition of IL-1β at low doses [339]. Our results show that estradiol, pro-
gesterone and testosterone were all negatively associated with effusion-synovitis volume for
females. The inverse relationship between estradiol and effusion-synovitis volume may be
a result of the anti-inflammatory effects of low dose estrogen which is characteristic in this
postmenopausal population. Circulating testosterone gradually decrease in postmenopausal
women and the low testosterone levels have been linked to increased pain sensitivity [340].
In this study, we also found that higher levels of testosterone for females were associated
with lower VAS pain score.
The interaction terms between sex hormones and age were added in the mixed-effect model
to explore the temporal relationship between sex hormones and MRI structures. The inter-
action terms appear to be statistically non-significant in our analyses, suggesting that the
strength of the association may not change over time. Although this study was unable to
show that changes in sex hormones preceded MRI structural changes, it is biologically un-
likely that MRI structural changes could cause alteration of sex hormone levels.
There were several potential limitations. This study is conducted as a post-hoc analysis
within a subsample of an RCT, and the results applied to the population sample of the orig-
inal study, which is in the context of symptomatic knee OA with vitamin D insufficiency,
but may not generalizable to the general population of knee OA. While allocation to vitamin
D treatment may intervene in the relationship between sex hormones and MRI structures,
repeated analyses adjusted for vitamin D levels yield very similar results (data not shown).
Another limitation of this study is that information regarding previous reproductive histories
and concurrent use of hormone replacement therapy was not obtained during the clinical
visit because the original RCT was not designed to study the effects of sex hormones in
knee OA patients. Also, we did not select the timing of blood sample collection for sex
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hormone testing, as blood was collected at each clinical visit scheduled based on the original
RCT. However, the women in this study were to be postmenopausal due to age, so their sex
hormones should not fluctuate as they do in premenopausal women. Even if fluctuation did
occur in women, the increased variance in hormones would lead to bias towards the null,
therefore, our findings would not be expected to change due to hormonal fluctuation.
There are a number of strengths in our study. First, it examines the sex hormone levels in a
symptomatic knee OA population, in comparison to previous literature where sex hormones
are examined in asymptomatic healthy population. Second, we utilized state-of-the-art MRI
scan to analyze multiple structural changes in the knee as a whole. Lastly, our study is a
prospective longitudinal analysis with sufficiently large sample size to establish any rela-
tionships between sex hormones and the knee structures.
In conclusion, endogenous estradiol, progesterone and testosterone may be protective for
joint structural changes in women but not men. This may contribute to observed sex differ-
ences in knee OA.
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CHAPTER 8
MRI Markers and the Prediction of Total
Knee Replacement
8.1 Introduction
Magnetic Resonance Imaging (MRI) allows a non-invasive, three-dimensional assessment of
the entire joint and is increasingly used in knee OA research. MRI provides higher sensitivity
than x-ray in detecting early knee OA with a semi-quantitative assessment of cartilage defect,
bone marrow lesion (BML), effusion-synovitis, and meniscal pathology [341, 342]. These
structural pathologies are associated with the clinical and structural progression of knee OA
[325, 343, 344, 345].
Total knee replacement (TKR) is an important clinical endpoint for end-stage knee OA.
TKR is considered when knee OA patients have progressively increasing pain and decreasing
physical function. During 2014, over 54,277 knee replacements were performed in Australia
with each procedure costing between $15,000 to $31,900 [346]. The incidence of TKR
for knee OA is rising steeply, and expected to increase by more than 6-fold in the US by
2030 [347]. MRI could detect early structural abnormalities on MRI and therefore identify
potential targets for effective treatment, which may ultimately lower or delay the need for
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TKR in the long term.
The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
(ESCEO) suggested MRI as a viable alternative to radiography for prediction of TKR in a
literature review [348]. One study of 117 patients with knee OA reported that high cartilage
defect scores were associated with a six-fold increased risk of TKR over 4 years compared
with those with lower scores [186]. In another longitudinal study of 109 patients with knee
OA, severity of BMLs was associated with increased risk of TKR over 4 years [214]. The
risk for TKR was significantly increased in knees with MRI abnormalities, such as more
than two subregions with severe cartilage loss, more than two subregions with BMLs, me-
dial meniscal maceration but not extrusion, and effusion or synovitis [215]. However, the
independent predictive value of each structural pathology has not been examined in these
studies. Also, the clinical implication of these studies is limited by their relatively small
sample size and short follow-up time, and most of the studies examined participants with
definite knee OA, which has very high rates of knee replacement (>10%), thus the data may
not be applicable to the general population. Therefore, the independent predictive validity
of MRI structural pathologies for TKR needs to be further examined in a large community-
based cohort with longer-term follow-up.
Previous data from our community-based study showed that cartilage defects [178] and
BMLs [199] predicted risk of TKR over 5 years but there were relatively few TKRs. The
aim of this study was to examine whether cartilage defects, BMLs, meniscal tear, meniscal
extrusion and effusion-synovitis at baseline predict long-term TKR over 10 years.
115
Chapter 8. MRI Markers and the Prediction of Total Knee Replacement
8.2 Methods
8.2.1 Study design, setting and participants
This study used the data from the Tasmanian Older Adult Cohort Study (TasOAC) as de-
scribed in Section 3.1.
8.2.2 MRI scans
The full details of MRI specifications are described in Section 3.6
Cartilage defects
Cartilage defects were assessed on T1-weighted MRI and graded at medial tibial, medial
femoral, lateral tibial, lateral femoral and patellar regions using a modified Outerbridge sys-
tem: grade 0, normal cartilage; grade 1, focal blistering and low-signal intensity change
with an intact surface and bottom; grade 2, irregularities on the surface or bottom and loss
of thickness of less than 50%; grade 3, deep ulceration with loss of thickness of more than
50%; grade 4, full thickness cartilage loss with exposure of subchondral bone [177]. A car-
tilage defect also had to be present in at least two consecutive slices. The total cartilage
defect score was the highest score of all compartments of the knee. Intra-observer reliability
(expressed as ICC) was 0.89–0.94 and inter-observer reliability was 0.85–0.93 [177].
Bone marrow lesions
Bone marrow lesions (BMLs) were defined as poorly marginated areas of increased signal
adjacent to the subcortical bone on T2-weighted MRI and scored at medial tibial, medial
femoral, lateral tibial, lateral femoral and patellar regions using a modified version of Whole-
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Organ Magnetic Resonance Imaging Score (WORMS): grade 0, absence of BML; grade 1,
area smaller than 25% of the region; grade 2, area between 25% to 50% of the region; grade
3, area larger than 50% of the region [322]. The total BML score was the highest score of
the region out of all the regions. The inter-reader reliability of this BML scoring system has
been shown to be excellent [212, 323].
Effusion-synovitis
Effusion-synovitis was assessed on sagittal T2-weighted MRI and graded using a modified
version of WORMS at suprapatellar pouch, central portion, posterior femoral recess and
subpopliteal recess. Grading from 0 to 3 was based on the maximal estimated distention of
the synovial cavity: grade 0, normal; grade 1,<33% of maximum potential distention; grade
2 to 33%–66% of maximum potential distention; grade 3, >66% of maximum potential
distention [16]. The intra-rater reliability (expressed as weighted ) was 0.63–0.75 in different
subregions and the inter-rater reliability was 0.65–0.79 [225].
Meniscal pathologies
Meniscal abnormalities, including meniscal tear and extrusion, were assessed on T1-weighted
MRI. Each meniscus was divided into three areas (anterior horn, body and posterior horn).
For meniscal tears, the following scale was applied: 0 = no damage; 1 = one of three meniscal
areas involved; 2 = two of three areas involved; 3 = all three areas involved [349]. Extrusion
was scored on a scale from 0 to 2: grade 0, no extrusion; grade 1 (partial extrusion), meniscal
tissue extends beyond the tibial margin; and grade 2 (complete extrusion), the meniscus has
no contact with the joint space [350]. The highest score of both medial and lateral menisci
was used for analysis.
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8.2.3 Knee replacement surgery
At the follow-up visits, participants were asked whether they had undergone a TKR since
their first visit. Although MRI scans were taken on the right knee only at baseline, knee
replacement data were collected on both knees.
8.2.4 Radiographs
The specifications for knee radiographs is detailed in Section 3.5
8.2.5 WOMAC score
Knee pain at baseline was assessed using the Western Ontario and McMaster Universities
Osteoarthritis (WOMAC) score, which is a self-administered questionnaire consists of 3
subscales and 24 items (5 pain, 2 stiffness and 17 function items) [230]. We used a 10-
point Likert version of WOMAC from 0 (no pain, stiffness or function deficit) to 9 (most
severe pain, stiffness or severe function problems). A total WOMAC score was generated
by summing up all the items.
8.2.6 Data analysis
T-tests or chi-square tests were used to assess the differences between groups of participants
who underwent TKR and those who did not. The association between baseline cartilage de-
fects, BMLs, effusion-synovitis, meniscal tear and meniscal extrusion and the risk of TKR
was measured with a hazard ratio (HR) using a Cox proportional hazards model after ad-
justment for baseline WOMAC pain score and ROA, which are the two main factors that
predict TKR in clinical practice. The model was further adjusted for other MRI structural
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pathologies to evaluate the independent association of each structural feature.
8.3 Results
8.3.1 Characteristics of the study participants
A total of 972 subjects had all structural markers measured on baseline knee MRI scans.
Over the course of 10.7 years, a total of 37 participants (3%) reported 43 TKRs, including
23 on the same knee of the MRI scan and 20 on the opposite knee. Table 8.1 shows the
differences in the baseline characteristics between study participants who had a TKR com-
pared to those who did not. Participants who reported a TKR had a higher mean BMI, higher
WOMAC scores, and higher prevalence of cartilage defects, BMLs and effusion-synovitis.
While participants who had TKR all had meniscal tears, there was no difference in meniscal
extrusion between those who had TKR and those did not.
Table 8.1: Baseline characteristics of participants.
No knee replacement Knee replacement
P value†
(n=935) (n=37)
Age (years) 62.8 ± 7.4 63.9 ± 7.7 0.35
Female (%) 50% 59% 0.25
BMI (kg/m2) 27.6 ± 4.6 29.4 ± 5.6 0.02
ROA (%) 59% 74% 0.09
WOMAC score 15.1 ± 27.5 46.5 ± 41.3 <0.01
Pain 3.3 ± 6.0 9.3 ± 7.5 <0.01
Stiffness 1.5 ± 2.7 4.1 ± 3.9 <0.01
Function 10.2 ± 19.9 33.2 ± 32.6 <0.01
Cartilage defects (%) 51% 84% <0.01
BMLs (%) 43% 73% <0.01
Effusion-synovitis (%) 22% 43% <0.01
Meniscal extrusion (%) 4% 4% 0.93
Meniscal tear (%) 81% 100% 0.01
BMI, body mass index; ROA, radiographic osteoarthritis; BMLs, bone marrow lesions;
WOMAC, Western Ontario and McMaster Universities Osteoarthritis Score;
Data reported as the mean ± standard deviation, except where indicated.
†By student t-test or chi-square test; bold values indicate statistical significance at α = 0.05
119
Chapter 8. MRI Markers and the Prediction of Total Knee Replacement
Table 8.2: Association between baseline MRI structural markers and total TKR over 10.7 years.
Multivariable 1* Multivariable 2†
HR 95% CI HR 95% CI
Cartilage defects 2.32 (1.67, 3.21) 1.84 (1.21, 2.80)
Grade 0/1 Ref.
Grade 2 2.31 (0.70, 7.61) 1.24 (0.33, 4.64)
Grade 3 8.61 (3.07, 24.14) 3.98 (1.24, 12.77)
Grade 4 10.95 (3.50, 34.27) 4.77 (1.21, 18.80)
Bone marrow lesions 2.00 (1.49, 2.68) 1.48 (1.00, 2.18)
Grade 0 Ref.
Grade 1 0.99 (0.30, 3.22) 0.47 (0.11, 1.98)
Grade 2 5.51 (2.17, 14.00) 2.47 (0.76, 8.02)
Grade 3 6.42 (2.61, 15.81) 2.11 (0.63, 7.12)
Effusion-synovitis‡ 2.41 (1.21, 4.81) 1.56 (0.66, 3.68)
Grade 0/1 Ref.
Grade 2 0.92 (0.37, 2.29) 0.58 (0.19, 1.76)
Grade 3 2.29 (0.96, 5.47) 1.09 (0.37, 3.25)
Meniscal extrusion 1.40 (0.68, 2.86) 1.01 (0.51, 2.00)
Grade 0 Ref.
Grade 1 1.47 (0.60, 3.61) 1.37 (0.55, 3.41)
Grade 2 1.73 (0.22, 13.45) 0.57 (0.07, 4.65)
TKR, total knee replacement; HR, hazard ratio; CI, confidence interval.
* Adjusted for radiographic osteoarthritis and baseline pain.
†Further adjusted for other MRI structural pathologies.
‡Comparison of grade 3 effusion-synovitis against the rest of the cohort.
Bold values indicate p value <0.05.
8.3.2 Association between baseline MRI structural markers and TKR
The associations between MRI structural markers (cartilage defects, BMLs, effusion-synovitis
and meniscal extrusion) and TKR are described in Table 8.2. After adjustment for baseline
WOMAC pain score and ROA, cartilage defects, BMLs and grade 3 effusion-synovitis at
baseline were statistically significantly associated with higher hazard for TKR. In subre-
gional analysis, grade 3 effusion-synovitis in the suprapatellar pouch was significantly as-
sociated with TKR (HR=3.96, 95% CI 1.94–8.09). Both cartilage defects and BML grades
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showed a dose-response association with risk of TKR, while only grade 3 effusion-synovitis
showed a significantly increased risk of TKR (Figure 8.1). The associations for cartilage
defects remained statistically significant after further adjustment for other MRI structural
markers. The association for BMLs became weaker but remained statistically significant
after further adjustment for other MRI structural changes. Effusion-synovitis was not asso-
ciated with TKR after further adjustment. Meniscal extrusion was not associated with the
risk of TKR over 10.7 years.
Figure 8.1: Cumulative hazard of total knee replacement stratified by cartilage defects (a), bone
marrow lesion (b) and effusion-synovitis (c).
8.3.3 Association between baseline number of MRI pathologies and
TKR
Table 8.3 describes the associations between the total number of MRI pathologies present
at baseline and TKR over 10.7 years. The risk of TKR increased significantly when more
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MRI pathologies were simultaneously present at baseline (HR=1.84/unit, 95%CI 1.35–2.51).
Interestingly, baseline number of MRI pathology present in the right knee was associated
with the risk of TKR on the same knee (HR=1.80/unit, 95% CI 1.23–2.64), and the risk
of TKR on the opposite knee (HR=1.66/unit, 95% CI 1.09–2.52). There was also a dose-
response relationship between the number of MRI pathologies at baseline and the risk of
TKR (Figure 8.2).
Table 8.3: Total number of baseline MRI pathology and knee replacement over 10.7 years.
Number of Right knee Left knee Total†
pathologies Count % Count % Count %
0 (n = 105) 0 0.0% 0 0.0% 0 0.0%
1 (n = 307) 1 0.3% 5 1.6% 5 1.6%
2 (n = 262) 7 2.7% 3 1.1% 8 3.1%
3 (n = 219) 11 5.0% 8 3.7% 16 7.3%
4–5 (n = 95) 4 4.2% 4 4.2% 8 8.4%
Hazard ratio (95% CI)* 1.8 (1.23, 2.64) 1.66 (1.09, 2.52) 1.84 (1.35, 2.51)
†Total number of patients who underwent either right or left knee replacement.
* Adjusted for radiographic osteoarthritis and baseline pain.
Bold values indicate p<0.05.
8.4 Discussion
To our knowledge, this study is the first longitudinal population-based study to describe the
long-term associations between cartilage defects, BMLs, meniscal pathologies and effusion-
synovitis and TKR in older adults over 10.7 years. Our data showed that baseline knee
cartilage defects, BML, meniscal tear but not grade 3 effusion-synovitis or meniscal extru-
sion were associated with an increased risk of TKR. In addition, the number of pathologies
present on MRI predicted the occurrence of TKR over 10.7 years.
This study demonstrates a dose-response and independent relationship between baseline car-
tilage defect grade and the risk of TKR. The cumulative risks for TKR increased with higher
grades of cartilage defects at baseline, and the risk reached nearly 50% in those with grade
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Figure 8.2: Cumulative hazard of total knee replacement stratified by number of MRI pathologies.
4 defects after 10 years. This is similar to our previous published data in the same cohort
where higher cartilage defect grade at baseline predicted higher risk of TKR over 5 years
[178]. The relationship is also supported by another study which showed that the severity
of tibiofemoral cartilage defects at baseline was an independent risk factor for TKR over 4
years [186]. They found that the higher cartilage defect scores were associated with higher
risk for surgery in comparison to lower scores.
BML is associated with clinical and structural progression of knee OA and is increasingly
suggested by researchers as an outcome measure in clinical trials [351]. We found that base-
line BMLs were an independent predictor of TKR after adjustment for all other structural
pathologies. This is consistent with our previous data showing that the severity of BMLs was
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a strong predictor of TKR over 5 years after adjustment for some structural factors [199]. In
addition, a follow-up study of the randomized controlled trial (RCT) of knee OA population
found that medial BML (OR=1.48, 95% CI 1.21–1.82) was one of the strongest predictors of
TKR [175]. Similarly, different studies have shown that BMLs in knee OA predicted TKR
in the following year [215], within three years [213] and after four years [214].
Meniscal pathology is very common in older population [352] and is associated with struc-
tural and clinical progression of knee OA [352, 353]. Baseline severe medial meniscal tear
is one of the strongest independent long-term predictors of TKR in knee OA patients [175].
In our study population, 82% of participants had some degree of meniscal tear and we found
that all the participants who underwent TKRs had a meniscal tear at baseline. This finding
suggests the importance of a severe meniscal tear in the progression of knee OA leading to
TKR. However, meniscal extrusion was not associated with TKR in this population-based
sample. This could be due to the very low prevalence of extrusion in this population (4%)
and the number of TKRs in this group was too small to detect a statistical significance.
However, similar results were observed in a study where the risk for TKR was significantly
increased for knees that exhibited two or more subregions with MRI structural pathologies
except extrusion [215].
Recent evidence suggests the involvement of effusion-synovitis in the progression of knee
OA [225, 85] and its role as a treatment target for knee OA [354]. However, there is very
few data on the predictive validity of effusion-synovitis on TKR. Roemer et al suggest that
the risk for TKR was significantly increased for knees that exhibited two or more subregions
with effusion-synovitis, when compared with knees that did not exhibit these features [215].
The present study found that the association between total effusion-synovitis and TKR was
only significant for grade 3 effusion-synovitis, but this did not persist after adjustment for
the other factors. This suggests the association is confounded by the other pathologies or on
the causal pathway between these pathologies and TKR. If it is on the casual pathway, then
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effusion-synovitis remains a valid target in OA trials.
A recent study suggested that all MRI tissue abnormalities, except for meniscal extrusion
could be used to predict TKR [215]. This leads us to question whether there is incremental
risk for TKR when multiple MRI structural abnormalities are present. This study is the first
to show that the number of MRI pathologies present at baseline significantly predicted the
occurrence of TKR over 10 years in a dose-response manner. On average, the risk of having
a TKR increased by 84% for each structural abnormality present. The risk of having a TKR
in those who had 4-5 structural abnormalities could be as high as 5.25 times of that in those
who had only one abnormality.
The major strength of our study is that it is a prospective population-based study with a
large sample size and a long follow-up period. Our results have good external validity and
are generalizable to all older adults in the population. Our study utilizes all the data from
multiple clinical visits throughout the 10.7 years of follow-up, adding extra validity and
reliability of our findings. We also acknowledge that there are some limitations in our study.
Cartilage defects were assessed on T1-weighted GRE MR images and some may argue that
GRE sequences are less suited for cartilage defect measurement [355]. However, there is
evidence that GRE sequences have high sensitivity and specificity detecting cartilage defects
compared to observations under arthroscopy [356, 357]. The retention rate in our study after
10.7 years was 67%. Participants who were lost to follow-up were older and had more
cartilage defects and higher WOMAC scores at the baseline compared to those who were
followed up (data not shown). It is most likely that the loss of those with more severe
disease may underestimate our findings.
In conclusion, cartilage defects, BMLs and meniscal tears, but not effusion or meniscal ex-
trusion in the right knee were independent predictors of TKR in either knee over 10.7 years.
Presence of multiple pathologies increased the risk of TKR, suggesting that MRI structural
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markers are good predictors of rapid knee OA progression in the general population.
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Summary and Future Directions
9.1 Summary
OA is the most common joint disease in the world and it is one of the most frequent causes
of pain, loss of function, and disability in Western populations [301]. The knee is the most
common joint affected by OA and pain is the prominent symptom. In Australia, it was esti-
mated to over $1.8 million or 8.0% Australians was affected by OA [3]. The disease was one
of the most expensive diseases in Australia, costing $1.6 billion (2.5%) of the total health
care expenditure each year in Australia. With an aging population and a rising obesity rate,
the social and economic burden associated with OA is increasing. Despite its heavy so-
cioeconomic burden, there are no proven preventative strategies and no registered effective
treatments which stop or delay the progression of the disease. Conventional treatment op-
tions for knee OA are mostly palliative and costly. There is an urgent need for identifying
modifiable risk factors and developing a cost-effective treatment for this disease. Recently,
knee OA is recognized as a disease of the whole joint with multiple structural abnormalities.
MRI is becoming a popular tool in knee OA research for the visualization of all structures
within in the joint. This thesis has examined the roles of systemic risk factors (low-grade
inflammation, adiposity and sex hormones) in disease progression and the predictive values
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of MRI markers for knee replacement, as well as the effects of vitamin D supplementation
on the disease. Several novel and important findings presented in this thesis are summarized
below.
Chapter 4 systematically reviews 32 relevant studies for the relationship between serum CRP
levels measured by a high sensitivity method (hs-CRP) and OA, as well as the correlation
between circulating CRP levels and OA phenotypes. Serum hs-CRP levels in OA were
modestly but statistically significantly higher than controls (mean difference = 1.19 mg/l,
95% CI 0.64 to 1.73). The levels were significantly associated with pain (r = 0.14, 95% CI
0.09 to 0.20, p<0.001) and decreased physical function (r = 0.25, 95% CI 0.13 to 0.39).
No significant associations were found between hs-CRP levels and radiographic OA. This
suggests low-grade systemic inflammation may contribute to the pathogenesis of OA. The
role of low-grade systemic inflammation may be greater in causing symptoms rather than
radiographic changes in OA.
Adipose tissue is a dynamic endocrine organ that secretes a number of factors that are in-
creasingly recognized to contribute to systemic inflammation [358]. Chapter 5 describes
the longitudinal relationship between adiposity and change in knee pain in a population-
based sample over 5.1 years. Baseline BMI and body fat mass were deleteriously associated
with consistent knee pain over follow-up. BMI was consistently associated with increases
in weight-bearing and non-weight-bearing pain. Fat mass was associated with an increase
in non-weight-bearing pain. In mixed-model analyses, WOMAC total pain score was asso-
ciated with BMI (beta = 1.27, 95% CI 0.89 to 1.66) and body fat mass (beta = 1.17, 95%
0.76 to 1.59).The association of lean mass was not significant after adjustment for fat mass.
These results show that BMI is the most consistent correlate of knee pain. Fat mass is asso-
ciated with non-weight-bearing knee pain suggesting systemic and metabolic mechanisms
are involved.
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Observational studies suggest vitamin D supplementation as a potential cost-effect treatment
for knee OA [304]. Chapter 6 compares the effects of vitamin D supplementation versus
placebo on knee pain and knee cartilage volume in 413 patients with symptomatic knee OA
and low vitamin D levels in a multi-center randomized clinical trial. Monthly 50,000IU
vitamin D supplementation, compared with placebo, did not result in significant differences
in change in MRI-measured tibial cartilage volume (-3.44% versus -4.23%, p = 0.132) or
WOMAC knee pain score (-49.9 versus -35.1, p = 0.102) over 2 years. Although the vitamin
D group had greater improvement in VAS knee pain (-15.4 mm vs. -8.9 mm, p = 0.048)
in the secondary analyses, there were no significant differences in changes of tibiofemoral
cartilage defects or BMLs. There are slightly more participants in the vitamin D group than
in the placebo group (56 versus 37) who had at least one adverse event. These findings
do not support the use of vitamin D supplementation for preventing tibial cartilage loss or
improving WOMAC knee pain in patients with knee OA.
Chapter 7 describes the longitudinal associations between endogenous sex hormones and
MRI knee structural changes in 107 men and 93 women with symptomatic knee OA. For
women, after adjustment for confounding factors, progesterone was associated with cartilage
volume(β=0.12/quarter, 95% CI 0.03 to 0.21)and estradiol levels were associated with lower
grades of BMLs (β=-0.45/quarter, 95% CI -0.86 to -0.05), while estradiol (β=-1.26/quarter,
95% CI -2.50 to -0.02), progesterone (β=-1.60/quarter, 95% CI -2.77 to -0.43) and testos-
terone (β=-1.49/quarter, 95% CI -2.71 to -0.27) were inversely associated with effusion-
synovitis volume. No consistent associations were observed for men. Overall, these findings
suggest endogenous sex hormones may be protective for joint structural changes in women
but not men. The drop in sex hormones at the time of menopause in women may contribute
to observed sex differences in knee OA.
Chapter 8 describes the independent association of magnetic resonance imaging (MRI)
markers and total knee replacement (TKR) over 10.7 years in older adults aged 50 to 79
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years from a general population. After adjustment for baseline pain and radiographic knee
OA, cartilage defects (HR = 2.32/grade, 95% CI 1.67 to 3.21) and BMLs (HR = 2.00/grade,
95% CI 1.49 to 2.68) at baseline predicted increased risk of TKR over 10.7 years. Grade 3
total and suprapatellar effusion-synovitis (HR = 2.41, 95% CI 1.21 to 4.81 and HR = 3.96,
95% CI 1.94 to 8.09, respectively) predicted TKR over 10.7 years; however, these associa-
tions were partially dependent on other structural pathologies. Those who had TKR all had
grade 3 meniscal tears at baseline. The number of pathologies was significantly associated
with the risk for TKR (HR = 1.84/unit, 95% CI 1.35 to 2.51). These results demonstrate
that MRI structural markers such as cartilage defects, BMLs and meniscal tears, but not ef-
fusion or meniscal extrusion in the knee were independent predictors of TKR. The risk of
TKR increased as more MRI structural markers were present, suggesting that MRI structural
markers are good predictors of rapid knee OA progression in the general population.
In conclusion, this series of studies indicate that knee OA is a complex disease affected by
systematic factors such as low-grade inflammation, adiposity and sex hormones. Vitamin D
supplementation does not significantly prevent knee cartilage loss and knee pain in patients
with symptomatic knee OA. MRI structural markers are good predictors of end-stage knee
OA in the general population. Recommendations for the future direction of each chapter are
provided in the following section.
9.2 Future directions
OA has long been considered as a “wear and tear”disease leading to cartilage loss. Progress
in molecular biology has profoundly shifted this paradigm in recent decades. Recent studies
have shown that OA is a much more complex disease which involves the release of inflam-
matory mediators [359, 360]. Chapter 4 highlights that chronic low-grade inflammation,
as reflected by increased hs-CRP, is present in patients with OA. The literature is rich in
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data suggesting that inflammation play a pivotal role in the development and progression
of OA. The source of inflammation could be local or systemic. While local production of
inflammatory mediators are well known to contribute to cartilage degradation and synovi-
tis, additional data show that local inflammatory events may be reflected outside the joint
in peripheral blood in patients with OA. The findings of increased levels of hs-CRP in OA
patients concur with the “inflammatory theory”. The confirmation of low-grade inflamma-
tion in OA builds the foundation for future research to examine inflammatory factors as
important components of the disease. Inflammatory biomarkers, which could readily detect
sub-clinical and/or sub-acute inflammation, may be developed and included in a panel of
novel diagnostic or prognostic tests for OA [361].
OA could be also initiated and/or aggravated by the presence of a systemic low-grade in-
flammation. The release of inflammatory mediators into the blood could be a result of aging
and/or metabolic syndrome (adiposity). OA is a prototypic age-related disease, the underly-
ing molecular mechanisms remain largely unknown. One theory is that cellular senescence
could trigger internal mechanisms leading to increased production of inflammatory media-
tors and oxidated proteins. These mechanisms increase the concentration of reactive oxygen
species (ROS) in cells, further adding to the oxidative damage triggering a low-grade in-
flammation [96]. The risk of OA is increased in obese patients. The increased risk cannot be
explained by the mechanical effect of overload alone. Systemic factors, namely adipokines,
released by abdominal adipose tissue, have been extensively studied and may contribute to
the increased risk of OA in obese patients. Chapter 5 has identified significant associations
between adiposity and knee pain. In particular, body fat mass is only associated with increase
in non-weight-bearing knee pain, suggesting systematic mechanisms other than mechanical
loading are involved. However, we could not infer the exact causal pathway underlying the
relationship between adiposity and knee pain because blood samples are not collected for
adipokines measurement. In future research, deciphering these inflammatory and metabolic
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pathways is critical for the discovery of disease-modifying OA drugs.
Women older than 50 years have a considerably higher prevalence of OA than men of the
same age group. The drop of sex hormones after menopause in women has been suggested
to increase the risk of OA. The findings of Chapter 7 suggest endogenous estrogen, pro-
gesterone and testosterone are only protective for structural abnormalities in women with
symptomatic knee OA but not in men. In particular, these hormones appear to be inversely
associated with effusion volume, which is a clinical feature of local inflammation. Sex hor-
mones are known to play a regulatory role in human immune response [335], therefore,
the beneficial effects of sex hormones may be a result of reducing local and systemic in-
flammation. One randomized controlled trial showed that community dwelling women aged
50-79 years who received unopposed estrogen had modest but sustained reduction in joint
pain [362] and lower rates of joint replacement [149], although this was not found in those
women who received both estrogen and progesterone. However, it remains unclear whether
hormone replacement therapy would prevent structural progression on MRI. Future research
on the effects and potential benefits of sex hormones is needed to fully clarify their role in the
development of knee OA. Also, the findings in this thesis suggest that the effects of sex hor-
mones on MRI knee structures may differ between males and females, future studies should
be sufficiently powered to conduct a gender-specific analysis to examine gender differences
in the relationship between hormonal factors and the prevalence of knee OA.
Chapter 6 examines the effects of vitamin D supplementation in symptomatic knee OA pa-
tients with low vitamin D levels. Compared with placebo, vitamin D supplementation does
not significantly reduce cartilage volume loss on MRI or improve WOMAC knee pain. De-
spite the p-values of the statistical analyses are not significant, the direction of estimated ef-
fects on all outcome measures point to favor vitamin D supplementation. In addition, modest
effects are observed in secondary and post-hoc analyses on VAS knee pain, WOMAC func-
tion, 50% improvement in WOMAC pain, OMERACT-OARSI response. These findings are
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largely consistent with previous two randomized clinical trials, while one showed no effects
on pain and cartilage volume [129], the other one showed small effects on symptoms [130].
There are certain degree of heterogeneity among our study and the two randomized clinical
trials in terms of study participants and study design, which may contribute to the inconsis-
tencies in findings. Future research could perform a systematic review and a meta-analysis
with individual patient data, which will be able to increase the power to show the true ef-
fects of vitamin D supplementation on symptoms and structural changes on MRI other than
cartilage volume. A subgroup analysis according to individual patient data may be able to
identify the subgroup of OA patients who would benefit the most with vitamin D supple-
mentation.
Chapter 8 demonstrates the importance of MRI biomarkers in the prediction of TKR in the
general population. The findings from our research and other studies [348] have provided
evidence to support the important role of MRI in clinical decision making and practice in
the context of knee OA. MRI biomarkers has the potential to provide sensitive and specific
information for disease progression, to monitor treatment and help in the development of
new management strategies for OA. The next step is to further to develop image analysis
algorithms which may foster a more automated analysis of these MRI biomarkers and to
establish a weighted scoring system which would allow standardized and overall assessment
of these MRI biomarkers in clinical practice. Also, future research should focus on develop-
ing effective therapeutic interventions which target at MRI biomarkers, particularly cartilage
defects and BMLs. Once disease-modifying drugs become available, quantitative MRI mea-
sures will be a particularly useful clinical tool to monitor the treatment response in large sets
of OA patients.
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Table A.1: Results of the studies not included in the meta-analysis
Study ID Joint CRP measurement No. of cases No. of controls
Difference in hsCRP (mg/l)
Cases Controls p Value
Bos 2008 Hand Nephelometry 353 739 1.83 (0.21–56.8)* Not stated 0.06
Engstrom 2009
Knee Nephelometry 89 5082 1.62 1.40 Not stated
Hip Nephelometry 120 5044 1.64 1.40 Not stated
Loose 1993 Not stated ELISA 365 40 5.0 (0.1–173)* 1.9 (0.5–3.1)* Not stated
Pearl 2007 Knee or hip ELISA 52 Not stated 3.4 (4.7)§ 0.29 (0.6) § 0.007
Punzi 2005 Hand Nephelometry 67 31 4.7 (2.4–6.9)# 2.1 (0.5–4.9)# 0.002
Spector 1997 Knee EIA 105 740 2.4 (1.0–5.1)# 0.7 (0.3–1.8)# <0.001
Kerkhof 2010
Knee Nephelometry 718 2306 1.74 1.53 0.001
Hip Nephelometry 349 3065 1.56 1.48 0.30
Hand Nephelometry 861 2164 1.56 1.48 0.12
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Search Strategy for MEDLINE via Ovid (1992-2012.12) 
 
1. Osteoarthritis/ 
2. Degenerative arthritis / 
3. Osteoarthrosis/ 
4. Arthritis/ 
5. OR/1-4 
6. C-reactive protein/ 
7. inflammatory marker$.tw 
8. c reactive protein.tw 
9. protein c reactive.tw 
10. CRP.tw 
11. OR/6-10 
12. 5 AND 11 
13. Exp Epidemiologic studies/  
14. Exp Case control studies/ 
15. Exp Cohort studies/ 
16. case control.tw  
17. (cohort adj (study or studies)).tw. 
18. cohort analy*.tw 
19. (follow up adj (study or studies)).tw. 
20. (observational adj (study or studies)).tw. 
21. longitudinal.tw. 
22. retrospective.tw. 
23. cross sectional.tw. 
24. Cross-sectional studies/ 
25. OR/13-24 
26. 12 AND 25 
27. limit 26 to (English language and human) 
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Search Strategy for EMBASE via Ovid (1992-2012.12) 
 
1. Osteoarthritis/ 
2. Degenerative arthritis / 
3. Osteoarthrosis/ 
4. Arthritis/ 
5. OR/1-4 
6. C-reactive protein/ 
7. inflammatory marker$.tw 
8. c reactive protein.tw 
9. protein c-reactive.tw 
10. CRP.tw 
11. OR/6-10 
12. 5 AND 11 
13. clinical study/ 
14. case control study/ 
15. family study/ 
16. longitudinal study/ 
17. retrospective study/ 
18. prospective study/ 
19. randomized controlled trials/ 
20. 18 NOT 19 
21. cohort analysis/ 
22. (cohort adj (study or studies)).mp 
23. (case control adj (study or studies)).tw 
24. (follow up adj (study or studies)).tw. 
25. (observational adj (study or studies)).tw. 
26. (epidemiologic* adj (study or studies)).tw. 
27. (cross sectional adj (study or studies)).tw. 
28. OR/13-17, 20-27 
29. 12 AND 28 
30. limit 29 to (english language and human) 
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Search Strategy for CINAHL via EBSCO (1992-2012.12) 
 
S1. (MH “Osteoarthritis”+) 
S2.  TX osteoarthritis 
S3.  Degenerative osteoarthritis 
S4.  (MH “Arthritis”+) 
S5.  S1 OR S2 OR S3 OR S4 
S6.  (MH “C-Reactive Protein”) 
S7.  TX c reactive protein 
S8.  TX protein c-reactive 
S9.  TX crp 
S10. TX inflammatory marker* 
S11.  S6 OR S7 OR S8 OR S9 OR S10 
S12. S5 AND S11 
S13. (MH “Prospective Studies”+) 
S14. (MH “Case Control Studies”+) 
S15. (MH “Correlational Studies”) 
S16. (MH “Nonconcurrent Prospective Studies”) 
S17. (MH “Cross Sectional Studies”) 
S18. S13 OR S14 OR S15 OR S16 OR S17 
S19. S12 AND S18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Search for ongoing trials (Feb 10th-12th, 2013) 
Key word used:  ‘osteoarthritis’. 
Trial registry:  
 ClinicalTrials.gov 
(http://clinicaltrials.gov/) 
 WHO International Clinical Trial Registration Platform Search Portal 
(http://apps.who.int/trialsearch/) 
 Australian and New Zealand Clinical Trial Registry 
(http://www.anzctr.org.au/TrialSearch.aspx)   
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 Inclusion/Exclusion Form for Primary Studies 
 
Study ID:  
Reviewer:  
Date: 
 
Identification Details 
Author Year Journal/ Conference Source 
    
 
On Endnote database ..................................Yes/ No 
 
Full text availability …………………………..Yes/ No 
 
Study Eligibility 
Study design is one of the following: 
         Cohort study/ cross-sectional study/ case control study........................... Yes/ No  
The study concerns osteoarthritis...................................................................... Yes/ No  
The study concerns C-reactive protein............................................................... Yes/ No  
The study is a human study, not animal/laboratory experiment………………… Yes/ No 
 
Please Tick Only One Box Below 
 
Included Excluded Pending* 
   
 
 
* Issue relates to selective reporting – when authors may have taken CRP measurements, but not reported these within the paper. 
Reviewers should contact correspondent author for information on possible non-reported CRP levels & reasons for exclusion from 
publication. Study should be listed in ‘Pending’ until clarified. If no clarification is received after three attempts, study should then 
be excluded.  
 
References to Other Trials 
 
Did this report include any references to published reports of potentially eligible trials not 
already identified for this review? 
First author Journal / Conference Year of publication 
   
   
Did this report include any references to unpublished data from potentially eligible trials 
not already identified for this review? If yes, give list contact name and details 
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Data Extraction Form 
 
Study and Participants characteristics 
Study characteristics 
 Further details 
Study design (e.g. cross-section, case control*)  
Country / Countries  
Single centre / multicentre  
How was participant eligibility defined? 
(e.g. How osteoarthritis was defined?) 
 
How CRP level was measured?   
How many people were recruited?   
Duration of study (applicable to cohort, longitudinal studies)  
Other  
Participant characteristics 
 Further details 
Number of participants (cases versus controls)  
Age (mean, median, range, etc)  
BMI (mean, median, range, etc)  
Female of OA participants (numbers / %, etc) Female of OA participants (numbers / %, etc) 
Type of OA (hand, knee, hip, etc)  
Other   
 
* When a case control design is part of a larger clinical controlled trial, it should be regarded as case control.  
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Measures relevant to the review 
Prevalence/Incidence of OA Prevalence / Incidence/ Progression 
Radiological OA Yes / No 
Clinical features WOMAC/ Pain/ Physical Function 
Others  
For dichotomous data 
OR/ RR 
(95% CI, p value) 
Case group (n) 
n = number of participants, not number of events 
Control group (n) 
n = number of  participants, not number of events 
   
   
Other Information (eg. adjustment, cut-off, etc): 
 
For continuous data 
Unit 
Case group Control group 
Details 
n Mean (SD) n Mean (SD) 
      
      
For correlational data 
Independent factor Correlation coefficient (r) Adjustments 
   
   
   
Other relevant data 
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Modified Newcastle – Ottawa Quality Assessment Scale 
 
Selection: 
S1. How is osteoarthritis defined? 
a) By ACR Clinical Classification Criteria for Osteoarthritis♦ 
b) By Kellgren-Lawrence radiographic grade >= 2♦ 
c) Total joint replacement due to primary osteoarthritis♦  
d) By record linkage (e.g. ICD codes in database) or self-reports 
e) No description  
S2. Representativeness of the cases 
a) All cases over a defined period of time♦ 
b) All cases  in a community♦  
c) Consecutive cases from a medical setting or multicentre♦ 
d) Random sample from a population♦ 
e) Potential for selection biases 
f) No information on recruitment. 
S3. Selection of Controls 
a) Community controls (i.e. same community as cases and would be cases if the definition of 
cases meets)♦ 
b) Hospital controls (i.e. same community as cases but derive from a hospitalised population 
c) No description 
S4. Definition of Controls 
a) No history of osteoarthritis♦ 
b) No history of rheumatic joint diseases, inflammatory and malignant diseases♦ 
c) No description of source 
Comparability: 
C1. Cases and controls are matched in age and/or age is adjusted for in the statistical analysis 
a) Yes♦ 
b) No 
C2. Cases and controls are matched in BMI and/or BMI is adjusted for in the statistical 
analysis 
a) Yes♦ 
b) No 
Exposure: 
E1. Measurement of C-reactive protein (CRP) 
a) Description of CRP measurement♦ 
b) No description 
E2. Same method of measurement for cases and controls (e.g. nephelometry, ELISA) 
a) Yes♦ 
b) No 
E3. Non-response rate 
a) Same rate for both cases and controls♦ 
b) Description of non-respondents or exclusion of data in the analysis (i.e. CRP>20 mg/l)♦ 
c) Number of subjects differ in the analysis and no explanation provided 
 
Study  S1 S2 S3 S4 C1 C2 E1 E2 E3 Total 
           
Reviewer: ____________ 
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ID Number
Prof. Graeme Jones
TASOAC
Phase 4 Questionnaire
IDENTIFYING DATA
Instructions for completing the questionnaire:
All questionnaires will be submitted electronically. By following these instructions you
will be assisting with this process.
Indicate your response by filling in the circle next to the most appropriate
answer or by writing clearly in the box or space provided.
Use a blue pen
Example:
Write in BLOCK LETTERS using the boxes where provided
Your answers will be completely confidential.
Please notate any queries and they will be reviewed at your appointment.
Please answer all questions to the best of your ability (leave blank if unknown).
Do not put lines through irrelevant questions as it upsets the scanning machine.
Date Phase 2 Questionnaire Completed: / /
Cross out any mistake & write correct answer just below the relevant box
Date Phase 1 Questionnaire Completed: / /
Date Phase 3 Questionnaire Completed: / /
Date Phase 4 Questionnaire Completed: / /
1324122296
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4.7 Rate the following today for your RIGHT knee
(if your RIGHT knee has been replaced rate your left knee)
1.   Referring to your knee only how much pain do you experience
when
1 2 3 4 5 6 7 8 9 10
none severe
a. Walking on a flat surface
1 2 3 4 5 6 7 8 9 10b. Going up and down stairs
1 2 3 4 5 6 7 8 9 10c. At night while in bed
1 2 3 4 5 6 7 8 9 10d. Sitting or lying
1 2 3 4 5 6 7 8 9 10e. Standing upright
2.   Referring to your knee only how much stiffness do you experience
1 2 3 4 5 6 7 8 9 10
none severe
a. After first awakening
3.   Referring to your knee only how much functional deficit do you experience when
1 2 3 4 5 6 7 8 9 10
none severe
a. Descending stairs
1 2 3 4 5 6 7 8 9 10b. Later in the day
1 2 3 4 5 6 7 8 9 10
b. Ascending stairs
1 2 3 4 5 6 7 8 9 10
c. Rising from bed
1 2 3 4 5 6 7 8 9 10
d. Rising from sitting
1 2 3 4 5 6 7 8 9 10
e. Putting on socks
1 2 3 4 5 6 7 8 9 10
f. Taking off socks
1 2 3 4 5 6 7 8 9 10
g. Bending to the floor
h. Lying in bed
This section assesses pain, stiffness and functional deficit on a scale from 1 - 10
Example of no pain
Example of severe pain
Example
1 2 3 4 5 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10
none severe
6707122296
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4.7 Question 3 continued
1 2 3 4 5 6 7 8 9 10
none severe
i. Walking on flat surface
1 2 3 4 5 6 7 8 9 10j. Getting in/out of the bath
1 2 3 4 5 6 7 8 9 10k. Standing
1 2 3 4 5 6 7 8 9 10l. Sitting
1 2 3 4 5 6 7 8 9 10m. Getting in/out of the car
1 2 3 4 5 6 7 8 9 10n. Getting on/off the toilet
1 2 3 4 5 6 7 8 9 10o. Heavy domestic chores
1 2 3 4 5 6 7 8 9 10p. Light domestic chores
1 2 3 4 5 6 7 8 9 10q. Shopping
3994122291
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VIDEO Study: WOMAC
VIDEO WOMAC
Instructions:  Please read carefully
Your answers will be completely confidential.
Please answer all questions to the best of your ability (leave blank if unknown).
Date: / /
Initials:
Randomisation Code:
Site Number:
Visit Number:
0053640334
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Please place a mark on the line to rate the following today for your knee
1.   Referring to your knees only how much pain do you experience when
None Severe
a. Walking on a flat surface
b. Going up and down stairs
c. At night while in bed
d. Sitting or lying
e. Standing upright
2.   Referring to your knees only how much stiffness do you experience
None Severe
a. After first awakening
3.   Referring to your knees only how much functional deficit do you experience when
None Severe
a. Descending stairs
b. Later in the day
b. Ascending stairs
c. Rising from bed
d. Rising from sitting
e. Putting on socks
f. Taking off socks
g. Bending to the floor
h. Lying in bed
Example of no pain
Example of severe pain
Examples None Severe
Office
use only
1964640336
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Question 3 continued
i. Walking on flat surface
j. Getting in/out of the bath
k. Standing
l. Sitting
m. Getting in/out of the car
n. Getting on/off the toilet
o. Heavy domestic chores
p. Light domestic chores
q. Shopping
None Severe
Office
use only
7943640339
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Effect of Vitamin D Supplementation on Tibial Cartilage
Volume and Knee Pain Among PatientsWith Symptomatic
Knee Osteoarthritis
A Randomized Clinical Trial
Xingzhong Jin, MD; Graeme Jones, MD, PhD; Flavia Cicuttini, MD, PhD; Anita Wluka, MD, PhD; Zhaohua Zhu, MD;Weiyu Han, MD; Benny Antony, PhD;
Xia Wang, MMSc; Tania Winzenberg, MD, PhD; Leigh Blizzard, PhD; Changhai Ding, MD, PhD
IMPORTANCE Observational studies suggest that vitamin D supplementation is associated
with benefits for knee osteoarthritis, but current trial evidence is contradictory.
OBJECTIVE Tocompare theeffects of vitaminDsupplementationvsplaceboonkneepain and
knee cartilage volume inpatientswith symptomatic kneeosteoarthritis and lowvitaminD levels.
DESIGN, SETTING, AND PARTICIPANTS Amulticenter randomized, double-blind,
placebo-controlled clinical trial in Tasmania and Victoria, Australia. Participants with
symptomatic knee osteoarthritis and low 25-hydroxyvitamin D (12.5-60 nmol/L) were
enrolled from June 2010 to December 2011. The trial was completed in December 2013.
INTERVENTIONS Participants were randomly assigned to receive monthly treatment with oral
vitamin D3 (50000 IU; n = 209) or an identical placebo (n = 204) for 2 years.
MAIN OUTCOMES ANDMEASURES Primary outcomeswere change in tibial cartilage volume
(assessed using magnetic resonance imaging [MRI]) and change in theWestern Ontario and
McMaster Universities Arthritis Index (WOMAC) pain score (0 [no pain] to 500 [worst pain])
from baseline to month 24. Secondary outcomes were cartilage defects and bonemarrow
lesions (assessed using MRI).
RESULTS Of 413 enrolled participants (mean age, 63.2 years; 50%women), 340 (82.3%)
completed the study. The level of 25-hydroxyvitamin D increasedmore in the vitamin D group
(40.6 nmol/L) than in the placebo group (6.7 nmol/L) (P < .001) over 2 years. There were no
significant differences in annual change of tibial cartilage volume orWOMAC pain score.
There were no significant differences in change of tibiofemoral cartilage defects or change in
tibiofemoral bonemarrow lesions. Adverse events (1 per patient) occurred in 56
participants in the vitamin D group and in 37 participants in the placebo group (P = .04).
End Point
Change, Mean
Difference (95% CI) P ValueVitamin D Placebo
Tibial cartilage volume, %/y −3.4% −4.2% 0.8% (−0.2% to 1.8%) .13
WOMAC pain −49.9 −35.1 −14.8 (−32.5 to 2.9) .10
Tibiofemoral cartilage defects 0.3 0.5 −0.2 (−0.4 to 0.1) .21
Tibiofemoral bone marrow
lesions
−0.1 0.3 −0.5 (−0.9 to 0.0) .06
CONCLUSIONS AND RELEVANCE Among patients with symptomatic knee osteoarthritis and
low serum 25-hydroxyvitamin D levels, vitamin D supplementation, compared with placebo,
did not result in significant differences in change in MRI-measured tibial cartilage volume or
WOMAC knee pain score over 2 years. These findings do not support the use of vitamin D
supplementation for preventing tibial cartilage loss or improvingWOMAC knee pain in
patients with knee osteoarthritis.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01176344; anzctr.org.au Identifier:
ACTRN12610000495022
JAMA. 2016;315(10):1005-1013. doi:10.1001/jama.2016.1961
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S ymptomatic knee osteoarthritis occurs among 10% ofmen and 13% of women aged 60 years or older.1 World-wide, knee osteoarthritis, together with hip osteoar-
thritis, are the 11th leading cause of global disability, account-
ing for 2.2% of total years lived with disability.2 Medical costs
of osteoarthritis account for 1% to 2.5% of the gross domestic
product in developed countries.3 Currently there are no
disease-modifying therapies for osteoarthritis; therefore,
there is a need to develop cost-effective approaches to pre-
vent the development and progression of osteoarthritis.
Vitamin D can reduce bone turnover and cartilage degra-
dation, thus potentially preventing the development and
progression of knee osteoarthritis.4,5 Epidemiological studies
showed that low serum 25-hydroxyvitamin D levels were
associated with greater knee pain,6,7 a higher prevalence of
radiographic knee osteoarthritis,8 and higher risk of pro-
gression.9,10 However, observational studies are subject to in-
herent bias and confounding factors such as physical activity
and sun exposure.11 In addition, 2 small existing randomized
controlled trials (RCTs) reported contradictory results.5,12 The
inconsistencies are likelybecauseofvariations in inclusioncri-
teria, outcomemeasures, follow-uptime,andsamplesize.13An
updated systematic review called for further larger well-
designedRCTs to determinewhether vitaminD supplementa-
tion can slow disease progression.14 Therefore, we conducted
anRCTofparticipantswithclinicallyrelevant inclusioncriteria,13
to evaluate theeffects of 2years of vitaminDsupplementation
vs placebo on knee pain and knee cartilage volume in patients
with symptomatic knee osteoarthritis combined with low
25-hydroxyvitaminDlevels.Effectsonotherkneestructuralab-
normalities, including cartilage defects and bone marrow le-
sions, were also assessed.
Methods
Trial Design
TheVitaminDEffectonOsteoarthritis (VIDEO)studywasaran-
domized, double-blind, placebo-controlled trial, which was
conducted between June 2010 and December 2013.15 Partici-
pants were recruited from June 2010 to December 2011 in
Tasmania and Victoria, Australia, through advertisements in
local media and community groups, as well as referrals from
general practitioners, rheumatologists, and orthopedic sur-
geons. A telephone prescreening was conducted to inquire
about knee pain status, comorbidities, participation in other
studies, andwhether the survey recipient anticipated kneeor
hip surgery within next 2 years. Potentially eligible partici-
pantswere subsequently assessedduring a clinic visit that in-
cluded aphysical examination, knee radiography, and assess-
ment of serum25-hydroxyvitaminD levels. The trial protocol
appears in Supplement 1.
Participants
Inclusion and exclusion criteria were described in the pub-
lished protocol.15 In brief, eligible participants were aged 50
to79years, had symptomatic kneeosteoarthritis (assessedac-
cording toAmericanCollegeofRheumatology [ACR] criteria16)
forat least6months,andhadpainof20to80mmona100-mm
visual analog scale. In addition, participants hadanACR func-
tion class rating of I, II, or III (I [complete ability to perform
usual activities of daily living] to III [ability to perform usual
self-care activities but limited in vocational and avocational
activities]) andrelativelygoodhealthscoreof0to2ona5-point
Likert scale (0 [very good health] to 4 [very poor health]) ac-
cording to the investigator assessment of disease status. Par-
ticipants were included if their serum 25-hydroxyvitamin D
levels were between 12.5 nmol/L and 60 nmol/L. Ethics ap-
proval was received from the Tasmania Health and Human
MedicalResearchEthicsCommittee (referencenumberH1040)
and Monash University Human Research Ethics Committee
(reference number CF10/1182-2010000616). Informed writ-
ten consent was obtained from all participants.
Exclusion criteria included grade 3 radiographic changes
according to theAltman andGold atlas,17 severe knee pain on
standing (more than80mmona 100-mmvisual analog scale),
contraindication tomagnetic resonance imaging (MRI), rheu-
matoid or psoriatic arthritis, lupus, cancer, severe cardiac or
renal impairment,hypersensitivity tovitaminD, conditionsaf-
fecting oral drug absorption, anticipated knee or hip surgery
within the next 2 years, history of significant traumaof knees
(eg, arthroscopy or injury to ligaments ormenisci <1 year pre-
ceding the study), andhistory of taking vitaminDor an inves-
tigational drug within the last 30 days.
Theknee thatmet thepreviously described inclusion and
exclusion criteriawas selected as the study knee for outcome
measures. When both knees met the criteria, the study knee
was defined as the onewithworse pain assessed using the vi-
sual analog scale.
Randomization andMasking
Participantswere allocated to either the vitaminD or placebo
group at a ratio of 1:1 based on computer-generated random
numbers. Allocation concealmentwas confirmedby a central
automated allocation procedure that was independent of the
investigators. Treatment assignmentwasmasked fromall par-
ticipants, research coordinators, and investigators andmain-
taineduntil alldatawerecollected, confirmedforaccuracy,and
cleaned, and statistical analyses were performed.
Interventions
Participants in the treatment groupwere givenamonthly cap-
sule of 50000 IU (1.25mg) of vitamin D3 (cholecalciferol) for
24 months (Nationwide Compounding Pharmacy).18 Partici-
pants in the control group received an identical inert placebo
provided by the same company.
Outcomes
Kneepainwas addedas anadditional primaryendpoint to the
protocol on June 6, 2012, after commentswere received from
reviewers of the methods article.15 The secondary outcomes
included on clinicaltrials.gov slightly differ from the pub-
lishedprotocolbecauseseveraloutcomemeasureswereadded
in the substudies as secondary outcomes on clinicaltrial.gov,
whereas theosteoarthritisoutcomeswere the focus in thepub-
lished protocol.15
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In this article, only the primary outcomes and a subset of
secondary outcomes (as listed in the study protocol
[Supplement 1]) are reported. Primary outcome measures
were change in knee pain assessed using the Western
Ontario and McMaster University Index of osteoarthritis
(WOMAC) score19 and change in tibial cartilage volume on
MRI from baseline to month 24. There were 5 prespecified
secondary outcomes (cartilage defects; tibial plateau bone
area; subchondral bone marrow lesion; meniscal tear and
extrusion; and lower limb muscle strength), but only the
outcomes for cartilage defects and bone marrow lesions on
MRI are reported in this article. Post hoc analysis outcomes
include 20% and 50% improvement rates in WOMAC pain
score, WOMAC function and stiffness scores, visual analog
scale knee pain, and the responder criteria developed by the
OutcomeMeasures in Rheumatology Arthritis Clinical Trials-
Osteoarthritis Research Society International (OMERACT-
OARSI) criteria.
Assessment of Pain
Kneepainwas assessed at baseline and atmonths 3, 6, 12, and
24. Five items ofWOMACpain scale in 100-mmvisual analog
format were used to assess pain during walking, using stairs,
in bed, sitting or lying, and standing. Items were summed to
create a total pain score (range, 0-500).20 Knee pain in most
days of the previousmonthwas assessed using a 100-mmvi-
sual analog scale.
Explanation ofWOMAC Scoring
The total WOMAC score indicates the sum of subscale scores
including pain, stiffness, and physical function. Missing re-
sponsesweremanagedaccording to theWOMACuser guide.21
TheWOMACpainscorewasconsideredvoid ifmore than1 item
was missing. In the event of a missing item, the remaining 4
items were averaged and then multiplied by 5.
OMERACT-OARSI Responder Criteria
TheOARSIStandingCommittee forClinicalTrialsResponseCri-
teria Initiativedevelopedasetof respondercriteria (OMERACT-
OARSI) to categorize individual response to treatment as a
single variable for clinical trials.22 Response using the exact
OMERACT-OARSI criteria could not be directly evaluated be-
causepatient global assessmentwasnot recorded in this trial;
therefore, we used a modified OMERACT-OARSI responder
definition without patient global assessment. OMERACT-
OARSI responders in this study were defined as participants
with (1) at least 50% improvement and an absolute change of
at least 20 points in the mean WOMAC pain score or mean
WOMAC function score; or (2) at least 20% improvement and
an absolute change of at least 10 points in both the mean
WOMAC pain score and the meanWOMAC function score.
MRI Assessment of Knee Structural Changes
MRIscansof the studykneewereobtainedaccording toa stan-
dardized protocol using a 1.5 T whole-body MRI unit with a
commercial transmit-receive extremity coil. The sequences
used for cartilage volume assessment were sagittal fat satu-
rated (FS) T1-weighted spoiled gradient echo (GRE). Cartilage
defects and bone marrow lesions were assessed using
T2-weighted/proton density–weighted fast spin echo (FSE)
sequences. MRIs were assessed by trained readers blinded to
treatment allocation according to methods described
previously.15
Cartilage Volume | Cartilage volume was determined using the
previously described image processing techniques.8 The vol-
umes of individual cartilage plates (medial tibial and lateral
tibial)were isolatedbymanually drawingdisarticulation con-
tours around the cartilage boundaries on a section-by-
section basis then resampled by means of bilinear and cubic
interpolationfor final3-dimensional renderingusingOsiriXLite
imaging software (32-bit version 5.9, Pixmeo SARL). The co-
efficient of variationwas2.1% formedial tibia and2.2%for lat-
eral tibia.23
Cartilage Defects | Cartilage defects (0-4) were graded on T2-
weighted imagesusingamodifiedOuterbridge classification24
atmedial tibial,medial femoral, lateral tibial, and lateral fem-
oral sites (described in the protocol).15 A total score was cal-
culated as the total of subregional scores. Intraobserver reli-
ability expressedasan intraclass correlationcoefficient ranged
from 0.77 to 0.94.
Bone Marrow Lesions | Bone marrow lesions, defined as dis-
creteareasof increasedsignal adjacent to the subcortical bone,
weremeasuredusingamodifiedWhole-OrganMagneticReso-
nance Imaging Score (0 = none, 1 ≤ 25% of the subregion,
2 = 25%-50%, and 3 ≥ 50%).25 A total score of the tibiofemo-
ral compartment was calculated as the total of 13 subregional
scores (0-39).The intraclass correlationcoefficientof thisbone
marrow lesion ranged from 0.93 to 0.98.
25-Hydroxyvitamin D Assays
Serum25-hydroxyvitaminDwas assayedat screening,month
3, and month 24 using direct competitive chemiluminescent
immunoassays (DiaSorin Inc). The intraassay and interassay
coefficients of variation were 3.2% and 6.0%.
Sample Size
Quantification of cartilage volume loss has been used to
monitor the progression of knee osteoarthritis.26 Previous
studies reported that mean annual loss of medial tibial carti-
lage volume loss in patients with knee osteoarthritis was
4.5%.27 Monthly intake of 50 000 IU of vitamin D would
achieve serum 25-hydroxyvitamin D levels greater than
60 nmol/L28 and this change was estimated to lead to an
absolute reduction in medial tibial cartilage loss of 2.2%
annually,8 which was expected to translate into a risk reduc-
tion of 44% for total knee replacement over 4 years.29 Sample
size calculation assumed α = .05 and β = .20 and was per-
formed based on the Cohen formula.30 We calculated that
400 participants at baseline (200 in each group), allowing
20% for dropouts, would have at least 80% power to detect a
2.2% between-group difference in medial tibial cartilage loss.
For change in WOMAC pain, we anticipated a standard devia-
tion of 70.5 on a score from 0 to 500.12 With 400 partici-
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pants, a difference between groups of 20 units on the score is
detectable with 80% power.
Statistical Analysis
WOMAC and visual analog scale knee pain scores were ana-
lyzed using a repeated-measuresmixedmodelwith terms for
age, sex, body mass index (calculated as weight in kilograms
divided by height inmeters squared), treatment, month, and
trial center. The correlationwithin the repeatedmeasureswas
addressed byusing an individual participant identification as
a randomeffect. The effect of treatmentwas evaluated by the
month × treatment interaction. In aposthocanalysis, thepro-
portionofparticipantswhoachievedat least 20%and50%im-
provement in WOMAC pain score was evaluated, which has
been shown to be clinically relevant.31
The independent t test was used to compare annual
changes in cartilage volume and absolute changes of carti-
lage defects and bonemarrow lesions between groups. An in-
crease in cartilage defects and bone marrow lesions was de-
fined as a change of more than 1 unit in score. Presence of an
increase in cartilagedefects or bonemarrow lesionswas com-
pared between the 2 groups using logistic regression.
Both intention-to-treat and per-protocol analyses were
used. Per-protocol analysis was defined as achieving a
25-hydroxyvitamin D level of greater than 60 nmol/L at the
month 3 visit. Multiple imputation by chained equationswas
used to address missing data caused by loss to follow-up and
nonresponses. Imputationswereperformedseparately foreach
treatment groupandeachoutcomeusingbaselinevalues, age,
sex, bodymass index, and serum25-hydroxyvitaminD level.
All statistical analyseswereperformedusingStataversion 13.0
(Stata Corporation) and a 2-sided P value of .05 was consid-
ered statistically significant.
Results
Participants
Figure 1 shows the flow of study participants. A total of 599
participants were screened for eligibility from June 5, 2010,
to December 1, 2011, and 413 participants were randomly
assigned to receive either vitamin D (n = 209) or placebo
(n = 204). The mean age of participants was 63.2 years, 208
(50%) were women, and mean body mass index was 29.6.
Participants’ demographic characteristics were comparable at
baseline between 2 groups (Table 1). Seventy-three partici-
pants withdrew from the study (28 [13.4%] in the vitamin D
group and 45 [22.1%] in the placebo group [P = .02]) and 340
participants (82.3%) completed the trial. There were no sig-
nificant differences between participants who completed the
study vs those who did not, except that among those who
withdrew, more were women and had lower tibial cartilage
volume (eTable in Supplement 2). Fewer participants discon-
tinued treatment in the vitamin D group (8) than the placebo
Figure 1. Flowchart of Participants in the VIDEO Study
599 Participants received telephone
prescreening and clinic assessment
for eligibility
186 Excluded
42 Current vitamin D use
26 Withdrew consent
33 Exclusionary comorbidities
26 Knee surgery scheduled
12 Physically unwell
22 Severe radiographic osteoarthritis
15 Ineligible visual analogue scale pain score
2 Ineligible age
4 Ineligible vitamin D level
4 Contraindication to MRI
413 Randomized
209 Randomized to receive vitamin D 204 Randomized to receive placebo
181 Completed protocol 159 Completed protocol
209 Included in the knee pain and MRI
cartilage volume loss analyses
204 Included in the knee pain and MRI
cartilage volume loss analyses
28 Lost to follow-up
5 Had knee surgery
8 Discontinued regimen
6 Relocated
6 Other reasons
2 Physically unwell
1 Died
45 Lost to follow-up
4 Relocated
21 Discontinued regimen
7 Had knee surgery
2 Physically unwell
11 Other reasons
MRI indicates magnetic resonance
imaging.
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group (21). The major reason for a higher drop-out rate
in the placebo group was that participants had their
25-hydroxyvitamin D levels checked by a primary care physi-
cian and started taking vitamin D after finding low vitamin D
levels. Consequently, they were withdrawn from the study.
All available data from the randomized participants were
included in the intention-to-treat analyses.
Primary End Points
The mean serum 25-hydroxyvitamin D level increased by
40.6 nmol/L in vitamin D group and by 6.7 nmol/L in placebo
group over 2 years. Overall, 165 (79%) participants in the vi-
taminDgroup and88 (43%) participants in theplacebo group
reacheda25-hydroxyvitaminD levelofgreater than60nmol/L
at month 3.
Changes inWOMACkneepain are presented inTable 2. At
baseline, themean(SD)ofWOMACpainscoreswere137.9 (88.8)
in the vitamin D group and 134.7 (83.4) in the placebo group
(difference, 3.2 [95%CI, −13.5 to 19.8]; P = .71). TotalWOMAC
pain decreased over 24months in both groups (Figure 2A). At
month 24, the mean (SD) of WOMAC pain scores were 87.0
(90.1) in the vitamin D group and 97.2 (87.5) in the placebo
group (difference, −10.2 [95%CI, −28.8 to8.4];P = .28). There
was no difference in change inWOMAC pain between groups
in the mixed-effect model in which all time points were in-
cluded (−49.9 for the vitaminD group vs −35.1 for the placebo
group; between-groupdifference, −14.8 [95%CI, −32.5 to2.9];
P = .10).
Tibial cartilage volume (mean [SD]) at baseline was not
different between the vitamin D group (3466 mm3 [1038])
and the placebo group (3640 mm3 [1036]) (between-group
difference, −174 mm3 [95% CI of difference, −375 to 27];
P = .09). At month 24, tibial cartilage volume was also not
different between the vitamin D group (3238 mm3 [989])
and the placebo group (3398 mm3 [1030]) (between-group
difference, −160 mm3 [95% CI of difference, −369 to 49];
P = .13). Change in tibial cartilage volume (Table 2) was not
different between the groups (−242.6 mm3 for the vitamin D
group vs −301.4 mm3 for the placebo group [between-group
difference, 58.8 mm3 {95% CI, −13.9 to 131.4}]; P = .11). Per-
protocol analysis comparing participants who achieved a
25-hydroxyvitamin D level of greater than 60 nmol/L at their
month 3 visit (n = 253) with those who did not (n = 146) (14
participants withdrew within 3 months) showed similar
results (−261.9 mm3 vs −284.8 mm3 [between-group differ-
ence, 22.9 mm3 {95% CI, −51.5 to 97.3}]; P = .55).
Secondary End Points
The results for tibiofemoral cartilage defects and bone mar-
row lesions are shown in Table 2. The difference in cartilage
defect scorewas not different between groups. Bonemarrow
lesion scores decreased in both groups and no significant dif-
ference was observed.
Post Hoc Analyses
In post hoc analyses (Table 2), participants in the vitamin D
group had statistically significant improvements in visual
analog scale knee pain (Figure 2E) scores when compared
with the placebo group. The vitamin D group had more
improvement in the total WOMAC score (Figure 2B) and
WOMAC function (Figure 2C) but not WOMAC stiffness
(Figure 2D). There were 115 (64%) participants in the vitamin
D group and 95 (57%) participants in the placebo group
(P = .16) who achieved a 20% improvement in WOMAC knee
pain score over 2 years. There were 90 (50%) participants in
the vitamin D group and 65 (39%) participants in the placebo
group (P = .04) who showed at least a 50% improvement in
WOMAC pain score. There were more OMERACT-OARSI
responders in the vitamin D group (74/209 [35%]) than the
placebo group (52/204 [25%]) (P = .03). The proportion of
participants who had an increase in bone marrow lesions
was lower in vitamin D group (44/183 [24%]) than in the pla-
cebo group (61/175 [35%]) (P = .03).
Adverse Events
Fifty six of the 209 participants (27%) in the vitamin D
group reported at least 1 adverse event vs 37 of the 204 par-
ticipants (18%) in the placebo group (Table 3). Four partici-
pants developed hypercalcemia in the vitamin D group vs 2
in the placebo group. One participant in the vitamin D group
had symptoms of hyperparathyroidism (eg, muscle cramps,
Table 1. Baseline Characteristics of the Vitamin D and the Placebo Groups
Vitamin D
(n = 209)
Placebo
(n = 204)
Study site
Hobart, No. (%) 129 (61) 132 (64)
Melbourne, No. (%) 80 (38) 72 (35)
Age, mean (SD), y 63.5 (6.9) 62.9 (7.2)
Women, No. (%) 106 (50) 102 (50)
Body mass index, mean (SD)a 29.6 (5.4) 29.6 (4.6)
Serum 25-hydroxyvitamin D,
mean (SD), nmol/L
43.7 (11.8) 43.8 (12.7)
Radiographic osteoarthritis,
No. (%)
163 (96) 157 (96)
Total WOMAC score (0-2400),
mean (SD)b
687.3 (426.3) 664.7 (390.8)
Pain (0-500) 137.9 (88.8) 134.7 (83.4)
Stiffness (0-200) 61.5 (41.5) 61.7 (40.1)
Function (0-1700) 487.9 (318.1) 467.6 (292.8)
Visual analog scale pain
(0-100 mm), mean (SD)b
48.7 (21.4) 46.4 (20.5)
Tibial cartilage volume,
mean (SD), mm3
3466 (1038) 3640 (1036)
Medial tibial region 1461 (463) 1522 (474)
Lateral tibial region 2005 (716) 2118 (681)
Cartilage defects, No. (%) 194 (93) 192 (94)
Medial tibiofemoral region 176 (84) 164 (80)
Lateral tibiofemoral region 159 (76) 157 (77)
Bone marrow lesions, No. (%) 134 (64) 147 (72)
Medial tibiofemoral region 90 (43) 95 (46)
Lateral tibiofemoral region 81 (39) 89 (43)
Abbreviation: WOMAC,Western Ontario andMcMaster University Index.
a Bodymass index was calculated as weight in kilograms divided by height in
meters squared.
bHigher scores inWOMAC and the visual analog scale pain indicate a more
severe stage of the condition.
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brittle bones, and kidney dysfunction) vs none in the pla-
cebo group. There was 1 episode of renal calculus in each
group.
Discussion
The purpose of this RCT was to determine whether vitamin
D supplementation could reduce knee pain and cartilage
loss and also prevent progression of other knee structural
abnormalities in patients with knee osteoarthritis and low
25-hydroxyvitamin D levels. Results showed that even
among study participants with low 25-hydroxyvitamin D,
supplementation did not slow cartilage loss or improve
WOMAC-assessed pain. These data suggest a lack of
evidence to support vitamin D supplementation for
slowing disease progression or structural change in knee
osteoarthritis.
Table 2. Change in Study End Points Over 2 Years Between Vitamin D and Placebo Groups, Mean (95%CI)a
Vitamin D
(n = 209)
Placebo
(n = 204) Between-Group
Difference in
Change, Mean
(95% CI)b,c P Value
Mean (SD)
Change,
Mean (95% CI)b
Mean (SD)
Change, Mean
(95% CI)bBaseline Month 24 Baseline Month 24
Primary End Points
WOMAC pain
(0-500)
137.9 (88.8) 87.0 (90.1) −49.9
(−62.2 to −37.6)
134.7 (83.4) 97.2 (87.5) −35.1
(−47.8 to −22.4)
−14.8
(−32.5 to 2.9)
.10
Tibial cartilage
volume, mm3
3466 (1038) 3238 (989) −242.6
(−294.6 to −190.6)
3640 (1036) 3398 (1030) −301.4
(−254.7 to −248.0)
58.8
(−13.9 to 131.4)
.11
Medial tibial
cartilage
volume, mm3
1461 (463) 1369 (464) −105.0
(−134.8 to −75.3)
1522 (474) 1407 (456) −136.7
(−167.3 to −106.1)
31.7
(−10.0 to 73.4)
.14
Lateral tibial
cartilage
volume, mm3
2005 (716) 1870 (673) −138.0
(−171.2 to −104.8)
2118 (681) 1992 (689) −164.7
(−198.5 to −130.9)
26.7
(−19.4 to 72.9)
.26
Change in tibial
cartilage volume
(%/y)
−3.4
(−4.2 to −2.7)
−4.2
(−5.0 to −3.5)
0.8
(−0.2 to 1.8)
.13
Medial tibial
cartilage
volume (%/y)
−3.3
(−4.3 to −2.3)
−4.4
(−5.4 to −3.4)
1.1
(−0.3 to 2.5)
.12
Lateral tibial
cartilage
volume (%/y)
−3.4
(−4.3 to −2.6)
−4.1
(−5.0 to −3.2)
0.7
(−0.6 to 1.8)
.29
Secondary End Points
Tibiofemoral
cartilage defects
(0-12)
9.3 (3.1) 9.7 (3.2) 0.3
(0.1 to 0.5)
8.7 (2.9) 9.2 (3.1) 0.5
(0.3 to 0.6)
−0.2
(−0.4 to 0.1)
.21
Medial
tibiofemoral
defects (0-6)
4.9 (2.1) 5.2 (2.1) 0.2
(0.1 to 0.3)
4.6 (2.1) 5.0 (2.2) 0.3
(0.2 to 0.5)
−0.1
(−0.3 to 0.1)
.20
Lateral
tibiofemoral
defects (0-6)
4.4 (1.9) 4.5 (1.9) 0.1
(−0.1 to 0.2)
4.1 (1.8) 4.2 (1.9) 0.1
(0.0 to 0.3)
−0.1
(−0.2 to 0.1)
.57
Tibiofemoral
bone marrow
lesions (0-39)
2.4 (2.9) 2.3 (3.0) −0.1
(−0.4 to 0.2)
2.6 (2.9) 2.9 (3.7) 0.3
(0.00 to 0.7)
−0.5
(−0.9 to 0.0)
.06
Medial
tibiofemoral
lesions (0-18)
1.3 (2.2) 1.2 (2.1) −0.1
(−0.3 to 0.1)
1.4 (2.3) 1.5 (2.6) 0.1
(−0.1 to 0.4)
−0.2
(−0.5 to 0.1)
.19
Lateral
tibiofemoral
lesions (0-18)
0.8 (1.4) 0.8 (1.4) −0.1
(−0.2 to 0.1)
0.9 (1.3) 1.0 (1.6) 0.2
(0.0 to 0.3)
−0.2
(−0.5 to 0.0)
.09
Post hoc End Points
WOMAC total
(0-2400)
687.3 (426.3) 434.3 (419.3) −239.2
(−290.5 to −188.0)
664.7 (390.8) 504.7 (435.7) −147.8
(−200.8 to −94.9)
−91.4
(−165.1 to −17.7)
.02
Function
(0-1700)
487.9 (318.1) 306.4 (303.7) −170.2
(−207.4 to −133.0)
467.6 (292.8) 361.8 (322.8) −97.3
(−135.7 to −58.8)
−72.9
(−126.4 to −19.4)
.008
Stiffness
(0-200)
61.5 (41.5) 41.1 (44.1) −19.7
(−25.4 to −13.9)
61.7 (40.1) 45.7 (41.1) −15.4
(−21.3 to −9.5)
−4.2
(−12.5 to 4.0)
.31
Visual analog
scale pain
(0-100)
48.7 (21.4) 33.7 (27.1) −14.8
(−18.5 to −11.1)
46.4 (20.5) 36.4 (25.1) −9.4
(−13.3 to −5.6)
−5.4
(−10.7 to −0.1)
.05
Abbreviations: WOMAC,Western Ontario andMcMaster University Index.
a Higher scores inWOMAC, visual analog scale pain, cartilage defects, and bone
marrow lesions indicate a more severe stage of the condition.
b Change inWOMAC scores and visual analog scale pain results are generated
frommixedmodels adjusted for age, sex, bodymass index, center, andmonth.
Change in cartilage volume, cartilage defect, and bonemarrow lesion results are
generated frommultiple imputed data sets.
c Between-group differences were calculated using vitamin D group values
minus placebo group values.
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Figure 2. Comparison Between Vitamin D Group and Placebo Group on Change in Clinical Symptoms: theWOMAC Pain Assessment and the Visual
Analog Scale for Pain
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statistical significance between the 2 groups in score change from baseline to
month 24.
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Although epidemiological studies suggest that knee os-
teoarthritis is more prevalent among individuals who are de-
ficient invitaminD,andvitaminDdeficiency isassociatedwith
cartilage loss8-10 and knee osteoarthritis symptoms,6,7,32 the
results from 2 prior RCTs were mixed. In one study, supple-
mentation of vitamin D3 (2000 IU/day) over 2 years showed
no benefit for symptoms and structural changes in patients
withkneeosteoarthritis, regardlessof their25-hydroxyvitamin
D levels.5 The other study reported a small but statistically
significant benefit on symptoms in patients with vitamin D
insufficiency over 1 year.12 Both studies have limitations.
The first study included patients without vitamin D defi-
ciency who may not benefit from vitamin D supplementa-
tion and patients whose disease was too severe to respond
to vitamin D treatment. Also, it had a small sample size (146
participants).13 The second study did not examine structural
changes and had a 1-year follow-up, which may be too short
to observe disease progression.33 Our study addressed these
limitations by recruiting patients without severe knee
osteoarthritis with low 25-hydroxyvitamin D levels and pro-
vided follow-up for 2 years. Nonetheless, our results are
largely consistent with the prior 2 trials.
Structural changes in cartilage andnoncartilaginous joint
tissue assessed using MRI, are now recommended outcomes
for clinical trials in osteoarthritis.34 An observational study
showed that lower serum25-hydroxyvitaminD levelswereas-
sociatedwith greater cartilage volume loss over 2.7 years.8 In
the current study, the amount of tibial cartilage volume loss
in the placebo group is consistent with the findings of a pre-
vious RCT.5 We did not find significant effects on change in
knee cartilage defects and bone marrow lesions.
Adverse effects of vitaminDusemay include hypercalce-
mia. Although intermittent use of very high-dose vitamin D
(eg,500000IU/year)maynotbesafe,35ourstudysuggests that
a monthly regimen at a dosage of 50000 IU is safe in elderly
patients, even though the serum 25-hydroxyvitamin D levels
of long-termusers are at theupper limit of thenormal range.36
The key strength of this RCT is the inclusion and exclu-
sioncriteria. This study includedonlyadult patientswithknee
osteoarthritiswhohadavitaminD insufficiency—patientswho
may be the most likely to benefit from vitamin D supple-
ments. We also used a predefined range of knee pain to pre-
vent a ceiling or floor effect in the statistical analyses. Pa-
tients with late-stage knee osteoarthritis were excluded
because of very little cartilage remaining; thus, any possible
benefits of therapy on cartilagewould be difficult to identify.
By using these criteria, we studied a patient population in
whom the likelihood of demonstrating an effect (if truly
present) of vitamin D supplementation was maximized.
This study also had limitations. First, WOMAC pain as a
second primary outcome was added during the recruitment
period at the time the protocol was published. However, this
change was made before the trial was completed, before any
data analyses, and the original sample size had sufficient
power to detect the expected difference in WOMAC pain.
Second, loss to follow-up was 17.7% and was less in the vita-
min D group (28 participants) than in the placebo group (45
participants) (P = .02). There were fewer participants who
withdrew from their assigned intervention in the vitamin D
group (n = 8) than in the placebo group (n = 21). Participants
who did not adhere to their assigned intervention could be
expected to have a worse outcome than those who did.
Although this could bias the result toward the null, similar
results were seen in per-protocol analysis, suggesting the dif-
ferential dropout rate had minimal effects on our results.
Last, this study did not prespecify clinical outcomes such as
visual analog scale knee pain and WOMAC physical function
as primary or secondary end points.
Conclusions
Amongpatientswith symptomatickneeosteoarthritis and low
serum 25-hydroxyvitamin D levels, vitamin D supplementa-
tion, when compared with placebo, did not result in signifi-
cantdifferences inchange inMRI-measured tibial cartilagevol-
umeor change inWOMACkneepain score over 2 years. These
findings do not support the use of vitamin D supplementa-
tion for preventing tibial cartilage loss or improvingWOMAC
knee pain among patients with knee osteoarthritis.
Table 3. Adverse Events
No. (%) of Participants
Vitamin D
(n = 209)
Placebo
(n = 204)
Serious adverse events
Death 1 (0.5) 0
Malignancy 4 (1.9) 2 (1.0)
Coronary artery disease 1 (0.5) 1 (0.5)
Severe infection 0 3 (1.5)
Major depression 1 (0.5) 0
Nephrolithiasis 1 (0.5) 1 (0.5)
Hospitalizationa 3 (1.4) 0
Adverse events
Hypercalcemia 4 (1.9) 2 (1.0)
Hyperparathyroidism 1 (0.5) 0
Renal 2 (1.0) 0
Falls 2 (1.0) 0
Musculoskeletal 1 (0.5) 1 (0.5)
Neurological 5 (2.4) 4 (2.0)
Gastrointestinal 7 (3.3) 5 (2.5)
Respiratory 2 (1.0) 2 (1.0)
Ocular 1 (0.5) 2 (1.0)
Infection 6 (2.9) 4 (2.0)
Cardiac arrhythmia 3 (1.4) 0
Chest pain 4 (1.9) 5 (2.5)
Pain 7 (3.3) 2 (1.0)
Allergy/immunology 0 2 (1.0)
Other eventsb 9 (4.3) 7 (3.4)
a Two participants were admitted to the hospital after a fall and 1 was admitted
because of severe diarrhea.
b Includes headache, lethargy, flu symptoms, and other events (neuroma,
dysphonia, hypotension, lipoma, hypersensitivity, and Sjögren syndrome).
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